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iAbstract
Despite there being pragmatic national guidelines for assigning risk to wo-
men with a family history of breast cancer, the evidence base is still sparse.
There are three major questions: First, how can an assignment of “low” risk
be made most efficiently? Second, what are the actual outcomes for higher-
risk women enrolled in special surveillance programmes? Third, what are
the costs and benefits of current management of members of breast cancer
families?
My thesis reviews the evolution of clinical services for familial breast cancer
and the existing literature in the field. I describe the gathering of inform-
ation from the service records of the Tayside Breast Cancer Family History
Clinic and from specific research exercises that involved collaboration with
other centres in the UK and abroad. My findings are as follows:
1. Histories provided by the families are not sufficient to assign risk accur-
ately. They must be extended and verified from other records by clinical
geneticists. Women assigned a low risk can be informed by post, but some
may require further support. The 2004 NICE guidelines for assigning risk
are fairly accurate, but may under-estimate it for some women aged 45–55
years.
2. Annual screening of young women at increased risk results in detection
of most cancers at a curable stage. Women who carry BRCA1 mutations fare
less well, even when tumours are detected at an apparently early stage.
3. Costs of accurate risk assessment are outweighed by savings from the bet-
ter targeting of surveillance programmes. Early cancer detection in young
women enrolled in these programmes achieves a substantial gain in life ex-
pectancy at a cost of £3,700 per quality adjusted life year (QALY). Prophy-
lactic surgery for carriers of BRCA1 mutations is highly cost-effective.
The thesis concludes with a discussion as to how these findings might be
extended and clinical practice improved in the future.
Declarations
I, Marta de Azevedo Moreira Reis, hereby certify that this thesis, which is approximately
63,000 words in length, has been written by me, that it is the record of work carried out
by me and that it has not been submitted in any previous application for a higher degree.
Date: 11/12/2006
Signature of Candidate
I was admitted as a research student on 25th September 2000 as a candidate for the
degree of Doctor of Philosophy in November 2000: the higher study for which this is a
record was carried out in the University of St Andrews between 2000 and 2005.
Date: 11/12/2006
Signature of Candidate
I hereby certify that the candidate has fulfilled the conditions of the Resolution and
Regulations appropriate for the degree of Doctor of Philosophy in the University of St
Andrews and that the candidate is qualified to submit this thesis in application for that
degree.
Date: 11/12/2006
Signature of Supervisor
I hereby certify that the candidate has fulfilled the conditions of the Resolution and
Regulations appropriate for the degree of Doctor of Philosophy in the University of St
Andrews and that the candidate is qualified to submit this thesis in application for that
degree.
Date: 11/12/2006
Signature of Supervisor
Copyright declaration
In submitting this thesis to the University of St Andrews we understand that we are
giving permission for it to be made available for use in accordance with the regulations of
the University Library for the time being in force, subject to any copyright vested in the
work not being affected thereby. We also understand that the title and the abstract will be
published, and that a copy of the work may be made and supplied to any bona fide library
or research worker, that my thesis will be electronically accessible for personal or
research use unless exempt by award of an embargo as requested below, and that the
library has the right to migrate my thesis into new electronic forms as required to ensure
continued access to the thesis. We have obtained any third-party copyright permissions
that may be required in order to allow such access and migration, or have requested the
appropriate embargo below.
The following is an agreed request by candidate and supervisor regarding
the electronic publication of this thesis:
Access to Printed copy and electronic publication of thesis through the University
of St Andrews.
Date: 21st April 2009
Signatures:
Acknowledgements
Words of acknowledgement are not enough, for the unconditional support, en-
couragement, unlimited patience and guidance through the long road that led
me to finalise this work by Professor C Michael Steel.
To you my husband, Luke, with your love, patient tolerance of my long hours
and support both emotionally and intellectually and to our little daughter for
her love and understanding I cannot thank you both enough for all this.
To my mother and Nena for their unconditional support, love and above all,
tolerance with the hurdles of several trips from Brasil were they live, to this
country to take the lead of the management of the running of the house allowing
me to dedicate more time for the writing of this thesis.
To my father and my brother Ricardo, for their continuous emotional support
and love.
There were trying moments during the course of my work starting with the sad
loss of Professor Mo Malek as my second supervisor on the Management side of
this work.
For a short period after his death, I was under the temporary supervision of Prof.
Hugh Davies, however, as he had embraced all his and Professor Maleks’ post-
graduate students, the School had re-allocated me to Dr Manouche Tavakoli and
he became my “second supervisor”.
Secondly, I became pregnant and gave birth to a wonderful daughter who is giv-
ing me bondless love, followed by several miscarriages but the support I have
received from my husband, my family and Michael Steel made me to continue
this road until the end.
This project would not have been successful without the willing help, support
from Dorothy Young, Lorna McLeish, Dr. David Goudie, Tayside Family His-
v
ACKNOWLEDGEMENTS vi
tory Clinic staff, Helen Vysny for her help in the collection and insertion of data
in the database created, secretaries from both ward 10 (Ninewells Hospital were
I work), and genetics dept for their help in finding all relevant case notes for me
required for the project, Jane Kenyon for the important input of her work on the
pilot study of “Breast Cancer in young women, clinical and economic implica-
tions of earlier detection” as this piece of work was of paramount importance
for the costing chapter of my thesis.
I would like to thank Mr David Carson (Head of Financial Performance Man-
agement—NHS Tayside), his assistant Yvonne Mitchell, Mark Parsons (Principal
Clinical Pharmacist, Surgery and Oncology—Ninewells Hospital) Angela Phil-
lips (Specialist Clinical Pharmacy Technician) and Dr John Dewar (Consultant
Oncologist) for all their comments and information gathered for me (at short
notice) in preparation of my costing chapter. The help of Derek Colley and Glen
Finnie from the Finance Dept at Ninewells Hospital in checking some of the cur-
rent costs per unit used in this thesis and discussion of some issues of costing in
the NHS system was also much appreciated.
I wish to acknowledge all the patients who through the years became the family
history clinic “family”. Of course, I also wish to acknowledge all those whose
names I might have inadvertently omitted.
O que me preocupa não é o
grito dos maus mas o silêncio
dos bons
Martin Luther King
List of abbreviations
BSO Bilateral salpingo-oophorectomy
CASH Cancer and Steroid Hormone study
CSO Scottish Executive—Chief Scientist’s Office
DCIS Ductal carcinoma in situ
ER Oestrogen receptor
FEC 5-Fluorouracil, epirubicin, cyclophosphamide
FIGO International Federation of Gynaecology and Obstetrics
FNA Fine-needle aspiration
HMO Health maintenance organisation
HNPCC Hereditary non-polyposis colorectal cancer
HRT Hormone replacement therapy
ICER Implied incremental cost-effectiveness ratio
ISD NHS Information Services Division
MARIBS Study Magnetic Resonance Imaging Breast Screening Study
MRI Magnetic resonance imaging
NBSP National Breast Screening Programme
NICE National Institute for Clinical Excellence
NIS Norwegian National Insurance Service
vii
LIST OF ABBREVIATIONS viii
OCCR Ovarian cancer cluster region
PBMA Programme Budgeting and Marginal Analysis
POHEM Statistics Canada—Population Health Model
PROSE Prevention and Observation of Surgical Endpoints
QALY Quality Adjusted Life Year
SIGN Scottish Intercollegiate Guidelines
TAYREN Tayside Primary Care Research Network
TRAM flap Transverse rectus abdominus myocutaneous flap
WLE Wide local excision
Contents
Declarations ii
Copyright declaration iv
Acknowledgements v
List of abbreviations vii
Contents ix
List of Figures xii
List of Tables xiii
1 Introduction 1
1.1 Breast cancer: its causes and management . . . . . . . . . . . . . . 1
1.2 Familial breast cancer . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 A short history of “breast cancer family history” clinics . . . . . . 6
1.4 Purpose and content of the work presented in this thesis . . . . . 14
2 Literature review 19
2.1 Ascertainment of risk; guidelines and their implementation . . . . 19
2.2 Structure of clinical services for familial breast cancer in the UK . 24
2.3 Evaluation of breast cancer genetics services . . . . . . . . . . . . . 29
2.4 Management of breast cancer . . . . . . . . . . . . . . . . . . . . . 31
2.5 Cost effectiveness issues . . . . . . . . . . . . . . . . . . . . . . . . 36
2.6 Breast screening controversies . . . . . . . . . . . . . . . . . . . . . 37
2.7 Introduction to economic evaluation . . . . . . . . . . . . . . . . . 43
2.8 The role of prophylactic surgery . . . . . . . . . . . . . . . . . . . . 50
ix
CONTENTS x
2.9 Prophylactic surgery versus regular surveillance . . . . . . . . . . 53
2.10 Conclusion: current views on cost effectiveness of breast cancer
family history clinical services . . . . . . . . . . . . . . . . . . . . . 55
3 Material and Methods 58
3.1 Basis of the linked studies and funding . . . . . . . . . . . . . . . . 58
3.2 Study setting and patients . . . . . . . . . . . . . . . . . . . . . . . 60
3.3 Detection and recording of cancers in the “family history” clinic . 67
3.4 Psychological issues . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
3.5 Accuracy of “low risk” as defined by guidelines . . . . . . . . . . 69
3.6 Health economic and management data (sources) . . . . . . . . . 70
3.7 Personal contribution to related studies in this thesis . . . . . . . . 71
4 Verification of family history 74
4.1 Evaluation of risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.2 Cost implications of applying resources to checking family history 85
4.3 Patient and GP satisfaction . . . . . . . . . . . . . . . . . . . . . . . 88
4.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5 Cancers detected in the surveillance programme 95
5.1 Tayside experience . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
5.2 European collaborative study data . . . . . . . . . . . . . . . . . . 102
5.3 Surveillance of women at high risk . . . . . . . . . . . . . . . . . . 105
5.4 The place of prophylactic surgery . . . . . . . . . . . . . . . . . . . 108
5.5 Bilateral salpingo-oophorectomy . . . . . . . . . . . . . . . . . . . 112
5.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
5.7 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
6 True incidence of breast cancer in “low risk” women up to age 55 years 120
6.1 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
6.2 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
7 Costs and cost-effectiveness issues 131
7.1 Background and methods to obtain cost figures and their accuracy 131
7.2 Basis of calculations . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
7.3 Sensitivity analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
7.4 Carriers of BRCA mutations . . . . . . . . . . . . . . . . . . . . . . 140
CONTENTS xi
7.5 Savings (direct health care) from prophylactic surgery . . . . . . . 142
7.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 143
8 Conclusions and recommendations 145
8.1 Summary of the work recorded in previous chapters . . . . . . . . 146
8.2 A return to the original questions . . . . . . . . . . . . . . . . . . . 149
Bibliography 154
Appendices 176
A Published papers 177
B Clinic letters 232
C Patient questionnaire 255
D GP questionnaire 265
List of Figures
1.1 Analytical framework . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3.1 Summarised distribution of the referrals and eligibility for the “triage”
study period here. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
4.1 Trial project summary . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
5.1 Percentage of breast cancers detected as prevalent (first visit) incid-
ent (screened) or incidental (interval) tumours according to year of
attendance at the Tayside clinic. . . . . . . . . . . . . . . . . . . . . . . 97
6.1 Observed and expected breast cancer cases in “low” risk women seen
through the family history clinics across Scotland (1994–2003) . . . . 125
6.2 Breast cancers detected by year of diagnosis in “low risk” women
across Scotland during study period . . . . . . . . . . . . . . . . . . . 127
6.3 Number of breast cancers detected in “low risk” women by the age
at diagnosis (all cases 1994–2005 included) . . . . . . . . . . . . . . . . 129
8.1 Optimal organisation of a regional breast cancer genetics service . . . 153
xii
List of Tables
1.1 TNM classification of breast tumours . . . . . . . . . . . . . . . . . . . 2
1.2 Correlation of UICC staging and TNM classification of breast cancers 2
1.3 Common familial syndromes associated with breast cancer . . . . . . 7
2.1 Criteria for identification of patients for specialist genetic services . . 21
2.2 NICE guidelines criteria for referral of women likely to be at “mod-
erate” or greater risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
3.1 Management protocol followed by the Tayside Breast cancer family
service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.2 Data recorded on breast cancers diagnosed among patients attending
the breast cancer genetics clinic . . . . . . . . . . . . . . . . . . . . . . 67
4.1 Percentage of referrals placed in different risk categories at each stage
of the assessment process . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.2 Sensitivity and specificity of risk assignment . . . . . . . . . . . . . . 83
4.3 Details and costs of the additional investigations performed accord-
ing to the risk category distribution of the women attending the Tay-
side clinic. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.1 Breast cancer cases since “family history” clinic started in Tayside. . . 98
5.2 Comparison with findings at diagnosis and outcome of young wo-
men with breast cancer according to screening history. . . . . . . . . . 101
5.3 Cumulative data of breast cancers diagnosed under surveillance pro-
gramme in collaboration with other European Centres . . . . . . . . . 102
5.4 Bilateral salpingo-oophorectomies carried out in women attending
the Tayside breast cancer family service. . . . . . . . . . . . . . . . . . 113
xiii
List of Tables xiv
6.1 Summary of the study findings on the incidence of breast cancer in
“low risk” women discharged from regular surveillance programmes. 124
6.2 Findings from the survey of “low risk” women breast cancer dia-
gnosis (according to pathological findings) . . . . . . . . . . . . . . . 124
7.1 Costs for “typical” pre-menopausal women that developed breast
cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
7.2 Representative costs of management options for familial breast can-
cer in North America (quoted in1). Conversion £1 = 1.8 US$ . . . . . 136
7.3 Effects of changing sensitive parameters (numbers of breast cancers
detected per year and percentage of patients who benefit from “stage
shift” of their cancer) on cost effectiveness of surveillance programme
for familial breast cancer . . . . . . . . . . . . . . . . . . . . . . . . . . 140
7.4 Cost of prophylactic surgical intervention for BRCA1 mutation carriers.141
Chapter 1
Introduction
1.1 Breast cancer: its causes and management
The oldest recorded information about breast cancer was from ancient Egypt;
tumours and treatment were described in at least three papyri dated from 1600
BC: the Ebers, Smith and Petrie papyri.2 Edwin Smith in 1862 discovered the
papyrus (Smith Papyrus) that recorded eight cases of tumours of the breast that
were treated by cauterisation using what was called the “fire-drill”,3 as was com-
mon practice in Egypt.
At the time, surgery was used in cases without any form of anaesthesia or an-
tisepsis and, more often than not, the patient would either die from the crude
procedure with continuous bleeding or from infection afterwards.
Gradually the disease became more familiar to physicians and its treatment has
developed throughout the centuries. Andreas Vesalius, during the Renaissance,
recommended mastectomies with ligatures of the bleeding areas to control blood
loss.
A physician called Le Dran first recognised that breast cancer could spread to
regional lymphatic tissue. This was a major development in the understanding
of the disease.
Only in the mid-1800s did surgeons begin to record details about their cases of
breast cancer. The common treatment at that time was complete removal of the
breast gland and lymph nodes in an attempt to avoid further disease develop-
ment in the area. Radical mastectomies with total removal of the regional lymph
1
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nodes were commonly carried out, including removal of the pectoral muscles,
leaving the patients with wounds that were difficult to heal and the stigmata of
this aggressive surgery.
Oophorectomies were introduced as part of breast cancer treatment towards the
end of the nineteenth Century by Beatson in Glasgow as a means of restraining
uncontrolled growth of tumours in the breast. It was the first time that hormone
therapy was used in the management of any form of cancer.4, 5
Survival rates began to improve at the beginning of the 20th century, with not-
able advances during and immediately after the Second World War. Ten-year
survival rates following mastectomies were around 10% in the 1920s; this im-
proved to about 50% in the 1950s. The figure is still gradually improving as new
methods of detection and treatment become available.
Breast cancers are traditionally classified according to tumour size (T), nodal
involvement (N) and the presence or absence of distant metastases (M) as shown
in Table 1.1. This classification can be correlated with the staging of the disease
as in Table 1.2.
Table 1.1: TNM classification of breast tumours
T0 Cancer in situ
T1 ≤ 2 cm
T2 2–5 cm
T3 > 5 cm
T4 Involvement of chest wall and/or skin, and/or inflammatory cancer
N0 No regional node metastases
N1 Palpable mobile ipsilateral axillary nodes
N2 Fixed involved ipsilateral axillary nodes
N3 Ipsilateral internal mammary node involvement
M0 No evidence of metastasis
M1 Distant metastasis
Table 1.2: Correlation of UICC staging and TNM classification of breast cancers
UICC stage TNM classification
I (early) T1, N0, M0
II T1, N1, M0; T2, N0−1, M0
III (locally advanced) Any T, N2−3, M0; T3, any N, M0; T4, any N, M0
IV (advanced) Any T, any N, M1
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With better understanding of the disease and better data collection, clinicians
and scientists developed new treatments based on clinical trials. It was then that
staging systems were developed, dividing breast cancer patients into groups
according to clearly defined clinical signs of the disease. It became clear that the
earlier a breast cancer was diagnosed and treated, the better the patient’s chance
of long term disease survival (reviewed by Dixon6).
In the 1970s, interest in the molecular basis of human cancer expanded enorm-
ously with the emergence of techniques for DNA analysis and manipulation.
Researchers at the University of California, were among the first to report that
certain genes in the normal cells of the body could somehow become abnormal
(“transformed”) and could therefore spur cancerous cells to grow7–9 and that
the growth regulation of the cell involved a complex chain of events from ex-
tracellular regulators interacting with the cell plasma membrane and thereafter
mediators in the cytoplasm would transmit signals from the plasma membrane
to the nucleus where they would control DNA-binding proteins.
The transformed cell would be unable to respond to regulatory signals and
therefore the cells would grow without control.10
In 1975, Dulbecco was one of the first to advance the hypothesis that, if the
growth regulators specific for the aberrant behaviour of cancer cells were to be
identified, they could be used for stopping the growth of the malignant cell.7
Others have pointed out, that most carcinogens are promutagens (generating
mutagenic substances that induce cancer) so that a reduction in the incidence of
cancer could be achieved by the identification of promutagens and their elimin-
ation from the environment.11
1.2 Familial breast cancer
The evolution of a tumour cell clone involves a series of oncogene activations
and tumour suppressor gene inactivations, each of which will confer some phen-
otypes on the cancer cell, the sum of these phenotypes constituting malignancy.8
Thereafter, it became clear that inherited mutations in growth-regulatory genes
could account for some familial cancers though, in fact, this had been predicted
CHAPTER 1. INTRODUCTION 4
as early as 1914 by Boveri.12 As is often the case, that work was so far ahead of
its time that it lay largely neglected for some seventy years.
A striking feature of breast cancer occurring in obvious family clusters is early
age of onset, often with presentation before age 40. In the 1990s, Hall and col-
leagues13, 14 mapped the first gene linked to major early-onset breast cancer risk
(BRCA1) to chromosome 17q.
The finding was rapidly confirmed by Steven Narod et al.,15 who showed that
the locus is also linked to predisposition to carcinoma of the ovary. It is thought
that this gene is responsible for 2–4% of all breast cancers and 5–10% of ovarian
cancers15 and that individual mutation carriers are at increased risk for both
breast cancer and ovarian cancer.16
The BRCA1 gene was isolated and characterised three years after the locus was
mapped.17 It is large, with twenty-four exons spanning over 100 kilobases of
DNA and bears very little homology to any other known genes.
Female carriers of mutations in this gene experience a high lifetime risk for de-
veloping breast cancer (as high as 85–90%, compared to an 11% risk for the nor-
mal female population who do not carry the faulty gene). It was confirmed that
they also have a high risk of ovarian cancer (variously estimated at 35–60%).
Though familial ovarian cancer is less clearly associated with early age of onset
than familial breast cancer and very rarely presents under the age of 35 years.18
In 1994, a second breast cancer susceptibility gene was tracked down to chro-
mosome 13q12–13 and was called BRCA2.19 It was cloned and characterised the
following year.20 This gene is even larger than BRCA1 with twenty-seven exons
and the two genes show almost no sequence homology. In contrast to BRCA1,
male breast cancer cases are relatively common in BRCA2 mutation families but
the risk for ovarian cancer is lower (27%). However, mutations in the central
part of the BRCA2 gene appear to carry a high relative risk of ovarian cancer
(hence the term ovarian cancer cluster region – “OCCR”).18–21
Searching for BRCA1 and BRCA2 mutations is a major task because the genes
are so large and the cost and effort involved in the analysis will require strict
criteria for screening. The likelihood that a germline mutation is present in one
of the genes is simply derived from the family history that should have been
verified.22
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The very large Cancer and Steroid Hormone (CASH) model study, in the USA,
was a population based, case-control study that estimated the proportion of
breast and ovarian cancer cases in the general population that were likely to
be attributable to mutations in breast/ovarian cancer genes. In the general pop-
ulation, it generated estimates of approximately 10% of ovarian cancer cases and
7% of breast cancer cases as being in carriers of a breast/ovarian cancer suscept-
ibility gene.23, 24
There are several clues to raise the suspicion that an individual may be carrying
a mutation in one of BRCA genes, for example: early age onset of breast cancer,
bilateral disease, history of both breast and ovarian cancers in the family with
several cases of breast and/ or ovarian cancers, the presence of male breast can-
cer and Ashkenazi Jewish background (because certain inherited mutations in
both BRCA1 and BRCA2 occur with high frequencies in this population group18).
The Breast Cancer Linkage Consortium25 found that overall some 52% of fam-
ilies with at least four cases of breast cancer are linked to BRCA1; 32% linked
to BRCA2 and 16% to neither gene. The majority of the breast-ovarian families
were attributed to BRCA1 mutations (81%) and most of the others due to BRCA2
(14%) while the majority of families with female and male breast cancers were
due to BRCA2 (76%).18
Tumours in BRCA1 mutation carriers have some distinct features that charac-
terise their disease aggressiveness. They are mostly aneuploid, with a hyper-
diploid DNA index and high S-phase fraction, indicating rapid proliferation.
Those tumours tend to be of high nuclear grade and also have a deficit of DCIS
(ductal carcinoma in situ) around the invasive tumour and tend to show signific-
ant lymphocytic infiltration, yet may metastasise to distant sites before regional
lymph nodes are involved. They are almost invariably oestrogen receptor and
progesterone receptor negative. BRCA2 tumours may show similar features but
to a lesser degree and, in general are pathologically more heterogeneous.26
The medullary or atypical medullary carcinoma types are found more frequently
in BRCA1 than in BRCA2 mutation carriers. The review of pathological find-
ings from breast cancer families (though some of these cases are almost cer-
tainly sporadic) in the Breast Cancer Linkage Consortium study suggests that
the cancers due to BRCA1 mutations have a different natural history when com-
pared to BRCA2-related and sporadic cancer cases, with potentially different
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implications for the management of the disease as well as for the surveillance
programmes.25–27
Sporadic cancers (not inherited) are defined as the remaining cancers that are
not due to “high penetrance” defects in genes such as BRCA1 or 2, though they
may include cancers with genetic “low penetrance” defects.28 Penetrance in this
context is defined as the probability of disease development in individuals who
carry a mutation in a breast cancer predisposing gene.
Other genes linked to breast cancer have since been discovered and further
searches for “BRCA3” are under way as there is a strong possibility that it ac-
counts for other forms of familial breast cancer.29 There are several familial syn-
dromes associated with breast cancer, as illustrated in Table 1.3.
The fundamental cause of breast cancer is still unknown: prevention is still not
possible and further research is currently being carried out to enable better un-
derstanding of the disease process and pathways that may lead ultimately to
prevention. The currently available dietary or pharmacological forms of inter-
vention may reduce the risk of breast cancer but total prevention will only be
possible when full understanding of the disease process is achieved.
1.3 A short history of “breast cancer family history”
clinics
From the late 1980s, there has been growing recognition of the need to identify
women at increased risk and to offer them close surveillance. As indicated
above, there is evidence that most high penetrance inherited breast cancer is
characterised by early onset of the disease, so that only a few families will have
a predisposition to later onset disease.
Breast cancer genetics clinics were introduced with the purpose of identifying
those at increased risk and referring them to breast specialists for regular surveil-
lance.32, 33 Such programmes have been widely adopted but many have evolved
from research projects and service provision in the UK was not structured, from
the outset, in a uniform way. On a Europe-wide scale, provision has been even
more diverse.34
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Table 1.3: Common familial syndromes associated with breast cancer22, 30, 31
Syndrome Features
Li-Fraumeni Classically composed of early onset breast cancer; soft
tissue sarcomas in childhood, acute leukaemias, brain
tumours and carcinoma of the adrenal gland. Gene in-
volved: TP53. Autosomal dominant syndrome; multiple
primary tumours characteristic. Li-Fraumeni-like syn-
drome sometimes involving CHEK2 gene.
Gorlin Multiple naevoid basal cell carcinomas; dental and bone
cysts and other skeletal malformations. Mental retarda-
tion can also be found; possible excess of ovarian cancers
and increased frequency of breast cancer. There is also an
increased risk of medulloblastoma / astrocytomas. Auto-
somal dominant; gene PTCH mapped to 9q22-31.
Site-Specific breast
cancer
Males are occasionally affected and no excess of cancers
other than breast is noted. Autosomal dominant: gene in-
volved: BRCA1 and BRCA2. (Same genes implicated in
familial breast/ovarian cancer. Absence of ovarian cases
in some families unexplained: may simply be chance)
Cowden disease Multiple hamartomas of skin and oral mucosa. Other or-
gans are also affected by adenomas mainly: thyroid, GI
tract and CNS. Palmar pits are noted. Autosomal dom-
inant. Breast cancer in up to 50% of women affected and
thyroid cancer in 10%. Gene involved: PTEN on chromo-
some 10.
Peutz-Jegher Syndrome characterized by hyperpigmentation, mainly
in and around the mouth; multiple polyps in the small
intestine and some excess of colorectal and other cancers
(includes breast and ovarian cancers). Gene involved:
STK11 mapped to chromosome 19p. Autosomal domin-
ant.
Ataxia Telangiectasia Syndrome characterized by progressive cerebellar ataxia,
telangiectasia mainly of the conjuntiva, immunological
defects. Increased risk of other malignancies, typically
leukaemias. Autosomal recessive syndrome, gene ATM
on chromosome 11q. Female heterozygotes may have in-
creased risk of breast cancer.
Muir-Torre syndrome Skin lesions (sebaceous adenomas and keratoachanth-
omas) are associated with colorectal, laryngeal or duo-
denal cancers. There is some excess of breast, ovarian
bladder and uterine cancers, Gene involved: MSH2,
MLH1. Autosomal dominant. Overlap with other RER
(replication error repair) gene syndromes.
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There is a great need to evaluate the different models and to establish an evid-
ence base on which to make recommendations for the most acceptable and cost-
effective protocols for ascertainment and management of women at high risk
of breast cancer. This need was spelled out in the 1996 Report of the Working
Group on Genetics and Cancer35 that presented the first national (UK) recom-
mendations for the scope and organisation of the services for breast (and other)
cancer families.
Data are therefore being collected to provide an evidence base for the kind of
surveillance or intervention that should be offered, the levels of familial risk
that justify such surveillance/intervention and the ages at which programmes
should be initiated and discontinued. The present study is a contribution to
these ends.
In the UK, breast cancer genetics clinics were introduced in the late 1980s.32, 33
Manchester was the first centre to introduce a structured clinic for the identific-
ation of patients at risk and provision of a surveillance programme. However,
in Dundee, a breast clinic had been set up by Professor Sir Alfred Cuschieri and
Mr Robert Wood as early as 1977.
Data on family history of breast cancer were collected prospectively on each
patient attending the Tayside breast service for any reason and those recording
a positive family history were kept on regular surveillance thereafter, even if the
original reason for referral was satisfactorily dealt with.
It is important to highlight that at this point there was no input from genetics col-
leagues in evaluating the level of risk for each individual with a family history
of breast cancer and therefore, in many instances, the reported family history
would not satisfy criteria currently used by geneticists for assessing patients’
individual risks.
Nevertheless these surgeons were true pioneers in the field as for over 17 years
women were kept on regular surveillance based on the limited information about
their family history given at the original (symptomatic) consultation. With hind-
sight, of course, resources available at that time were not accurately targeted and
doubtless there was some unnecessary exposure of well women to procedures
that could lead to complications.
In 1994, Mr Paul Preece, in association with Prof Michael Steel, geneticist from
St. Andrews University and Dr David Goudie geneticist at Ninewells Hospital,
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introduced the first structured joint family history clinic in Tayside. The aim of
the clinic was to investigate the patients with a family history of breast cancer
who had been on regular follow up since 1977 (accounting for approximately
half of all attendees), as well as new referrals, and to assess their actual risk for
inherited breast cancer using new predictive models.23, 24, 36
With increasing awareness of the importance of family history in determining
individual risk for breast cancer, the number of new referrals escalated, with a
few patients initiating the referrals themselves or patients being advised by a
clinician to seek guidance on the management of familial breast cancer. As a
result, a long waiting list developed rapidly for patients to be seen at the clinic.
In 2000, Eccles et al.,37 on behalf of the UK Cancer Family Study Group, recom-
mended, in line with the 1996 Working Group Report, that women referred to
those clinics but thought not to be at substantially increased risk for breast cancer
could in fact be seen by GPs and reassured of their “low” risk status, while only
“high risk” women should be seen by geneticists. In this context the term “low
risk” is based on categories also defined in other widely adopted guidelines (e.g.
SIGN 199838 and more recently, NICE 200439). It refers to women whose family
history places them at lifetime risk for breast cancer estimated at less than 1.7
times that of the general female population. Such women are not considered to
require special counselling nor clinical/mammographic screening, beyond that
provided by the National Breast Screening Programme from the age 50 years.
The 1996 Working Group did, however, emphasise the need for these women
“to receive accurate risk information in a sensitive and supportive manner”.
Of course, implementation of selection and reassurance at Primary Care level
would require the GPs to be knowledgeable in cancer genetics and able to un-
dertake full assessment of the patient’s risk. However, by this time, evidence
was beginning to accrue – and has subsequently become overwhelming - that
GPs felt insecure in their “gatekeeper/counsellor” role and that a high propor-
tion of onward referrals to specialist services were of women whose genetic risk
fell below the guideline “threshold” for enrolment in surveillance/intervention
programmes.40–47
In the face of the growing demand and the apparent impracticability of “first
stage” screening at Primary Care level, a need for some reorganisation of the
Tayside clinic was recognised and in 1999, funds were granted by the Scot-
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tish Executive (CSO) to examine the feasibility, acceptability and efficacy of a
“postal” means of establishing which referral patients were in fact at low risk,
then reassuring them of that without the need for a formal clinic appointment.
This would free up clinic time and personnel so that “moderate” and “high risk”
women could be seen more promptly and have their surveillance programme
discussed and initiated.
That the issues faced in Tayside were not unique to that centre was shown in a
UK- wide study, to which Tayside contributed, of clinical provision for women
at increased genetic risk of breast cancer.45
In general, regular surveillance in UK clinics is offered until age 50 years (genetic
risks by then will have declined) and thereafter participation in the National
Breast Screening Programme is encouraged. However, some of the women will
still have significantly increased risk beyond age 50 years, perhaps justifying
alternation of cancer family clinic surveillance with the National Breast Screen-
ing Programme (i.e. an 18 monthly screening schedule), though practice in this
regard is not uniform across the UK.
Tayside also participated in a programme that ran in parallel with the Breast
Cancer Linkage Consortium, in which several European countries gathered and
shared essential information on the provision and evaluation of services for wo-
men at risk of familial breast cancer. This was the 1996-1999 BIOMED 2 Demon-
stration Programme on Clinical Services for Inherited Breast Cancer, funded by
the European Commission and co-ordinated from Scotland.
After collection of data from ongoing collaborative prospective studies, the Demon-
stration Programme reported on the outcome of early diagnosis and treatment
of inherited breast cancer as measured by screen detection and interval cancer
rates, stage and survival after diagnosis. Consensus recommendations for close
surveillance of the women at “high risk” were offered, based on the findings
of this programme, which still continues as an informal collaboration. This is
discussed more fully in later sections.
The high risk women should be offered genetic counselling, education in breast
self examination (breast awareness) and regular annual mammography as well
as regular breast examination by a breast specialist from around the age of 30
years or five years before the youngest case onset in the family.
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From the age of 50 years, mammography would be performed every second
year for those still at significant risk or at eighteen monthly intervals, alternating
with a local population-based breast screening programme. It was also sugges-
ted that BRCA1 mutation carrier patients may benefit from even more frequent
examinations and that their cancer risk could be reduced further if they under-
went prophylactic oophorectomy at around 40 years of age.
There are still some controversies, for example, in relation to frequency and
mode of screening and the role of prophylactic mastectomy for BRCA1 mutation
carriers since, as discussed later, the most recent data from the European collab-
oration confirm earlier suspicion that these patients fare poorly (compared to
BRCA2 mutation carriers or those with no demonstrable mutation) even when
tumours are screen-detected and at an apparently early stage.48–50 The effects of
all such interventions need to be well documented so that management strategies
can be matched more accurately to individual estimates of risk.51
Screening the general population before age 50 years is unlikely to be cost-
effective and the reason behind it is that the pick-up rate of early breast can-
cers would fall below the normal target of 6 per 1000 investigations. The pre-
sumption is that this would not apply to a highly selected group such as the
“high/moderate” risk women.22
The increase in demand for genetic services is probably a reflection of women’s
concerns about familial breast and/or ovarian cancers in view of a media release
of scientific information with, as a result, an incomplete understanding of the in-
terventions available as well as poor understanding of genetic testing as pointed
out by Nelson and colleagues.52
Health care organisations are responsible for both management and delivery of
healthcare to a population, meeting its needs in the best possible way under the
current constrains of resource allocations. Priority setting has been part of this
process, in view of the need to make choices on funding of services, known in
the UK as “commissioning of services”.53
Political and/or historical patterns influence centralised resource allocation, which
may contribute to sub-optimal use of the scarce resources.54
In order to set priorities in a health care system, as described by Mitton and
Donaldson,53 at least two key economic principles should be applied: one is
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opportunity cost (defined as “the health benefits lost because the next-best altern-
ative was not selected”55). In other words, it compares the relative (financial)
benefits of alternative strategies. The second one is margin, which essentially
means the difference between incremental cost of a new drug or procedure and
the incremental gain (again in cost terms) to the health care system. Both are rel-
evant to measuring the costs and benefits of a given intervention or task. They
should help decision-makers to balance the costs and benefits of any proposed
changes by placing a “price tag” on any proposed “shift or change in the re-
source mix”.53 The price tags attached to all proposed innovations can then be
considered along with their potential health benefits in setting priorities for the
allocation of limited resources within the NHS, or any other health care system.
In principle, this should allow a fair assessment of the competing claims of such
diverse objectives as increasing numbers of community midwives or provision
of a new MRI scanner for a given population.
One of the approaches used in priority setting is called “Programme Budgeting
and Marginal Analysis” (PBMA). It uses an advisory panel in charge of identi-
fying areas of service growth and areas of resource release (“cut back”) in order
to fund the proposed growth within a given budget.56 Over recent years it has
gained a lot of credibility in the transparency of priority setting processes.
Choices in most areas of health care have become much more extensive in recent
years. Cancer prevention, and specifically provision of cancer genetics services,
illustrate this very clearly. As discussed earlier, there is a widely perceived need
to develop high quality cancer genetics services and to get those services in-
tegrated into the healthcare systems.57 Health economic evaluation of cancer
genetics services should address issues of costs and benefits of the services to
the community. They cannot simply be provided uncritically in response to de-
mand.
Existing guidelines, outlined above and discussed in detail in later chapters,
provide a starting point. However, the scale of service provision is in constant
change and this needs to be reviewed regularly so that, if there is a benefit from
a given service with efficient use of resources, expansion of service provision
can be considered. This would imply constant re-evaluation of health economic
issues.
With the existing gap between what the NHS can provide (with current levels
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of funding) and what it could provide if more resources were available; priority
setting is paramount to enable quality of care for all, as quoted by Professor
Peter Baylis on behalf of the Royal College of Physicians Working Party58 on the
prescribing of costly medicines.
The demand for access to genetics services has exceeded their availability and,
as a result, the NHS had to set priorities to achieve equity of healthcare provision
within this field. Rationing is one of the key options available to the government
when dealing with NHS budgets. Cost of treatment is clearly a necessary con-
sideration when resources are limited.
Since the early 1990s, there has been an increase in reforming health care pro-
grammes in many European Countries and in the United States in view of the
need to restrict costs “as there are fears that health services that are publicly
funded may be inundated by demands for services that could be both inappro-
priate and excessive”.59 The NHS services in the UK have been affected in the
same way, as Elliot and Popay59 have described in their study looking at how
policy makers apply evidence in the NHS. Many of the service reforms in this
country coincided with further interest in evidence-based practice.
Decision-making processes should be based on the best evidence of practice
currently available. Priority setting in health expenditure should be based on
research evidence looking at differences between interventions, in terms of ef-
fectiveness, in order to make a service more responsive to the users.59 These
authors were concerned with how policy makers used research that was con-
sidered by them to be relevant to their own work. One of their case studies of
interest to this thesis looked at an initiative to incorporate existing knowledge
into guidelines for best practice for both commissioners and health providers
using decision analysis, but also monitoring the influence of those guidelines
on decision-making processes. There was a move to create techniques for im-
provement of decision-making and, as a result, to promote dialogue between
purchasers and health care providers. The authors also reported the monitor-
ing and evaluation of a service’s effectiveness. Agreed outcome measures were
used in this exercise as one of the aims was to develop a model of setting and
monitoring outcomes. One of their findings was that research could clarify and
contribute to the decision-making process but was not there to provide answers
to all questions posed. Research was just one of the many sources of informa-
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tion used by policy makers during the process of decision-making, together with
constrains on budget, national and local policy guidance. With the introduction
of clinical governance and risk management in health care, there has been a
drive for services to provide a standard of care that is transparent, sensitive and
based on evidence of good effective practice. Risk management is an essential
element, with the objective of assessment and reduction of risks or harms to the
patient and staff involved in the delivery of given services.
Standards of service provision have been drawn up by the NHS and regular
visits to each service are undertaken to evaluate how the local services are meet-
ing all criteria set and to make sure that appropriate policies and procedures
are being implemented. As a result, continuous quality improvement should be
achieved, ensuring that effective operational frameworks are in place.60
1.4 Purpose and content of the work presented in
this thesis
The purpose of the linked series of studies reported in this thesis is to evaluate
the cost-effectiveness of current provision of risk assessment and surveillance
for women who may be at increased genetic risk of breast cancer and hence to
provide a constructive review of the current guidelines for management of fa-
milial breast cancer. The approaches taken include a randomised trial of “postal”
risk assessment, an investigation of costs involved in the clinical service, plus
measures of the detection rate for breast cancers and the clinical stage and out-
come of these cancers, compared to an age-matched cohort of patients who had
not been enrolled in any surveillance programme. They also incorporate stud-
ies designed to measure directly age-specific breast and ovarian cancer risks for
women assigned to the “low risk” category on the basis of their family histories.
The work has involved:
1. Investigating the accuracy of risk assignment for women referred to the
breast cancer family clinic, in relation to the effort expended in verifying
and extending reported family histories: evaluating the economic and psy-
chological implications of rigorous implementation of guidelines exclud-
ing “low risk” women from access to special surveillance.
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2. Undertaking and documenting diagnostic procedures (clinical examina-
tion, standard mammography, extra mammographic views, ultrasound of
the breast, FNA, core biopsies, open biopsies) for women in the familial
surveillance programme and investigating the costs associated with these
procedures.
3. Sharing data with colleagues from other European Centres on follow-up
of patients enrolled in the surveillance programme and in whom breast
cancer was subsequently diagnosed, in order to establish whether the aim
of early detection was being achieved and to evaluate its efficacy in terms
of reduced morbidity and mortality.
4. Sharing data with the same colleagues on the short- and long-term out-
come of prophylactic mastectomy in women at high genetic risk of breast
cancer.
5. Comparing the outcome (and associated costs) of breast cancer in young
women (under 50 years of age) diagnosed at stage I (small tumours, node
negative) or in later stages (bigger tumours, node positive) to assess the
potential cost savings achievable through early detection of cancer (i.e.
through “stage-shift”).
6. Expanding through a Scotland-wide retrospective study, a Tayside pilot
study of breast and ovarian cancer incidence in women referred to cancer
family clinics, whose familial risk did not, according to current guidelines,
place them in a high enough risk category for inclusion in surveillance
programme – i.e. testing validity of the “threshold” specified in the current
guidelines.
The work of Nelson and colleagues52 was based on an analytical framework
looking at interventions and, health outcomes of a population seeking advice
on the issues of inherited breast and ovarian cancer risk. They have addressed
several key questions that arise along the path followed by a woman with a
family history of breast or ovarian cancer.
With this in mind, I have designed a similar analytical framework to address
specifically the issues related to interventions available for those at increased
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risk for the disease and also to evaluate the current guidelines for those services
in this country (see Figure 1.1).
The series of 7 key questions in the framework are addressed through real ‘hard’
data from the Tayside familial breast cancer clinic and observational studies car-
ried out during the course of my work, rather than the hypothetical approach
adopted by Nelson’s group.52
While the work I am reporting has involved many individuals and groups, I
have personally taken either the lead or a substantial contributory role in all the
above elements. The analysis of clinical implications and future directions is my
own.
Are we managing the demand for genetic services well with the current avail-
able resources and provision of services facilities? Ideally, we should concen-
trate the efforts of regular screening for women at significant familial risk for
breast and ovarian cancer, selecting carefully who should benefit most from reg-
ular screening at the specialist genetic clinics. For the high genetic risk group
resources should be allocated to offer them genetic testing and risk reducing
procedures in addition to regular screening. In other words, it would be import-
ant to demonstrate whether the provision of those services can produce benefits
to justify the costs and not simply responding to the demand for the this type of
service provision.
In an ideal setting, familial breast cancer genetic clinics should be evaluated
by randomisation (i.e. randomise to get or not to get counselling and regular
screening) but this would be ethically unacceptable and therefore follow-up ob-
servation analysis of patients has been used.
It has emerged from assessment of familial ovarian cancer services (by a similar
process of follow-up and observation) that clinics for regular screening of wo-
men at significant genetic risk for the disease have not achieved their primary
objective as they fail to detect cancers at early stages of the disease.61 Conversely,
in the case of breast cancer surveillance, there are indications that regular screen-
ing programmes for women at significant genetic risk for the disease can be ef-
fective in the detection of cancers in early stages and that the patients do well
as a result of it. This is obviously a crucial issue and is the principal theme of
Chapter 5.
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Figure 1.1: Analytical framework
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While this encouraging conclusion seems to apply to the great majority of wo-
men with a family history of breast cancer, different considerations may apply
to BRCA1 mutation carriers. Specifically, they may benefit less from regular sur-
veillance so for them more effective interventions need to be examined. These
may include prophylactic salpingo-oophorectomy, bilateral mastectomy or both
as discussed in detail in Chapter 5.
MRI (magnetic resonance imaging) screening for those women may be more be-
neficial than mammographic and clinical surveillance but long-term evaluation
of results will be required and is outside the scope of this thesis.
UK services concentrate on applying strict risk assessment criteria selecting those
at “moderate” and “high” risk for regular surveillance but is the definition of
‘moderate’ risk valid? The Australian guidelines62 define any breast cancer risk
higher than normal population level as “moderate” risk, but they limit provision
of surveillance to those at “high” risk so extending the definition of ‘moderate’
risk carries no cost implications. In the UK, to offer surveillance for women be-
low the current risk ‘threshold’ could be expensive. The question then is what is
the most cost-effective ‘cut-off’ level? That is the theme of Chapter 6.
These are some of the issues addressed in this thesis. Several will, require longer-
term evaluation and further analysis which hopefully will be forthcoming through
other work of this kind. Within this thesis, I am keen to identify areas that will
provide enough evidence for review of the currently available guidelines. As I
hope to demonstrate, genetic services, as currently organised within the NHS,
can generate reasonably accurate measures of breast cancer risk, based on fam-
ily history. They can also facilitate design, implementation and evaluation of
preventive programmes aiming at the saving of both life and public money.
Chapter 2
Literature review
The literature review has been based on PUBMED search using the following
terms:
“Cost effectiveness familial breast cancer clinics”; “familial breast cancer clin-
ics”; “familial breast cancer follow-up clinics”; “ management of familial breast
cancer”, “policy framework for cancer genetic services in the UK”, “priority set-
ting in health care” as well as by other relevant key words and individual re-
searcher names with relevant linked papers.
2.1 Ascertainment of risk; guidelines and their
implementation
Cancer genetics referrals have been on the increase in line with expanding know-
ledge of genes that can be linked to breast cancer and other cancers.34, 63 Selection
criteria have been proposed, aiming at considerable reduction of inappropriate
referrals by means of a ‘filtering’ system, retaining the ones most likely to benefit
from preventive interventions.64
The need to identify individuals who are genuinely at risk for breast cancer has
led to creation of multidisciplinary clinics, mainly on an ad hoc basis, with re-
search funds. These clinics aim to counsel those at increased risk of cancer and
to offer risk management to reduce mortality and morbidity.
19
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However, the NHS is gradually incorporating these research-based clinics into
new regular service provision; hence the continuing requirement for education
and referral guidelines for primary care to identify individuals who require de-
tailed assessment of their risk. There is a lack of consensus on how the cancer
genetic services should be delivered and consequently there is a need for evid-
ence to inform the developing service.65
The principal activities of such services embrace clinical care (remembering that
most of the individuals seen in those clinics are healthy), registers of genetic
conditions that will identify individuals at increased risk for the condition, edu-
cation of both post- and under-graduates, research and audit.
Clinical genetics services deal with referrals of individuals seeking advice for
a given condition, (in our case, breast and/or ovarian cancer) and certainly
involve a considerable amount of time in the collation of information needed
for individualised risk assessment, drawing of family pedigree and, of course,
providing clinic consultation with those likely to benefit. The time taken to ob-
tain all the necessary information should be considered by the services commis-
sion workforce and will be reflected in the costing exercise.
Policy makers and general practitioners have different views on definition of the
role of GPs in implementing the so called “New Genetics” creating some tension
between the two parts.66 Transformation of the current practice to include new
specialised roles and skills, including some level of genetic service provision
within primary care, is seen by some as an answer to increasing public demand
for genetic counselling.
Historically, regional health authorities were in charge of commissioning genetic
services. However, this responsibility was devolved back to individual health
authorities, meaning that commissioning of those services would be competit-
ive, in terms of services purchasing decisions, between acute and local services.64
The practical remit of cancer genetics services is set by guidelines for risk assess-
ment, commonly based on the number of affected relatives, age at diagnosis and
closeness of relationship.67–69
A “close relative” means a parent, sister, brother, son or daughter, grand-parent,
aunt, uncle, nephew or niece.38 These criteria are virtually identical to those
applied in England and Wales before publication of the NICE guidelines:39 but
see Table 2.2.
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Table 2.1: Criteria for identification of patients for specialist genetic services that
may indicate a moderate or high risk of inherited breast/ ovarian cancer in Scot-
land38
Breast Three or more relatives diagnosed at any age
Two close relatives diagnosed under 60 years of age
Mother or sister diagnosed under 40 years of age
Father or brother with breast cancer diagnosed at
any age
One close relative with bilateral breast cancer dia-
gnosed at any age
Breast / Ovarian One close relative diagnosed with ovarian cancer at
any age and at least two close relatives diagnosed
with breast cancer under 60 years of age
One close relative diagnosed with ovarian cancer at
any age and at least one close relative diagnosed
with breast cancer under 50 years of age
One close relative diagnosed with breast and
ovarian cancer at any age
Ovarian Two or more close relatives diagnosed with ovarian
cancer at any age
Very precise risk assessment is not expected to be calculated in primary or sec-
ondary care settings but the health professionals should be able to utilise the
simplified criteria in Tables 2.1 and 2.2 to allocate women to “low”, “moderate”
or “high” risk categories.
In 1999, NICE (National Institute for Clinical Excellence) was created, setting
priorities in healthcare, appraising clinical and cost effectiveness of health tech-
nologies that the Department of Health have referred for assessment and mak-
ing recommendations that are mandatory guidance to the NHS regarding what
should be made available to patients (this also includes new drugs). The authors
of the NICE guidelines39, 70 for the care of women at risk for breast cancer rightly
commented that the designation as “low risk” (cancer risk less than 1.7 times
greater than general population and less than 3% by age 50) could be some-
what misleading as those women still have a risk above the population level
and might perhaps be led to believe that they will never develop breast cancer.
NICE guidelines for the assessment of familial breast cancer also recognised the
paucity of solid evidence on which to base criteria for entry to counselling and
surveillance programmes, stating that “validation of risk assessment models is
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needed urgently”.
There are some differences between the referral criteria still used in Scotland
and those recommended by NICE. Notably, according to NICE, women with
two or more close relatives diagnosed at any age would be at “moderate” risk. In
addition, the “high” risk category specified by NICE is slightly broader, imply-
ing that more women would be eligible for molecular genetic testing. Table 2.2
shows the more recent criteria for designation of women as being at “moderate”
or greater risk for breast cancer, according to NICE guidelines.
Table 2.2: NICE guidelines criteria for referral of women likely to be at ‘mod-
erate’ or greater risk, meriting referral from primary care to secondary care in
England and Wales
Breast cancer in fe-
males
One first-degree female relative diagnosed with
breast cancer at younger than age 40 years
Two or more first or second-degree relatives with
breast cancer diagnosed at any age (if only two af-
fected, one must be first degree)
Male breast cancer One first-degree male relative with breast cancer
diagnosed at any age
Bilateral breast can-
cer
One first-degree relative with first primary tumour
diagnosed before age 50 (for bilateral breast cancer,
each breast has the same count as one relative)
Breast and ovarian
cancer
One first or second-degree relative with ovarian
cancer at any age and one first or second-degree re-
lative with breast cancer diagnosed at any age (one
of the above should be a first-degree relative)
A referral would require at least one of the above criteria.
Ten per cent of women diagnosed with breast cancer report having a positive
family history of the disease71 and by no means all of these are at increased
genetic risk, hence the need for explicit risk evaluation algorithms.
On the other hand, a proportion of women with affected relatives will belong
to families with mutations in dominant predisposition genes including BRCA1
and BRCA2, which are thought to be related to about 5% of all breast cancer
cases. Mutation-carriers are also at increased risk of other cancers (particularly
ovarian) and it is estimated that their overall lifetime risk for cancer will be 3–8
times the population risk.
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In the absence of known mutation status, familial risk will be substantially in-
creased if the first-degree relative was affected at a very early age and /or had
bilateral breast carcinoma. “Moderate risk” women will have a risk estimate for
the disease of 2 to 3 times the normal population level.72
The first document recommending a strategy for the delivery of breast cancer ge-
netic services in England was produced by a Working Group for the Chief Med-
ical Officer,35 chaired by Professor Harper, and was based on a three-tier model
(primary care, cancer unit and specialist cancer genetics centre). Gene testing
should only be offered by specialist cancer genetics clinics and undertaken after
appropriate information and genetic counselling have been delivered and with
specific consent.
If an unaffected individual has received a negative predictive test result, (that
is, the individual does not carry a genetic mutation which was identified in her
family) the risk of developing inherited breast cancer will be considered to be
essentially zero and surveillance programme will no longer be required for the
individual. Her risk will fall into the normal population range that is related
to age and she will be invited to participate in the National Breast Screening
Programme from age of 50 years.
As detailed in Section 2.2, in conformity with the Working Group Report, for
England, it has been recommended that only “high risk” families should be as-
sessed through specialist genetic services.34, 73 Those judged to be at “moderate”
risk are to be referred to regional breast units for enrolment in surveillance pro-
grammes.
Scotland, however, follows a two-tier, rather than three-tier system, all referrals
judged to be above “low risk” level (i.e. both “moderate” and “high risk” cat-
egories) being seen at the regional genetics centre en route to enrolment in a
clinical surveillance programme. This reflects the structure of specialist services
in Scotland where the populations served by regional breast units and regional
genetics centres are virtually identical.
A review of currently available services in England in 2001 indicates that sev-
eral aspects of the model suggested in the Working Group Report were still not
fully implemented as there was considerable variation in workloads and waiting
times across regions; some did not have the three-tier or indeed any structured
model in place.45 This is discussed more fully in section 2.2.
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To date, no clinic policy has been established for low risk breast cancer patients
who account for 25-40% of referrals to most specialist breast cancer genetics clin-
ics.45
It is assumed that those patients will be “screened out” by primary care though,
as pointed out earlier (page 9) experience shows that this does not happen and
many reports now record GP’s disquiet with their “gatekeeper” role in this situ-
ation and a need for clear guidelines for referrals and specialist community sup-
port identifying a model that facilitates the involvement of GPs but without in-
crease of their workload.40, 74
2.2 Structure of clinical services for familial breast
cancer in the UK
Cancer Genetics services for England and Wales should be organised in a three-
tier structure, according to the Working Group Report. Primary care doctors
would reassure individuals at normal population risk. Cancer units would provide
risk assessment and screening for those at moderately increased risk.
Specialist Genetics Centres would see only those patients who are potentially
at high genetic risk, for risk assessment, confirmation and extension of family
history, detailed genetic counselling about their risks (and perhaps those of other
family members) with provision of information relating to genetic aspects of
cancer and above all, how this would be communicated to them.
Discussion of options for intervention to reduce the threat of breast cancer would
also include the implications of molecular genetic testing for those at “high” risk.
Support is needed for referred women all the way through the process of risk as-
sessment and counselling by the specialist genetic centres.
Any living affected relative willing to give a blood sample for genetic testing
could be identified and contacted. From the counselling point of view, it is also
important to identify individuals who, as a result of an underlying mental health
problem, might not benefit from genetic testing and those who may need to
be seen at a specialist psychological service because of the actual or potential
impact of test results.
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Specialist genetics services would be linked to the specialist cancer centres, each
serving a population of 1–2 million and would ideally have a consultant trained
in both oncology and genetics with the support of nurse specialists, to deal with
high risk individuals.
In England and Wales, except for women who can give a clear account of a “high
risk” family history, the model used for evaluation of genetic risk, relies strongly
on GPs and surgeons in Regional Breast units.
In Scotland, as noted, a different model was proposed, (with no second tier). Re-
gional genetic services would support the surveillance units and primary care by
providing genetic counselling both centrally and in outreach clinics.72 In North-
ern Ireland the service is based on the Calman-Hine three-tier scheme but is
developing centralised referral mechanisms similar to Scotland.75
David Wonderling and colleagues45 described the cancer genetics services in
the UK in a 1998 survey of 22 regional cancer genetic services recording how
they are delivered in different regions. There is a wide variation among the
regions of the UK in provision of services, with referral rates being higher in
centres providing mammography directly and 75% higher in those centres with
a dedicated cancer genetics consultant. There was no significant difference in
waiting times between high risk and “population risk” patients. The use of
questionnaire-based referral “filtering” and the availability of a specialist can-
cer clinic did not appear to affect waiting times. Follow up rates depended on
screening strategies.
In the same survey,45 the Scottish centres interpreted referral criteria less restrict-
ively and, partly because of this, had almost twice as many referrals and con-
sultations per million of population as the rest of the UK. The Scottish centres
reported that genetic testing was only available for research purposes (though
this has since changed). A genetic test would only be discussed with 10% of the
individuals at moderate risk or above, compared with 73% for the rest of the UK.
There was no difference between centres in screening recommendations. The ex-
tent of relevant genetic risk information passed on to family members who may
be at risk was not known and it was found that only 35% of women mentioned
that one of the reasons for attending the clinic was to find out about the risk for
other family members.
Overall, the survey concluded that Scotland was closer to meeting the structure
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of their service model than the rest of the UK and that there were few family
history clinics outside the regional genetics services.
The findings showed that the genetic services in Scotland have more attendees
than in England and proportionally more patients at both moderate and at pop-
ulation-level risk, making the model more comprehensive but potentially more
expensive than the one proposed by the Working Group report where population-
level risk patients are (at least in theory) dealt with in the primary care setting
and those at moderate risk in the Regional Cancer Unit.
A more recent study by Holloway and colleagues76 evaluated a new mechanism
for the delivery of cancer genetic services in South East Scotland by means of
a trial which compared community-based service, provided by a genetic nurse
specialist assessing patient’s cancer risks in Primary Care premises, with a “con-
ventional” joint genetics/breast surgeon clinic in a regional centre.
Patients and GPs expressed no clear preference for the type of clinic or ser-
vice location (this means that there was no preference for either regional clinic,
which was hospital based, or for a “community” clinic that was near the pa-
tient’s home). Most of the “low risk” women assessed were less satisfied with
the service received than higher risk patients, because the former would have
liked to have access to other services (they wanted reassurance that they did not
have cancer and they perceived mammography and regular clinical check ups
as the means to achieve this).
Consultation time was greater in the community-based clinic, mainly because of
the time taken by the nurse specialist to document the patient’s family history
but it could also be due to a more relaxed atmosphere between the patient and
the nurse, with the result that the patient felt she could talk more openly to the
nurse, than to a doctor (“reluctance to take the doctor’s time”).
In essence, establishment of a genetic cancer service within GP locality areas led
to significantly increased rates of referrals but not measurable improvement in
the patient’s outcome.47
Fry and colleagues77 showed that the novel community-based model of deliv-
ering breast cancer genetics services, described above, was comparable to the
standard regional service when psychological outcomes were measured and that
perceptions of women’s risk for breast cancer were altered during the course of
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the study (assessing both the community-based and the conventional regional
services in South East Scotland).
Two separate studies in the UK40, 46 showed that there is a need for primary care
to be involved in the selection process of patients at risk to enable appropriate
referral to the specialist clinics. The GPs in South East Scotland, identified their
role in the cancer genetics services as provision of appropriate referrals after tak-
ing a family history from patients and giving general information on screening,
breast self-examination and emotional support. However, they felt that it was
not their role to calculate the patient’s cancer risk and admitted lack of confid-
ence in delivering genetic advice. They asked for clear guidelines for referring
patients.40 Genetic nurse specialists can support GPs, providing counselling and
follow up in “locality practice” clinics.
The Welsh genetics service has taken a particular interest in the cost-effective
organisation of cancer family clinics. Brain and others78 compared the psycho-
logical impact of providing specialist genetic input with surgical consultation
alone, in women at high, moderate and low risk for breast cancer. There was a
significant reduction in cancer risk perception and in worry among women at
low or moderate risk under both management protocols. The high risk patients
remained concerned about cancer and were less satisfied with their consultation
but, again, there was no clear preference for the dual (genetics specialist plus
breast surgeon) approach. This study, however, took “patient satisfaction” as
the principal end point (rather that any longer term measure of clinical effective-
ness) and it was acknowledged that the Welsh breast surgical team had unusual
expertise in breast cancer genetics, unlikely to be shared by breast surgeons in all
centres. In that study, molecular genetic testing for BRCA1 and 2 mutations was
offered to women at “high” risk but for those with no living relative, it was not
possible to offer genetic testing and it was not possible to examine the psycho-
logical impact separately for this group. There was a high level of satisfaction
within the “low” risk category after receiving personal risk information, redu-
cing the levels of anxiety and cancer related concerns. The conclusion was that
the initial assessment of genetic risk could be performed by breast care special-
ists with limited experience in this specific area of genetics, reassuring women at
“low risk” and selecting only the “high risk” women for referral to the specialist
cancer genetics clinics.
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Cancer genetics services in Wales operate a “Triage” system, whereby, on refer-
ral, a family history questionnaire is sent to all patients. If the questionnaire is
not returned, the patients will not be seen at the specialist clinic.79
If the questionnaire is returned, a genetics counsellor contacts the patient by
telephone and calculates her risk category, based on the information received.
“High risk” patients are offered an appointment with the cancer genetic ser-
vice. “Low risk” patients are counselled over the phone and returned to their
GP. “Moderate risk” patients are invited to attend a breast clinic and will be
managed according to the local protocol without further contact with a genetics
specialist.46
In general terms, management of women at moderate or high genetic risk of
breast cancer in virtually all UK centres means that, following their identifica-
tion, they will be enrolled in a close surveillance programme involving regular
follow-up with breast examinations and mammography where appropriate.
Prophylactic surgery will be offered in those cases where a patient has been
found to be a carrier of a specific mutation predisposing to breast cancer. Spe-
cialists from other fields besides genetics will obviously have a role in the man-
agement of mutation carriers, for example in ovarian cancer screening and pro-
phylactic surgery.
If a mutation carrier develops breast cancer, she will be at increased risk of a
second primary carcinoma (in the same or contra-lateral breast). This is estim-
ated at 2% or more per year, compared to an overall “second primary” risk of
0.5–1.0% per year in patients not selected on the basis of family history.80
Mutation-carrier cancer patients are also at increased risk of developing local
recurrence after conservation treatment, particularly if the patient is under the
age of 40.81
It is essential to maintain consistency and cohesion between the genetic services,
cancer units and primary care across the regions and at present it seems more
evident in Scotland than in the rest of the UK.45
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2.3 Evaluation of breast cancer genetics services
Cost effectiveness of breast cancer genetics services currently available across
the UK is being addressed at various levels but, as explained in Chapter 1, these
services evolved in response to demand. Further data are therefore needed to
evaluate them because the continuing increase in number of referrals is gener-
ating a workload stretching the capacity of the NHS, locally and nationally.82–84
This demand for clinical service is likely to be sustained in view of high media
interest in the discovery of breast cancer susceptibility genes and indeed in all
matters relating to both breast cancer and genetics, leading to widespread pub-
lic awareness of molecular genetic testing and possible prevention strategies.65, 85
For the commissioner of health services and, even in the UK, for health insur-
ance companies, there is a need to identify what is relevant to this new evolving
type of service as investment in those services may not have any evident return
(financial or clinical) for years to come.86, 87
In fact, full or even partial economic evaluations of the cancer genetics services
are currently sparse, as demonstrated by a review by Griffith and colleagues,87
in which it was recorded that cost effectiveness of screening young women is
raised by focusing those services upon patients with a family history of cancer,
rather than screening a wider segment of the population. Given the financial
constraints within which the NHS must operate, direct costs and financial be-
nefits are the primary components of cost-effectiveness calculations. Neverthe-
less, Griffiths and colleagues87 recommended that economic evaluation of breast
cancer genetics services in the future should take account of their overall impact
upon the individual, her family and society. In this, they were reiterating the
views of Hall and colleagues.88
Ideally, referrals should focus on individuals at substantially increased risk, for
whom surveillance and genetic testing are justified. Appropriate resources should
be allocated to achieve this, so that women’s choices of intervention can be de-
livered. Health economic evaluation of the currently available breast cancer ge-
netics services must also be based, at least in part, on consideration of the costs
of care for women following a diagnosis of breast or ovarian cancer.89
Several interventions outlined in the flow diagram in Figure 1.1 and specified
below, though provided through genetics services, are not routinely included
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in some current measures of cost-effectiveness90, 91 and there is a need to exam-
ine in some detail current practice in the clinics for a realistic analysis of the
cost-effectiveness of the services available in this country. I have concentrated
on practice in Scotland, which, as explained in Chapter 1, differs from that in
England and Wales. I believe this allows a more complete evaluation of the in-
terventions that can be offered, their costs and benefits.
Interventions that have not been taken fully into account in the health economic
evaluation of genetic services include costs of counselling, molecular testing
for mutation carriers and prophylactic surgery (both mastectomy and salpingo-
oophorectomy which are being carried out in increasing numbers of cases). Those
interventions will need to be included in future analyses of cost-effectiveness of
clinical practice in this field. Findings will become more robust when more uni-
form structured services are in place across the UK for screening or intervention.
Though currently there is only a limited literature in this area, Griffith et al.92
recently presented the results of micro costing of NHS cancer genetic services
in Wales (including counselling and genetic testing protocols). They found that
the costs of providing such services are substantial, particularly in “high risk”
cancer patients, (£2,510–£3,072 per patient). The overall mean cost per patient at
any genetic risk of developing breast or ovarian cancer was between £675 and
£2,909, with labour being the most expensive single element. Their conclusion
endorsed my own view that there is a need for further analysis of different pro-
tocols, in terms of both costs and outcomes, in view of the wide variation in
services, facilities and regional protocols in the UK.
Economic analyses are used to evaluate the intervention and assess the poten-
tial benefits of a given service (in other words, the value for money of a given
healthcare intervention or technology) to make the most efficient use of limited
resources. The principles of health economics, outlined in section 2.7, are ap-
plied to evaluate new methods of intervention. The outcome measures can be
expressed in a number of ways, including the cost per life-year saved, number of
adverse events reduced, the quality of life achieved and avoidance of healthcare
costs incurred under alternative management protocols.
When compared to other government expenditures, costs in the area of health-
care are growing rapidly and this raises serious concerns.93 The introduction
of new technologies—not only related to pharmaceutical products but also in
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new diagnostic facilities and new surgical interventions—increase unit costs but
also allow healthcare professionals to intervene in a growing number of more
complex diseases, the attendant benefits of which may not be fully assessable
for many years. With advances in health technologies, there is a rise in the pa-
tients’ (or consumers’) expectations which increases the pressure on healthcare
resources to make them available in a totally unrestricted way.93
With the increased demand for a given service, healthcare providers are under
pressure to justify every single procedure and product used for the management
of the disease. This certainly reflects the situation of genetics services in the UK.
It is essential that complete and accurate records are kept of what happens to
a patient attending the genetics clinic (and their relatives) to permit good audit
of the given service. A comprehensive prospective database, recording data on
pedigree structure, risk assessment, surveillance activity and interventions must
underpin evidence-based recommendations for the future development of these
services outcomes.34, 65, 73 As there are increased pressures on NHS to provide
economic justification for any developments in healthcare, this should be based
on the best available evidence (mainly determined by research).
2.4 Management of breast cancer
Cancer therapy accounts for a substantial segment of healthcare costs in all de-
veloped countries. While general principles of treatment for breast cancer (to
be discussed below) apply both to sporadic and familial cases, there are some
special considerations relevant to the latter group.
If a breast cancer is detected early, for example by means of surveillance pro-
grammes, it is expected that the affected individual will have a better prognosis—
meaning both lower treatment costs and a good prospect of cure or long-term
survival.
The clinical management of breast cancer varies in relation to the extent of the
disease. Early breast cancer diagnosis aims to obtain local control of the disease
and to prolong both disease free survival and overall survival. When the dis-
ease is detected at more advanced stages, local control of the disease becomes
difficult to obtain but, in some women, it is possible to prolong overall survival;
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when the disease is found in sites other than the breast (metastatic) the aim of its
management is palliation of the symptoms. Prolonging survival is not possible
in most cases.94 The majority of patients treated for operable breast cancer will
have surgery, followed by radiotherapy and systemic adjuvant treatment. Only
a small minority will be unsuitable for surgery by virtue of their poor general
health or simply because they are elderly. Medical management of the disease
in those few cases will be the only intervention.
When a tumour is large or locally advanced (with accompanying high risk of
local or distant relapse of the disease) it is usual practice to treat the patient
initially with systemic intervention (either endocrine therapy or chemotherapy).
This is termed neo-adjuvant treatment (or primary treatment). It is intended to
eliminate any possible metastatic cells that could be lodging in distant organs
and also to facilitate subsequent surgery and radiotherapy to the breast. Further
treatment will depend on the outcome of the initial interventions.
Palliative care for metastatic (“incurable”) disease will involve either endocrine
therapy or chemotherapy or both. Evaluation of the treatments available must
address the impact on survival and on the patient’s quality of life.
For both locally advanced and metastatic cancers, the interval between relapse
and patient’s death is very variable, from a few days to perhaps many years. On
average, survival of a patient with metastatic cancer is 2 years from the time of
the relapse diagnosis.
It is well documented in the literature that calculation of cost-effectiveness of
measures taken to reduce the incidence of advanced malignancy is only possible
if the recorded costs of treating those patients with advanced malignancy are
full and accurate.89 A study from Canada by Will et al.95 revealed that the costs
for treating breast cancer patients varied according to stage of the disease with
cost varying from CDN $ 36,340 for stage IV to CDN $ 23,275 for early stage
disease with in-patient costs for both treatment at diagnosis and terminal care
accounting for 63% of the lifetime costs of care. They used the Statistics Canada’s
Population Health Model (POHEM) to estimate lifetime costs, discounted at 0,
3 and 5% rates.
Another Canadian study by Wai and colleagues96 demonstrated similar results
to the study by Will et al.95 in that the costs of treating patients with incurable
breast cancer are increased when patients are admitted to hospital (accounting
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for over 50% of the costs in all age groups). The costs were highest in young wo-
men with metastatic cancer. The total mean cost to the health system in British
Columbia, Canada, was CDN $ 36,474.33 per patient. Even higher costs have
been reported from the USA in the same period.97
The (perhaps) surprisingly high cost of palliative or terminal care has a major
bearing on calculations of cost-effectiveness of breast cancer family services, as
discussed in more detail in Chapter 7.
These studies confirm the accepted belief that early diagnosis of breast cancer
(with improved prospect of cure) is the key to reducing healthcare costs asso-
ciated with the disease. Given that the cancer family clinics deal mainly with
younger women, the potential for reduction in healthcare costs is great if sur-
veillance programmes are effective. Kollias and colleagues,98 in a study eval-
uating the use of screening for young women (aged less than 50 years) with a
family history of breast cancer found that there was benefit from regular breast
screening as it led to early detection of in situ carcinomas (pre-cancers) in this
group of women.
Historically, breast cancer in younger women has tended to be detected at a
relatively advanced stage and to behave aggressively.99–101 Histological features
of the tumours tend to confirm their aggressive nature and predict poor survival.
It may be, therefore, that family history clinic clientele, among whom the risk of
early onset disease is increased, will require more intensive treatment of breast
cancer when it occurs. That will potentially increase costs, both ab initio and
because of the greater liability to unwanted side-effects of treatment. There are
also likely to be complex effects on intra-family relationships and both of these
factors will have implications for quality of life. Hence cost-effectiveness ana-
lysis in this setting is bound to be complex.
The diagnosis of breast cancer is made by “triple assessment” of a suspected
lesion (this includes: clinical examination, breast imaging and histological dia-
gnosis). Nowadays, it is common practice, to have a “one stop” clinic service
for women with a breast problem to be investigated by a team of expert in-
dividuals. The patients with suspected cancers will be seen and appropriate
measures will be taken for further management of the disease, while those with
non-malignant conditions will be reassured of the benign nature of their condi-
tion. A “one stop” clinic will ideally offer same day investigations and results.
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This is greatly valued by breast patients, particularly by the ones with cancer. It
is hoped that this approach will prove cost-effective because it reduces the num-
ber of visits a patient will have to make to the specialised centre and because
the patient will benefit both psychologically and in terms of eventual outcome
from being fully and promptly assessed, with results available on the same day.
However, the number of patients seen per consulting day is restricted by the
time and resources needed to allow investigations and reporting to take place,
with additional input from other specialities (i.e. radiologists and pathologists).
In fact, it has been demonstrated that “one stop” clinics cost more per patient
than a “conventional” breast clinic staffed mainly by breast surgeons and that
the psychological benefits of a multidisciplinary “one-stop” service were seen
only in the short term.102
A “one stop” clinic for patients with a positive family history of breast can-
cer will differ from the symptomatic clinic because the patient will usually be
asymptomatic and will not have breast investigations other than clinical exam-
ination and mammography, hence limiting calls upon specialist pathology ser-
vices. Follow up visits will follow the same pattern, using the same facilities in
place for the very first clinic visit.
The principal objective of such clinics is detection of cancer at an early stage and,
as indicated above, the economic rationale is that savings should result because,
in general, treating disease at an early stage is less difficult and costs less than
treating advanced disease.
Practice in the management of breast cancer is gradually evolving. Much re-
cent press comment has concentrated on the introduction of new drugs and the
question of how widely they may (or should) be available. As Dewar has illus-
trated, if treatment is changed, the costs of those changes depend not only on the
cost of each individual procedure (or drug) but also on the numbers of patients
involved.103
In the clinical management of breast cancer, these new cytotoxic drug regimes
are now available and provide benefits for a proportion of patients making an
impact on survival. The costs can vary but often are very expensive. Taxoid de-
rivates are commonly used in advanced breast cancer but their use as adjuvant
therapy is still under trial evaluation.
Recent advances in immunotherapy (e.g. Herceptin) also show potential be-
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nefits and are likely to figure prominently in future management of the dis-
ease.104, 105 However, most breast cancers associated with BRCA1 mutations
are negative for the HER-2 receptor and hence are unlikely to respond to Her-
ceptin.106 This illustrates another general issue of relevance to familial and sporadic
breast cancer, that is the growing recognition of subtle, but important, biological
differences within the spectrum of breast cancers. These will affect choice of
therapy, prognosis and costs.
Some changes, however can be shown to reduce costs; potential savings can
actually be realised when the disease is treated at an earlier stage, leading to
early discharge from hospital (wherever possible).107, 108 One practical example
of such a change in practice was a trial of nurse-led early discharge from hos-
pital for patients who had undergone surgery for breast cancer.108 There were
no adverse effects on quality of life for those patients, little effect on carer bur-
den and certainly improved communication between primary and secondary
care. The practice could safely be implemented in a rural/urban area. This
study concluded that the model of care with a nurse-led service was more cost-
effective than the conventional service because in-patient care represents a very
large component of surgical costs. The results from that study applied to 40%
of the women with breast cancer who were offered enrolment and who were
prepared to be discharged home earlier. However, sixty per cent of the patients
declined to enter the study. In the main, these were older patients, more anxious
and more likely to be living alone. This presents a dilemma for health care pro-
viders because the elderly population is increasing while at the same time there
is an increasing pressure to reduce hospital stay. This study also demonstrated
that, if the patient had a choice, she would prefer to stay in hospital until the
surgical drains were removed.
These findings resonate with comparable studies in other aspects of cancer man-
agement, including those related to cancer family services. Randomised trials
depend on patient participation which, in turn, is influenced by perceptions of
benefit, which may not be rational but raise issues of autonomy and choice. It
is clearly important, in gathering evidence on which to base changes in clinical
practice to engage patients as fully as possible, even if this slows the rate of
“progress”.
It is becoming a requirement that treatment for a given condition has to be based
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on evidence and enrolment into clinical trials at a large health maintenance or-
ganisation (HMO) did not lead to substantial increase in the direct cost of med-
ical care nor undermine the quality of the treatment.109
Evaluation of costs of clinical trials should make due allowance for the invest-
ment in research infrastructure, data collection and other outgoings, including
both direct and indirect costs of medical care considering that medical care out-
side clinical trials is likely to be more heterogeneous (in both cost and effective-
ness) when compared to the “control arm” of a given clinical trial as Fireman
and colleagues109 have demonstrated.
2.5 Cost effectiveness issues
The economic assessment of medical interventions has become an integral part
of decision making in health services with efficacy being the measurement of
benefit achieved. The comparison of costs and consequences of a given inter-
vention is part of economic evaluation methodology.
Evaluation is usually by means of structured clinical trials outcomes and effect-
iveness being measured as the decrease in disease morbidity and/or mortality
achieved by the application of a particular intervention over a non-homogeneous
population group.
Measuring cost-effectiveness of a practice involves the analysis of two or more
interventions in relation to the health and economic consequences93, 110 as what
the analysts term “health effects” such as “cases successfully treated” or “years
of life gained”. However, contemporary emphasis in disease management is not
only on prolongation of life but also on its quality.
The Department of Health has provided guidance on how to assess the impact of
policy making in health care (implications of a given policy in the identification,
value and quantification of cost and benefits of the proposed measure).111
Data collected from economic studies are used to track vital information on
costs, the coverage of health care, evaluation of access to care and, of course,
the resources allocated. The fundamental purpose is to compare the value of a
given intervention with the current “best” care provision, aiming to improve re-
source allocation and hence the efficiency of delivery of services involved.110, 112
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It is essential to identify efficient ways to make the best use of scarce resources
in health care (establish the potential direct and indirect effects of health policies
on the health of the population). This should be in form of development of
frameworks aiming to identify such health effects. However, it must be recog-
nised that different decision makers have different perspectives on costs and
consequences. Subjectivity is a perennial problem, for example, in clinical tri-
als where those administering the trial may have a different perspective on the
benefits and disbenefits of a novel treatment from that held by the participating
patients.113 In general, forms of economic evaluation differ in the extent to which
they can measure and value the consequences of intervention or therapy, but it
is recommended that, in the presentation of the results, there should always be
an incremental analysis included.93
Underlying the evaluation of all new developments (drugs, diagnostic and thera-
peutic technologies) in the NHS is the recognition that resources are scarce and
difficult choices must be made. As a consequence, economic evaluation has
become a much used tool in the NHS and pharmaceutical companies. Breast
cancer screening is a classical example of a new technology whose economic
evaluation has proved controversial (to say the least).
Before I present evidence on screening efficacy I think it is important to highlight
some relevant information surrounding breast screening programmes.
2.6 Breast screening controversies
Screening of the general population seeks to reduce breast cancer mortality rate
and there remain unreconciled arguments about screening outcomes. Accord-
ing to some critics, the actual benefit of breast screening programmes is over-
stated.114 Several studies on mammographic screening for breast cancer report
conflicting individual point estimates raising concerns about the quality of trials
methodologies and the measured outcomes115, 116 and generating much debate
amongst medical experts.117
The ongoing debates focus on whether screening for breast cancer in fact reduces
disease mortality. Large scale clinical trials take a long time to get the answers
to the questions posed at the beginning. As a result, studies may fail to gener-
ate a definitive answer because newer techniques become available while they
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are still under way. Yet, it is necessary to have such large scale studies as only
they can provide the detailed evidence-based information necessary to evaluate
a given procedure or technique.
The breast screening programme in the UK was launched in 1980s and some
screening units did not start until early 1990s. The target population was women
from the age of 50 to 64 years. Beyond 64 years of age, if a woman wanted
to continue to be screened she could do so but would have to make her own
appointment with the local screening unit. Eligible women receive a letter of
invitation for screening (every three years). General Practitioners provide the
list of eligible women for screening to the Regional Screening Centre. Several
units were invited to participate in research/audit projects within the screening
programme looking at different issues (for example, the value of a screening
programme for younger women typically from age 40 to 49 years; extension
of the screening programme by inviting women aged 65 to 70 years; double
reading of films; use of “two-view” films at the prevalent screening round).
Regardless of the precise arrangements made, the main aim of the programme
was to reduce mortality from breast cancer by detecting it at an early stage. For-
rest and Anderson,118 reviewing breast cancer screening services in the UK and
Australia, stated that the success or otherwise of screening will depend in part
on tumour size and axillary node status as well as how aggressive the tumour
is.
As in all screening programmes directed at a healthy population (which can be
seen as doing some good from the public health point of view) the question
arises “do the benefits really outweight the disbenefits, which may include dis-
comfort, inconvenience, cost, increasing anxiety and even physical risks?” In
the specific case of mammographic screening the most important negative as-
pects identified are anxiety, false reassurance, over diagnosis (and hence over
treatment) and radiation-induced cancer. This last point has been addressed
by Law,119 who determined that, using modern imaging equipment, the bene-
fits in terms of earlier diagnosis of cancer greatly outweigh the (miniscule) risk
of cancer induction unless the woman is extremely young (under 30 years of
age). Some authorities also suggested that compression of the breast by mam-
mography can cause spread of an early localised cancer as well as any biopsy
or operative intervention120, 121 in view of the disturbance of the dormant period
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of cancer cells accelerating the spread of micrometastatic cells induced by an-
giogenesis but the "evidence" on which this claim is based continues to be de-
batable.
The incidence of breast cancer is increasing, and some of the apparent increase
has been attributed to the rise of breast screening uptake. However, mortality
from breast cancer has also fallen and this has been correlated both with earlier
detection through screening and with improved treatment modalities. There
has been a drive for better understanding of the process of screening, its risks
and benefits, in order to improve the information and education provided for
women invited to take in screening programme.122–124
In an interview given to Medscape Medical News, Professor Michael Baum
stressed that when women attend for screening they should do so with full
knowledge of its implications and based on informed consent. That implies
weighing the benefits (lives saved) against the risks of false reassurance, uneces-
sary surgical interventions and psychological stress.125
The UK National and other breast screening programmes appear to have de-
livered measurable benefits but some authorities are of the opinion that it is
still too early to draw any conclusions about reduction in breast cancer mortal-
ity.74, 126
Analysis of several randomised controlled trials on screening for breast cancer
comparing outcomes of screened versus unscreened women demonstrated that
there was a mortality reduction of nearly 30% in the screened population about
seven to nine years from the start of the studies127 leading to both professional
and public increased demand for screening programmes. Nevertheless, it re-
mains possible to argue that the absolute benefit of screening may be smaller
than the associated risks.128
In a document reviewing recommendations on cancer screening in the European
Union, prepared by the Advisory Committee on Cancer Prevention,129 it is stated
that "reduction in the disease specific mortality achieved in trials depends on
the sensitivity, on the screening test, compliance, screening frequency, number
of screens an individual has, follow up and benefit of early treatment. The neg-
ative aspects are dependant on the sensitivity and specificity of the screening
test as well as possible side-effects of treatment". Indicators of performance of
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a given screening method should be monitored regularly in order to maintain
high quality screening.
Fletcher128 has shown that the principal risks associated with mammography are
directly related to false positive mammogram results, as further investigations
are likely to be performed before an "all clear" is given to the woman. Levels of
anxiety also relates to additional investigations. However, false positive mam-
mograms do not diminish the attendance of women for further screening. It is
important not to lower the "radiological threshold recall rate" in screening as that
incurs the risk of cancers being missed. To achieve optimum balance between
recall rate for suspicious findings and rate of missed cancers (i.e. between spe-
cificity and sensitivity) it is of paramount importance to maintain regular quality
control checks of the process. The recommendation in America by the Agency
for Health Care Policy and Research is that false positive (recall) rates should be
no more than 10 % of all examinations.
Mammographic screening for women at significant risk for breast cancer tar-
gets a different age group from population screening because hereditary breast
cancer tends to affect women at younger age. Until recently no substantive or
co-ordinated method of screening for those women was available. Significant
debate also arose about its potential efficacy, for several reasons. First, radio-
graphic breast density is higher in young women, which means that small tu-
mours may be more difficult to recognise. Second, breast tumours in this age
group tend to be fast growing so that the opportunity for early diagnosis may be
reduced. Third, these two factors could combine to increase both false positive
and false negative rates of mammographic abnormalities and the belief amongst
young women that they do not develop breast cancer at that age.128
Large-scale studies (discussed in detail later) have now generated adequate long-
term data which show that screening young women with a significantly in-
creased familial risk for breast cancer by regular mammography, with or without
clinical examination is effective. However, with the recent introduction of MRI
scanning of the breasts it became clear that this technology is more sensitive in
the assessment of breast tissue that is mammographically dense and hence is
particularly suited to screening young women. Several studies have suggested
that women at high genetic risk will benefit most from having MRI scanning in-
corporated in their screening programme with both mammography and clinical
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breast examination.
Recently, NICE guidelines70 have recommended that surveillance programmes
should be modified to take account of the new findings. Obviously there will
be cost implications to this70, 130 and it is also the case that a substantial propor-
tion of women cannot tolerate the claustrophobic experience of an MRI (mag-
netic resonance imaging) scan. MRI produces hundreds of images of the breast,
cross-sectional in all three directions with use of contrast agent injection to en-
hance the breast tissue to be analysed. MRI uses a range of "markers" for cancer
to allow the distiction between normal and abnormal breast parenchyma (these
include tumour blood flow, size and appearances of the lesion). It does not use
radiation, which is an important differentiation from mammograms (X-rays), a
known factor causing DNA damage: in fact, it uses magnetic fields and radi-
owaves in the production of images.
Evidence from a Dutch study on the short term effects of screening women at
significant risk for breast cancer revealed that women taking part in the screen-
ing programme had better quality of life in health-related matters when com-
pared with the general population. That study also examined the effects of hav-
ing a mammogram plus MRI in relation to anxiety levels. Relatively more wo-
men reported that mammography was more painful than MRI compared to the
reverse (30.1% vs 12%) but the anxiety levels were high in 10.2% of women hav-
ing MRI. This study showed that the impact of screening on the women sampled
was generally favourable on both short-term generic health quality of life and
general distress, perhaps reflecting the characteristics of women attending the
screening programme (well, educated, healthy women who voluntarily entered
the programme of surveillance).131
Several screening programmes have been fiercely criticised in view of their out-
comes, particularly the screening programmes from Scandinavia as some results
from meta-analyses have suggested that screening by mammography does not
save lives and does not reduce the number of women having mastectomies even
if cancer is detected early.132, 133 The report by Olsen and Gotzsche132 also gener-
ated much debate in the scientific world, with the International Agency for Re-
search on Cancer, the National Health Council of the Netherlands as well as the
Global Summit on Mammographic Screening all concluding that the concerns
and issues raised on the published analysis by Olsen and Gotzsche were mis-
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interpretations of the facts and the data. Those institutions agreed that screen-
ing mammography could reduce the number of women dying from breast can-
cer.117, 134
The Canadian screening programme which evaluated screening for breast can-
cer in women aged 40–49 years had also generated critics as the screened group
unfortunately demonstrated more deaths than the control group. This was at-
tributed to the poor quality of mammography and there were violations of basic
rules in a randomised controlled trial as the trialists did not randomise entry
into the study blindly.117, 135–138
Data on both mammographic screening and MRI screening should continue to
be collected and audited for long-term analysis of the efficacy of surveillance
programme for high risk women and they should have both investigations on a
yearly basis. With these combined, a measurable contribution to effectiveness of
breast cancer detection and treatment in this cohort can be anticipated.
A reasonable conclusion from this debate may be that allocating limited re-
sources for a proposed screening programme should be based on critical ana-
lysis of benefits, harm and costs of such intervention. On this basis, population
screening of young women (under 50 years of age) for breast cancer is of dubi-
ous value. There is wide agreement that the key component of any screening
programme in this group should be a short screening interval, which carries
large cost implications.139
It is recognised that improvements in breast cancer treatment, stage of disease
at presentation, new methods and techniques of breast screening as well as in-
creased public awareness of the disease may all contribute to reduction in mor-
tality. This will make it difficult to identify the specific effect of any screening
programme in the reduction of deaths from breast cancer but it should be expec-
ted that the programme, combined with the other factors described, will result
in further reduction in breast cancer mortality in the next 10 years.140
Women thought to be at high genetic risk for the disease should be screened at an
earlier age and at more frequent intervals than is the case for a population-based
screening programme.48, 51, 98 International differences in the design of screening
programmes are inevitable, given the differences in healthcare systems.51 De
Koning126 showed that the estimated cost-effectiveness of screening ranges from
2,650 Euros per life-year gained in Navarra to 9,650 Euros in Germany. The
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benefits of such programmes must be dependent on several factors: disease epi-
demiology, healthcare systems, quality of the screening programme, attendance
levels and healthcare costs. However, definitive evidence on survival benefit is
still awaited for this group of women.98
A uniform breast screening policy will not be possible in the foreseable future as
there are so many differences between countries in the factors listed above, that
contribute to cost-effectiveness.
2.7 Introduction to economic evaluation
For economic evaluation, a minimum of three elements are required in data
collection: efficacy of the interventions concerned, costs of resources used and
the impact of intervention on quality of life. However, reliance on these alone
has limitations and it is likely that in the future, economic evaluation will use
a wider combination of approaches, including the impact on families and on
society as a whole, as mentioned by Drummond.93
In health care, the resource costs need to cover all aspects of organisation and im-
plementation of a given programme, including any possible adverse events that
may occur. Health service consequences relate to changes in health state, cre-
ation of new value in the programme and of course the resources saved, which
can be calculated both for the individual and for the healthcare sector as a whole.
Improvement in health state relates to physical, emotional and social function-
ing of the individual. It may include reduced anxiety, increased mobility and
thus increased leisure and work. It could thereby result in lower costs in the
future and healthcare resources could then be freed up for use in other settings.
However, in a healthcare programme it may not be possible to measure and
price all relevant items for an overall economic evaluation of costs and con-
sequences. It is important therefore to identify the most relevant cost drivers.
Valuing costs gives an estimate of the worth of resources used by the programme.141
A measure that seeks to account for both changes in life expectancy and quality
of life is called the Quality Adjusted Life Years (QALYs), gains in which permit
the impact of treatment on a patient’s disease to be adjusted for improvements
or decrements in quality of life. This facilitates comparisons of cost-effectiveness
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between given interventions but, as in the case of drug trials mentioned earlier,
subjective evaluation of quality of life and indeed differences among patients
themselves in what they regard as either acceptable or intolerable, mean that
QALYs cannot provide an absolute standard but are, at best, an approach to that
end.55, 142, 143
The effects of treatment on disease-related symptoms and the impact of side-
effects can be measured by placing quality values on different life events, with
utility indices ranging from 0 (death) to 1 (perfect health); multiplied by the
time (years) spent in varying health states. The outcome of these calculations,
expressed as additional QALYs gained, is widely used to define utility.
The number of QALYs will always be less than the survival time unless the pa-
tient maintains perfect health. Furthermore, as pointed out above, the assign-
ment of QALYs to an individual patient is an inexact science. In large studies,
however, averaging the QALYs gained (or lost) should tend to reduce subjective
bias.
In cost-utility analysis it is normal to calculate medical savings related to the
effectiveness of a given treatment. Those savings take account of the medical
resources used in extending the life years, either by a novel treatment for that
condition or by new forms of screening and detection of the disease, minus the
resources used in treating a given disease without any new methods of screening
and therapy (the “conventional” or “best alternative” care).
When it comes to calculating cost-utility, controversies have risen in relation
to the inclusion or not of survivor costs—i.e. those healthcare costs which are
avoided or curtailed because the treatment has cured or mitigated the disease.
Those costs are not actually incurred but their absence is directly associated with
the treatment, if indeed it is clinically effective.
Various health economists have had different views as to what should be in-
cluded in the calculations and no consensus has been achieved.55, 141, 144 Those
in favour of including cost savings in the utility analysis maintain they should
be part of an ICER (incremental cost effectiveness ratio). In other words, if the
treatment is effective, the future medical costs that would arise in the absence of
the new treatment are avoided.
Nyman described an alternative set of principles that can determine which costs
should be considered for inclusion in the calculations of cost-utility. These prin-
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ciples are based on standard welfare economics and would include treatment
costs, downstream medical cost savings, travel costs, time receiving treatment
(not forgetting informal care) and time in recuperation. All these should be in-
cluded along with quality of life associated with the health status, when eval-
uating health costs.55, 144 Of course, from the perspective of the NHS, the most
crucial elements are those costs directly incurred by the healthcare system and
those savings that accrue directly to it, i.e. the impact on the NHS budget.
The simplest outcome of a given disease treatment that is effective is represen-
ted by the reduction in the probability of dying (or of an adverse health event
leading indirectly to the individual’s death) from the disease in question.
It is inherently difficult for a clinician to apply cost-effectiveness analysis to a
group or cohort of patients since that requires the generalisation of findings to a
large number of individuals, treating them as a uniform set, whereas in clinical
practice management is invariably individualised. There is no “typical” breast
cancer patient in reality, given the complex nature of the disease and treatment
available. This was confirmed by Radice and colleagues145 as the incidence and
mortality rates for breast cancer vary immensely in different countries. How-
ever, even in clinical practice, some generalisations are both necessary and help-
ful. For example, management and hence treatment costs (both direct and indir-
ect) are principally dependent on the stage of the disease at presentation.
Judgement on the effectiveness of an intervention for detection of early disease
among individuals at risk must take account of the overall effect on the patient’s
quality of life, including the negative impact of the screening tests (which may
include invasive procedures) with associated anxiety and discomfort, discussed
above in Section 2.6.
An issue that arises frequently in the evaluation of cost-effectiveness of an in-
tervention programme is “discounting”. It expresses costs and outcomes that
occur over a period of time, scaled to the costs at the starting date of the pro-
gramme under evaluation, based on the economic idea that resources invested
now will provide a return in future years and individuals have a time preference
that favours health benefits in the present time rather than in the future.146 Dis-
counting is of particular relevance to the economic evaluation of breast screen-
ing because the natural course of breast cancer is highly variable with survival
sometimes measured in decades rather than years, and recurrence is possible
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even after twenty years of apparent cure. The range of treatments available has
increased enormously over the past few years and so has the cost of drugs such
as taxanes, trastuzumab (Herceptin) and other receptor kinase antagonists. That
trend is likely to continue, so that costs of “salvage” therapy will grow even
higher. This means that early detection and treatment, which might add several
years of good quality of life but ultimately lead to late relapse, could incur very
much larger costs than if the patient is diagnosed with advanced disease in the
first instance and rapidly succumbs.
Furthermore, in relation to familial breast cancer services, the concept of dis-
counting is highly relevant since healthy women have choices for regular sur-
veillance over many years (with attendant anxiety surrounding each screening
episode) or even for prophylactic surgery with the associated stress, risks and
discomfort, to be set against possible long-term protection from the morbidity
and mortality associated with late-presenting cancer. Yet, in many instances
these women will never develop cancer at all, even if they decline to “take ad-
vantage” of the services offered by the cancer family clinic.
It has to be recognised that an unknown proportion of women at increased fa-
milial risk take the option of doing nothing at all about it—they discount long-
term risks against peace of mind provided by current avoidance of the issue. It
is, of course, almost impossible to obtain information about the psychological
state of these women and hence to estimate whether, overall, they benefit or
otherwise from non-use of cancer genetics resources.
Other conditions generate their own dilemmas regarding future (escalating) costs
and how they should be taken into account in current cost-benefit analyses. For
example, in childhood acute leukaemia, costly, but ultimately futile, treatment
was standard practice for many years in the 1960s and 1970s with apparently
little prospect of cure. However, nowadays over 70% of these patients are com-
pletely cured. Application of the discounting principle before cure was achieved
would have generated quite misleading economic data.
The use of discounting in economic evaluation has therefore generated much
debate.
Mansley and McKenna147 reported how economic analysis can differ depending
on the perspective taken by the decision maker. They identified several com-
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ponents in the variation of perspectives, greatly affecting the perceived costs
and benefits of cancer screening decisions.
Specifically, in relation to screening for breast cancer, the relative frequency of
positive tests (with consequent follow-up diagnostic procedures and other inter-
ventions) contributes substantially to the outcome of cost-effectiveness analysis.
In addition to prevalence of the disease, other factors that also influence the ana-
lysis of cost-effectiveness are the unit cost of genetic testing and life-year bene-
fits from the diagnostic interventions applied. A report by Brown and Kessler146
points to the need for further economic studies in determining how both genetic
testing and counselling can be delivered more cost-effectively.
Heimdal and colleagues148 calculated costs for the familial breast cancer genet-
ics services currently available in Norway, using the scale of charges levied by
the Norwegian National Insurance Service (NIS). They found that genetic coun-
selling and clinical follow-up interventions (clinical examinations and mammo-
grams) accounted for a much greater share of total cost than laboratory proced-
ures, a conclusion echoed more recently by Griffith et al.92 The Norwegian group
estimated that the cost per life year gained was Euro 753 and that to identify
high risk families through genetic tests of all incident breast and ovarian cancers
for Norwegian “founder” mutations in BRCA1 (see below) would increase that
figure to Euro 832.
The study by Heimdal and colleagues148 (discussed further in Chapter 7) also
assumed that if BRCA2 mutation-related cancer treatment has a better prognosis
than BRCA1 associated tumours, then molecular genetic testing for BRCA2 muta-
tions could be very cost-effective because the outcome would be substantially
improved by early detection.
Genetic testing is defined as analysis of human DNA, RNA chromosomes pro-
teins and other metabolites in order to detect inherited disease-related muta-
tions. For clinical purposes, identifying carriers of such mutations improves the
accuracy of risk assessment and can contribute to establishing clinical diagnosis
or prognosis but devising effective interventions to prevent manifestations of
the disease has proved difficult for both scientists and clinicians.149
The costs of molecular genetic testing will vary, depending on how commonly
specific mutations occur in the population examined (i.e. how easy it is, technic-
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ally, to undertake efficient laboratory screening). The variety of genes and muta-
tions implicated in many diseases can limit the predictive power of such tests.
Familial breast cancer is a case in point, as illustrated from Table 1.3. Given the
technical complexity of the work, special quality assurance is expected from the
laboratories performing genetic tests and contributes to the diagnostic costs.
In Norway, five relatively frequent “founder” mutations have been recognised,
some specific to certain regions of the country. “Population” screening, as con-
templated in the paper by Heimdal may therefore be economically justifiable.
Families at high risk, identified through this approach will be given priority ac-
cess to the resources of the “high risk” breast cancer genetics service.
In the absence of common “founder” mutations, mutation screening of both
genes (BRCA1 and BRCA2) is expensive (estimated at Euro 2,250 per sample).
There is some hope that when the process becomes automated, it will become
much cheaper to run these tests.
It is important to highlight the economically relevant point that several tests
used in screening high risk family members for cancer (notably mammography)
are generally performed several times; at least annually, over a prolonged period,
typically 15 years, while genetic testing for an individual at increased risk for a
given disease or condition is likely to occur only once.
In a recent study, Sevilla and colleagues150 raised concerns about the holding
of gene patents by a privately owned company. This could influence the de-
cision making process within healthcare systems, regarding identification and
adoption of the most efficient strategies for genetic testing (due to the mono-
poly of such a company in exploiting techniques for direct sequencing of the
genes). They demonstrated that other laboratory technical strategies could be
used with similar effectiveness, reducing the costs of the tests. The average cost
per mutation detected, when the mutation test was undertaken by the patent-
holding company, at 9,882.5 Euros, was the highest of all the alternatives con-
sidered. This also highlights the general point that calculations of cost/benefit
ratios must be influenced, to a degree, by the different ways in which health care
is financed in different societies. This adds to the difficulty of combining the lim-
ited data available from a range of sources, countries and healthcare systems.
An analysis of effectiveness and costs of a genetic counselling and mammo-
graphic screening programme in high risk breast cancer families was performed
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by a group in Barcelona.151 They estimated that the annual cost of screening
mutation carriers is 86.83 Euros until breast cancer is diagnosed. There was a
measurable cost benefit to the overall programme when mutations were detec-
ted because non-carriers of mutations could be identified and excluded from
further clinical surveillance. When breast cancer was identified, the patient
would be referred to the appropriate specialist department for treatment and,
though numbers were insufficient for definitive conclusions, there appeared to
be a trend towards lower cancer stage at diagnosis if the patient had been en-
rolled in the screening programme (as also demonstrated in a study by Kollias
et al. in 199898).
Balmana and colleagues’ study in 2004151 made use of a decision tree estimating
the survival benefit and cost-effectiveness of their clinical genetic counselling /
screening programme. They provided both genetic counselling and genetic test-
ing, which entailed a cost of 338.15 Euros/person in the first year of inclusion of
a given family in their programme. The study found that the cost effectiveness
ratio of their programme was 4,294 Euros per life-year gained and they con-
cluded that such programmes may be cost-effective. Unfortunately, this group
did not include the costs of treating the patients diagnosed, nor the cost savings
achieved through earlier diagnosis, nor the potential damage from a false posit-
ive result, all of which might have changed the cost-effectiveness ratio. They also
excluded from the analysis other interventions such as chemoprevention and
prophylactic surgery, due to the low numbers of relevant cases in their study.
It is a reasonable prediction that young women presenting with late stage (essen-
tially incurable) disease will require long term treatment and nursing care and
hence will be unable to contribute to the overall economy. In the absence of pre-
ventive intervention or early detection, therefore, costs to the community will
inevitably be higher. As discussed in relation to “discounting”, one may even
argue that diagnosing breast cancer at an advanced stage can lead to a shorter
period of morbidity (because of the patient’s earlier death from the disease) than
if a woman is treated for early breast cancer.
In general, existing data on the cost effectiveness of current services for familial
breast cancer are inadequate. Recommendations based on unproven assump-
tions are suspect and more firm evidence is required. Experimental approaches
should be supported, even if this means that, in the short term, some medical
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interventions have to be allocated more resources than would be justified if their
effectiveness were already known.152
2.8 The role of prophylactic surgery
The economic impact of prophylactic intervention was not discussed in the Nor-
wegian study as data were not then available.148 Subsequently, however, several
important studies have been published.
From a retrospective series, Hartmann et al.153, 154 demonstrated a reduction in
the risk of breast cancer, of at least 90%, if women at increased risk had un-
dergone prophylactic mastectomy. The residual risk depends on the amount of
breast tissue remaining after surgery. Total bilateral mastectomy is the proced-
ure of choice.
It is important to highlight that, regardless of the procedure chosen by the pa-
tient, the surgeon should remove as much breast tissue as possible to have the
risk reduction maximised. The recently published PROSE study155 showed that
the two women diagnosed with breast cancer after undergoing prophylactic sur-
gery (2/105 or 1.9%) had had what is technically termed “subcutaneous mastec-
tomy”. This is not optimal as a prophylactic procedure since it leaves substan-
tial residual breast tissue intact, including the nipple-areolar complex. This will
play a part in contributing to residual risk. However, 184 patients of 378 (48.7%)
in the matched control group who did not have any prophylactic intervention
developed breast cancer. There is therefore no doubt that prophylactic surgery
vastly reduces the risk for breast cancer in BRCA1/2 mutation carriers.155
Skin sparing mastectomy and breast reconstruction are now offered to virtually
all women comtemplating risk reducing surgery but this can complicate future
mammographic or clinical screening. In the Manchester series of prophylactic
mastectomy,156 8–10% of the women attending the clinic with a lifetime risk of 1
in 4 or above have sought advice on risk reducing surgery; 6% have proceeded
to surgery. This figure rose to 11% in women at 40% lifetime risk.
A second study from Manchester, recently reported,157 specified that patients
attending the regional family history clinic for regular screening were given in-
formation on risks for contra-lateral breast cancer when cancer was diagnosed.
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The issue of undergoing bilateral mastectomy and breast reconstruction at the
time of the (unilateral) diagnosis was also discussed with the patient and the
uptake was compared with that of women with breast cancer (and identified as
carrying a BRCA1/2 mutation) from other surgical clinics. They identified 70
such women. Sixty-five percent of the Manchester BRCA1/2 mutation carriers
and 59% of the ones at high risk for the disease (but without known mutation)
opted for contra-lateral mastectomy, while only 10% of the women identified
as mutation carriers from other clinics opted for such intervention (9/88). Data
have been gathered prospectively to assess whether salpingo-oophorectomy in
BRCA1 or BRCA2 mutation carriers could decrease risk of both breast and BRCA-
related gynaecological cancers.158 In that study, of 170 women who met the entry
criteria, 98 elected to undergo salpingo-oophorectomy and 72 underwent regu-
lar surveillance for ovarian cancer. Breast or BRCA-related gynaecological can-
cer was diagnosed in 4 women in the salpingo-oophorectomy group compared
to 12 women in the surveillance group demonstrating that the risk of breast
or BRCA-related gynaecological cancer was significantly lower in the salpingo-
oophorectomy group.
The recent findings of the PROSE study155 indicated that women with BRCA1
or BRCA2 mutations who undergo bilateral prophylactic mastectomy have their
risk for breast cancer reduced by 95% if they also have a previous or concurrent
prophylactic salpingo-oophorectomy.
In women who have kept their ovaries intact, the risk is reduced by 90%. Such
results provide strong evidence for inclusion of prophylactic salpingo-oophor-
ectomy in the discussion of risk-reduction management for women at risk of
hereditary breast or gynaecological cancers.158 A comparable study159 also found
that prophylactic oophorectomy in premenopausal carriers of BRCA1/2 muta-
tions led to a reduction in breast cancer risk of around 50%, with a follow-up
period of eight years and hence support the recommendation to perform pro-
phylactic oophorectomy in mutation carriers of BRCA1 or BRCA2 soon after
childbearing is completed. Surveillance alone for those women did not show a
reduction in the proportion of advanced ovarian cancers diagnosed nor any ef-
fect on ovarian cancer mortality (estimated to be 80% at 5 years for stage III dis-
ease). In this and other reports, a number of patients with germline mutations in
BRCA1 or BRCA2 genes have been found at prophylactic oophorectomy to have
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coincidental early ovarian tumours which were not detected by currently avail-
able screening tools, namely level of glycoprotein CA-125 marker in the plasma
and transvaginal ultrasound.48, 61, 160
Current evidence thus indicates that the screening tools for families at increased
risk for ovarian carcinoma are not reliable in detecting cancer at an early stage
according to FIGO (International Federation of Gynaecology and Obstetrics) cri-
teria.61 It is also important to highlight that when prophylactic oophorectomy
is planned it should include the removal of the fallopian tubes because of the
potential risk (although rare) of a serous papillary cancer arising from the intra-
mural portion and fimbriated end of the tube.
According to a Canadian study, 16% of all fallopian tube malignancies are caused
by germline mutations in BRCA1 or BRCA2 genes and should be considered
part of the hereditary breast-ovarian cancer syndrome.161, 162
Several other reports support the conclusions of the Canadian study. The present
recommendation is that women at risk for ovarian cancer should also have the
risk of fallopian tube carcinoma discussed when prophylactic risk reducing oo-
phorectomy is to be performed and as a result, this should always include re-
moval of the fallopian tubes.163, 164 Paley and colleagues even recommended that
those patients should also consider having a hysterectomy performed at the time
of oophorectomy, in view of the growing number of primary tubal carcinomas
in mutation carriers and given the biological parallels between ovarian and both
primary peritoneal and tubal carcinomas.163
Even after salpingo-oophorectomy, there remains a small and currently irredu-
cible risk of primary peritoneal cancer of ovarian type.165, 166 The best estimate
of this lifetime risk is around 1–2%.158, 159, 167
Given that ovarian cancer risk is very significantly reduced in BRCA1/2 muta-
tion carriers after prophylactic oophorectomy and that the risk for breast cancer
is substantially reduced by this procedure if the patient is premenopausal. There
remains some debate and uncertainty as to the use of hormone replacement ther-
apy (HRT) in those women.159, 168
A recent epidemiological study by Armstrong and colleagues demonstrated that
prophylactic oophorectomy extended life expectancy in women with BRCA1/2
mutations irrespective of the use or not of HRT post-oophorectomy and that the
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decision on the use of HRT after prophylactic surgery should be based on the
patient’s quality of life rather than life expectancy. HRT should be discontinued
at the time of expected natural menopause (that usually is around age 50 years)
for most women.169
The options of surgical management should be fully discussed with the pa-
tient as the decision to undergo such procedure is complex and could incur
long term psychological distress.170 All risk reduction interventions for breast
and/or ovarian cancer are not free of potential complications, which should be
discussed fully with the individual seeking risk- reducing interventions before
giving informed consent for the procedure.
Surgical complications have been more frequent in women who had both pro-
phylactic mastectomy and immediate breast reconstruction. Women who un-
derwent prophylactic mastectomy only, experienced fewer complications (pre-
sumably due to the less extensive nature of the procedure). Unfortunately it is
not possible to predict whether a given patient will develop complications or
not. However, it is possible to take measures prior to each form of intervention
to keep complications to a minimum.171
With regard to prophylactic oophorectomy, complications are fortunately rare.
For chemoprevention regimes, complications (side-effects) are generally under-
stood and are characteristic of each type of medication. Of course, the main
worry for prophylactic surgical interventions is the potential risk of breast and/or
ovarian cancer happening after the surgical procedure has been performed.165, 172
This will be discussed later in the thesis.
2.9 Prophylactic surgery versus regular surveillance
Screening young women for breast cancer is controversial; there is no consensus
on cost-effectiveness of population-wide screening for women under the age of
50 years. Selecting women who demonstrate a significantly increased risk for
the disease should be more efficient.173
The influential Schrag reports90, 91 on decision analysis to determine the relat-
ive merits of surveillance versus prophylactic mastectomy and oophorectomy
in young women with BRCA1 or BRCA2 mutations, predicted substantial gains
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in life expectancy for prophylactic mastectomy (range: 25–97% risk reduction)
patients but smaller gains from prophylactic oophorectomy (range: 25–75% risk
reduction). The gains noted in mutation carriers ranged from 2.9 to 5.3 years
of life expectancy from mastectomies and from 0.3 to 1.7 years of life expect-
ancy from oophorectomies. Neither approach gave complete protection against
cancer.
According to Schrag’s model, if a BRCA mutation-carrying woman diagnosed
with breast cancer has prophylactic surgery on the opposite breast at the time of
her treatment, this will achieve most benefit in terms of life expectancy. When
a mutation is detected some years after initial treatment for breast cancer, the
patient may wish to consider prophylactic surgery and it has been calculated
that she will still have survival benefit, provided there is no recurrence of the
original tumour either locally or in distant organs.
Not surprisingly, patients with sporadic (i.e. non-genetic) breast cancer gain
less from prophylactic surgery because their risk of a second primary tumour is
lower. The procedure is not currently recommended for them.
If mutation status is uncertain, in order to maximise the survival benefit from
available interventions, a cautious assessment should be made of the “histor-
ical” genetic penetrance levels which reflect the cumulative risk of developing
cancer within the individual patient’s own family. Those at risk within high pen-
etrance mutation families will have 85% cumulative incidence of breast cancer
and 40% of ovarian cancer. Those figures, used by Schrag and colleagues, were
based on Breast Cancer Linkage Consortium results.
A collaborative study (to which I contributed with Tayside data) reported by
Møller et al.,48 on the outcome of breast cancer diagnosed among women en-
rolled in special surveillance programmes provided data on 249 patients from 5
different countries, analysed by tumour characteristics, BRCA mutation status
and oophorectomy. They found that overall survival at 5 years was 89%, with
relapse-free survival being 87%. Mutations were unevenly distributed: 36 pa-
tients had BRCA1 mutations and 8 had BRCA2 mutations. Because numbers
were so low, the latter were excluded from subsequent comparison between
BRCA1 mutation-positive patients and non-mutation carriers. For both node-
negative and node-positive patients grouped together, 5-year survival was more
favourable for those not carrying the mutations (91% vs 63%) and, even among
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node-negative patients, 5-year disease-free survival was more favourable in non-
mutation carriers (96%) when compared to mutation carriers (75%). In BRCA1
mutation-positive patients who had undergone bilateral oophorectomy at the
time of breast cancer diagnosis, a much more favourable disease-free survival
was noted.48
In summary, BRCA1 mutation carriers have worse survival when cases were
compared to the total of the remaining group but mutation carriers appear to
benefit from undergoing bilateral oophorectomy. These findings are in keeping
with other reports of adverse prognosis among BRCA1 mutation-carriers (re-
viewed174, 175) and demonstrate that it is essential to collect data prospectively
to permit thorough evaluation of management options in distinct subgroups of
breast cancer families.48 A more complete discussion of this topic, with recent
data both from my own experience in Tayside and from the European collabor-
ation, is the main theme of Chapter 5.
In a recent study, Anderson and colleagues1 concluded that the most cost-effective
strategies for prevention of both breast and ovarian cancers in BRCA mutation
carriers were oophorectomy alone and oophorectomy with mastectomy. Those
strategies were both better than surveillance alone. They also deduced that the
survival benefit of those women who have had their surgery by the age of 30
years was 4.9 years and that there was an increment in the survival benefit to 7.8
years if the penetrance function of the mutations was raised. Unfortunately the
study was based on the application of a Markov model with hypothetical data
and may not reflect what happens in real life. Those issues will be discussed
later in the thesis.
2.10 Conclusion: current views on cost effectiveness
of breast cancer family history clinical services
Screening programmes for inherited breast and ovarian cancer high risk women
involve several stages: the assessment of the individual’s risk for the condition
and subsequently genetic testing for the ones at high genetic risk for the disease
plus other interventions that are available to them for consideration. It is import-
ant to recognise that the calculations in Schrag’s reports90, 91 have been based on
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theoretical predictions and rely on unproven assumptions about the efficacy of
screening and of prophylactic surgery for both breast and ovarian cancer risks.
The Møller (2002) study48 is the first substantial report of actual data relevant to
these questions, drawn from a prospective series.
Some specific flaws in modelling for the Schrag predictions have since been
identified. Women at increased genetic risk of breast cancer have been treated
as a homogeneous group, whereas, in fact, only a minority of women with a
positive family history are from BRCA1/BRCA2 families.18, 176 Screening is not
uniformly effective for all subgroups of women with a positive family history of
the disease.
Even when BRCA1 positive tumours are detected early (i.e. small, node negative
tumours), recurrence rate is high (much greater than the 20–38% assumed by
Schrag).48 The Schrag reports do not recognise the effect of oophorectomy or
recurrence rate on BRCA1 positive breast cancers.158, 159, 167, 177
Improvement in performance of clinical genetic services depends on the devel-
opment of clinical guidelines for both breast and ovarian cancer surveillance
screening. There are several strategies that are currently used to improve spe-
cific services in clinical practice varying from policy-level strategy, practice-level
strategy and motivation strategies. As a result, some studies demonstrated that
there is a need to implement multiple strategies for a more efficacious service.178
Accurate risk assessment (i.e. correct targeting of resources) is probably the most
important tool for maximising efficiency of breast cancer family services. Fur-
ther development of Cancer Genetics Services and allocation of resources to
them should clearly be based on accumulation of real evidence and the present
study is intended to contribute to that end. The issues reviewed herein are dis-
cussed in more detail in later chapters, and in the light of more recent (unpub-
lished) findings to which I have contributed.
In conclusion, the following key questions are addressed in order to meet the
aims and, objectives of this study:
1. Is it possible to “screen out” referrals to the breast cancer family clinic of
women whose risk is below the “moderate” level at which regular special
surveillance is considered appropriate?
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2. Can this be done accurately and cost-effectively and without detriment to
those below the “threshold” level of risk?
3. Are current settings for the “threshold” valid?
4. What are the appropriate roles in the selection processes for the families
themselves, primary care staff, personnel in the specialist genetics centre
and central data sources (Cancer Registry and Registrar Generals’ records)?
5. What are the outcomes of surveillance programmes for women at increased
genetic risk of breast/ovarian cancer?
6. What are the true costs of these programmes and what savings can be
achieved by early detection of cancers?
7. How do the estimates compare with costs and benefits of prophylactic sur-
gery?
8. What further studies are required to improve the quality of evidence?
Finally, by addressing these questions, can specific evidence-based recommend-
ations be made for cost-effective management of distinct categories of familial
breast cancer risk?
Chapter 3
Material and Methods
3.1 Basis of the linked studies and funding
The author has worked personally in the Tayside Breast Cancer Family History
Clinic since 1995, collaborating in close partnership with colleagues within the
BIOMED 2 Demonstration Programme (European Community BIOMED 2 Pro-
ject: “Familial Breast and Ovarian Cancer: Audit of a New Development in Med-
ical Practice in European Countries”) from 1996 to 1999. Relevant outcome data
from that programme are included in this thesis.
An “analytical framework” with current pathways of patient management since
referral to the Tayside breast cancer family history clinic was constructed, fol-
lowing the model adopted by the US Preventive Services Task Force.179 It iden-
tifies the key questions that should determine each element of the patient’s jour-
ney, including decisions about genetic testing, prophylactic surgery and breast
cancer treatment of women that have been under regular surveillance through
the clinic (Figure 1.1).
Following this analytical model, I have set out to address at least some of the key
questions and to adduce evidence upon which to base a modified clinic model
for the Tayside cancer genetic services, with implications for comparable pro-
grammes in other centres. The aim is to optimise clinical practice and resource
allocation in this emerging field of health care.
A grant from the Chief Scientist Office (Health Services Research Committee),
Scottish Executive Health Department for the project “Evaluating a New Model
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for Cancer Genetics Services: Co-operation between Primary care, Nurse Spe-
cialist and Hospital Clinic” was awarded in 1999 to the Tayside Breast Cancer
Genetics Group.
The author was one of the co-holders of that grant, with particular responsib-
ility for clinical examination of patients, collation of data on cancers arising in
women under surveillance and health economic aspects of the study.
A major element of that study was evaluation of the process of risk assessment,
carried out in the genetics department and making use of: a) Family history form
completed by each family, b) Access to NHS clinical records and cancer registry
and c) Access to Registrar General’s records of births, marriages and deaths. All
this could be done without requiring the referred family member to attend the
clinic in person.
One important question was whether it was acceptable (and “safe”) to carry out
this evaluation and communicate reassurance (for those at “low” risk) by post
or whether one face-to-face interview would be required. Suitable patients were
therefore randomised to “postal” or “interview” contact, the interviews being
conducted by a genetics nurse specialist or a genetics associate.
The duration of the period of evaluation of the new model was thirty months
and a triage protocol for the delivery of the cancer genetics services was used.
This study is referred to, for convenience, as the “Triage” project and is the sub-
ject of Chapter 4.
The other grant-holders were: Professor Michael Steel, Professor Frank Sulli-
van, Dr David Goudie, Professor Alastair Thompson, Professor Mo Malek (who
sadly died in 2001) and Dr Manouche Tavakoli (who took over supervision of
the health economics aspect of the study). The grant was activated in February
2000 with the appointment of Dr Dorothy Young as a Genetics Associate.
Within the terms of the grant there was a particular interest from the Chief Sci-
entist to have an evaluation of the economic implications of the new model.
Money for a full time PhD student was allocated in the research grant for this
specific purpose.
I was invited to undertake the economic evaluation and efficacy analysis on a
part time basis. Two sessions per week from my current work were allocated
specifically for the study. As I do not have formal training in economics or man-
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agement, I attended classes at the Department of Management and Economics
at the University of St. Andrews to gain greater understanding of the process
required for the analysis.
The study protocol was submitted to the Local Research Ethics Committee for
consideration and approval was granted. From February 2000 to August 2002,
all women referred to the Tayside breast cancer genetics clinic were invited to
participate in a randomised trial comparing the provision of information about
their risk for breast and/or ovarian cancer by letter or by a personal interview.
It is important to highlight that this would only apply to women thought to
be below the “threshold” level of risk for breast cancer (as defined by SIGN
guidelines) and hence not eligible for inclusion in a programme of regular clin-
ical and mammographic surveillance.
In addition to the above specifically funded research projects, in order to address
the issues listed at the end of Chapter 2, I have gathered material from observa-
tion of clinic operation over ten years and have participated in several exercises
in data analysis, usually starting with the Tayside clinic and then, if there ap-
peared to be interesting findings, extending studies to include the other Scottish
centres and, in some instances, other centres throughout Europe.
3.2 Study setting and patients
The Tayside Breast Cancer Family History Clinic provided the “ base” for the
studies recorded in this thesis. From 1994 onwards, the operation of the “ Breast
Cancer Family Service” was discussed with local General Practitioners and other
interested healthcare professionals (community nurses, staff of “well woman”
centres etc) at study days and through articles in the “Tayren” (“Tayside Primary
Care Research Network”) Newsletter and on the website of the Dundee Univer-
sity Department of Surgery and Molecular Oncology.
Referrals to the service were received from both primary care and other breast
units. The relative proportions coming from these two routes have changed
during the ten years of my involvement, as recorded later.
All referrals were forwarded to the Genetics Department at Ninewells Hospital
and, before any clinic appointment was offered, each woman referred was con-
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tacted by letter with a request to complete (as far as possible) and return a
standardised form (see appendix) detailing family structure and reporting any
instances of cancer among relatives, with as much information about these ill-
nesses as the family could provide.
With this information on the patient’s family history, risk assessment could pro-
ceed, though that often involved checking the information by gaining access to
the case notes of affected relatives (with appropriate informed consent) and in-
terrogating the Scottish Cancer Registry and/or Scottish Registrar General’s re-
cords of births, marriages and deaths.180 These further steps enabled validation
of information and extension of the family history as presented by the referred
woman.
On completion of these steps, a consensus decision was taken by the specialist
staff at the genetic department on the probable level of genetic risk, assigning
each referred women to “High”, “Moderate” or “Low” (“Below threshold”) cat-
egory, according to SIGN guidelines. In principle, management should then
have followed the protocols outlined in Table 3.1.
However, prior to the Triage study, we were concerned that if “low risk” women
were not seen in person, important information might be missed, leading to
errors in assignment of risk category. One purpose of the Triage study was to
evaluate these concerns.
An additional problem was the rather frequent failure of referred patients to
return completed “Family History” forms–some 25% failed to do so even after
a reminder letter. Many brought the completed forms with them when they
attended the multi-disciplinary clinic but this did not fully achieve their pur-
pose, which was to provide the geneticists, in advance of the appointment, with
complete information on which to base their risk assessment and counselling.
Therefore, from 1995 until 2000, all women referred to the service were seen at
least once at the multi-disciplinary clinic.
Those at “low” genetic risk were then discharged, but advised to remain “breast
aware” (i.e. to notify any breast symptoms to their GP), to inform the genetics
clinic of any new breast or ovarian cancers among close relatives and to join
the National Breast Screening Programme (NBSP) at age 50 years. All had a
clinical breast examination carried out by myself and many also had a “one-off”
mammogram prior to discharge.
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Those at “Moderate” or “High” risk were enrolled in a programme of annual
return visits, starting from age 35 years or five years younger than the earliest
age of onset of breast cancer in a relative.
Clinical examination and mammography were carried out at every visit for most
of these, with the exception of some “Moderate” risk women whose affected re-
latives had all been over 50 years at diagnosis, when mammography was un-
dertaken only every second year up to age 40 years and annually thereafter. At
each return visit, women were asked specifically about any new cases of breast
or ovarian cancer among relatives.
Personal information about all the women referred was recorded to enable ana-
lysis of all sources by age, social class, initial genetic risk category, genetic risk
category after checking of family history forms, extent of search (to establish risk
status), final genetic risk assessment.
The Tayside clinic was privileged to have NBSP personnel and equipment, en-
suring optimal quality. Mammography was not offered routinely to women
younger than 35 years of age or if it had been performed within the last 12
months unless the woman was thought, on clinical examination, to have an ab-
normality requiring further investigation.
For women who had a relative with onset before age 40 years, mammography
was generally performed at first consultation as a baseline and thereafter as per
protocol.
Regular annual surveillance continued until age 50 years, when all women be-
came eligible for participation in the NBSP which provides high quality mam-
mography at three year intervals and were subsequently discharged from the
clinic, provided no new cancers have occurred in their relatives and that they
themselves were free from any breast abnormality at their last surveillance ap-
pointment before discharge. However, NBSP represents a substantial reduction
in intensity of surveillance compared to the Breast Cancer Family Service (an-
nual) protocol.
For women judged to be at “High” genetic risk, therefore, surveillance was con-
tinued beyond age 50 years, but at eighteen month intervals rather than an-
nually. The same service was offered to those women in the “Moderate” risk
category who had two or more affected relatives diagnosed after age 50 years.
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In most cases (unless a BRCA1 or BRCA2 mutation had been identified) these
women were discharged to the NBSP by the age of 60.
Counselling was given by a genetics associate, genetics nurse specialist or one
of two consultant geneticists, while the surveillance of those women thought
to be at increased risk of breast cancer (i.e. above guidelines threshold) was
performed by a specialist breast surgeon (normally myself). Radiographers ob-
tained breast imaging and the films were read by a radiologist with breast screen-
ing expertise.
Investigations, such as further breast imaging by ultrasound, and biopsy pro-
cedures were carried out during clinic appointments when required. Referrals
for ovarian and/or other cancer screening were discussed with the patient; fur-
ther counselling appointments were made for those at high risk and/or known
to have a mutation in the family, in preparation for molecular gene testing.
For “High risk” women, identification of a living affected relative was needed
in order to obtain informed consent for DNA testing (current protocol requires
the affected living relative to be tested first).
Once consent was obtained, DNA testing was performed and any result was
reported to the affected relative tested. If this confirmed the presence of a patho-
genic mutation in BRCA1 or BRCA2, then counselling in respect of specific test-
ing was offered to the unaffected relative who had originally been referred.
Other “at risk” relatives were also offered information about the family muta-
tion and enrolment in the surveillance programme if this had not already been
arranged.
Information on prophylactic surgery was given to patients with a proven posit-
ive genetic test for mutation in BRCA1 or 2. Women at high risk for the disease
but who did not have any living relative to allow genetic testing to take place
also had the opportunity to discuss prophylactic risk-reducing surgical inter-
ventions.
The breast surgeon would discuss prophylactic breast surgery with the patient
and referral to the Plastic Surgery Department was made for those wishing to
consider breast reconstruction. When women decided on having both prophy-
lactic mastectomy and immediate reconstruction, this was performed by a breast
surgeon and plastic surgeon together.
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An appointment with the plastic surgeons was always offered to patients having
prophylactic risk reducing breast surgery (i.e. prophylactic mastectomy) giving
them the opportunity to discuss options of breast reconstruction and whether
they would prefer to have it performed at the same time or as a delayed proced-
ure. The plastic surgeons would also arrange for the patient to be seen by one
of their plastic surgery nurse specialists to discuss further the technicalities of
reconstruction options given to them and to show the patient a portfolio of case
photographs of breast reconstruction.
Detailed information on prophylactic oophorectomy (whenever appropriate) was
given by the gynaecologist at a separate consultation with the patient. Ovarian
screening issues were also discussed with women seeking advice on the subject.
They were given information on the pros and cons of having ovarian screening,
based on the most recent data available. Unfortunately, these did not show any
benefit from such intervention.61
With the increase in the numbers of patients on regular surveillance at the clinic,
it became evident that there was an urgent need for further staffing to share
the load of clinical breast examination under the direction of myself. Therefore
a research nurse working in the IBIS I chemoprevention trial181 was trained to
assist me as well as enrolling patients for the chemoprevention study.
With this help, we were able to ensure that the scheduled timetable for regular
repeat surveillance was met. This was important in view of the evidence from
the EC Demonstration Programme that delays or “slippage” in the planned fol-
low up of women at risk leads to an increase in the number of “interval” cancers
(i.e. those presenting clinically between screening rounds) and hence to loss of
opportunities for diagnosis at the earliest possible stage.182
During and after the Triage study (i.e. from February 2000), the protocol shown
in Table 3.1 was followed more stringently, though women who had not re-
turned a completed family history form were still being seen at the multi-disciplinary
clinic while effective ways of dealing with this problem, without discriminating
against women who have genuine difficulty in complying, are worked out with
local general practitioners. The Triage study is the subject of Chapter 4.
From the summary outlined below, the numbers relate to the distribution of
referrals for recruitment in the “triage” study.
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Table 3.1: Management protocol followed by the Tayside Breast cancer family
service. If malignancy was detected in any risk category, treatment would be
arranged as per local protocol.
LOW RISK Reassurance letter explaining why patient was at low risk
(patient and their GP)
One to one consultation with genetics associate to explain
the risk assessment. Clinical breast examination before dis-
charge.
Advised to be “breast aware” and enter National Breast
Screening Programme at 50 years of age
MODERATE
RISK
Appointment at the Joint Family History Clinic arranged,
consultation with both geneticist and surgeon: geneticist ex-
plained risks and the surgeon performed breast examination
and ordered mammography (wherever appropriate)
Follow up at the Family History Clinic arranged as per pro-
tocol (usually annual) if all was well.
HIGH RISK Appointment at the Joint Family History Clinic arranged,
consultation with both geneticist and surgeon: geneticist ex-
plained risks and offered counselling regarding genetic test-
ing and possible referral for ovarian cancer screening; the
surgeon performed breast examination and ordered breast
imaging, (with further investigations if necessary). Options
discussed included genetic testing, and prophylactic sur-
gery (salpingo-oophorectomy, with input from gynaecolo-
gist).
Prophylactic mastectomy (with input from plastic surgeon)
was discussed with patient after a positive genetic test or
sometimes if no mutation result was forthcoming. If a wo-
man declined surgery she would continue with regular sur-
veillance both from the breast and ovarian point of view.
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Figure 3.1: Summarised distribution of the referrals and eligibility for the
“triage” study period here.
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3.3 Detection and recording of cancers in the
“family history” clinic
A major purpose of the clinic was to detect breast cancer in women at increased
genetic risk at the earliest possible stage, in the expectation that this would min-
imise the costs and morbidity associated with treatment, while improving pro-
spects of cure. Data from Tayside were collated and checked by myself before
being contributed to the EC Demonstration Programme for analysis, thus gen-
erating sufficient numbers to evaluate the effectiveness of our own and similar
surveillance programmes.
For each cancer diagnosed among patients referred to the breast cancer genetics
service, (whether or not screen-detected) information on the method of detection
and its management was collected as shown in Table 3.2.
Table 3.2: Data recorded on breast cancers diagnosed among patients attending
the breast cancer genetics clinic
• Patient information
– Means of detection (screen or “interval”, mammography/MRI, palpable?)
– Histological diagnosis and grade
– Oestrogen and Progesterone receptors
– Nodal status
– Patient age at diagnosis
– Assessed risk status
– Number of previous screening rounds
– BRCA1/2 mutation test result
• Management and outcome
– Surgical procedure as per protocol (lumpectomy, mastectomy, bilateral
mastectomy)
– Radiotherapy
– Chemotherapy
– Hormone therapy
– Annual follow-up data
– Complications of therapy
– Local or distant recurrence
– New primary cancer
– Death from cancer or other cause
Cancers cases diagnosed through the “old” breast family history clinic (before
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1994) were also collected, though it should be noted that the criteria used for
enrolment in regular surveillance had been less systematic at that time. Details
of all these findings are presented and discussed in Chapter 5.
A related local pilot study, assessing the clinical and economic implications of
early detection and treatment of breast cancer in young women, was carried out
under my direction. The aim of this small study was to compare the stage, out-
come and management costs of breast cancer diagnosed before age 50 years in
women who had or had not been enrolled in a regular surveillance programme.
It was hoped that this would provide a base for comparison of the potential
reduction in direct healthcare costs if surveillance of those at high risk is effective
in achieving diagnosis of breast cancer at an earlier stage of the disease.
3.4 Psychological issues
Within the Triage study, we wished to measure acceptability of managing “low
genetic risk” women without offering them appointments at the multi-disciplin-
ary clinic. Women who were eligible and consented to enter the trial were ran-
domised to receive a letter or personal interview for discussion of their risk.
They were also asked to complete and return a “satisfaction questionnaire” three
months after receiving their risk assessment.
The satisfaction questionnaires were based on the instrument used in the TRACE
study in Wales183 and included standardised and validated measures of psycho-
logical health and also specific reactions to the service that they had received
(see appendix).
Analysis of the questionnaires was performed using the global experience and
satisfaction scores. Statistical analysis of these scores were performed using the
SPSS (statistical package for social sciences) programme.
A satisfaction questionnaire was also sent to the referring GPs eighteen months
after the end of the study, asking them to complete and return it to Genetics
Department. This simply asked for an evaluation of the service provided and
specifically whether they had been contacted at any time by women discharged
from the clinic, after being told of their “low risk” assessment, with any further
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concerns about their risk assessment or any matter related to continuing cancer
worry.
Focus groups for Tayside GPs and practice nurses have been planned to obtain
their views on the new model for cancer genetic services in Tayside and how the
triage model has affected their practice, particularly regarding the management
of women at “low” familial risk who may express high levels of cancer-related
anxiety. These are taking place at the time of writing.
My own contribution to this element of the study was limited to participation in
planning discussions and clinical evaluation of those patients who mentioned
breast symptoms during interview with a genetics associate or genetics nurse
specialist. Nevertheless, as patient evaluation of the service provided is an im-
portant element in judging its cost effectiveness, I felt it right to include a brief
account of it in this thesis (see Chapter 4).
3.5 Accuracy of “low risk” as defined by guidelines
In order to obtain information about the true breast cancer incidence among wo-
men judged to be at “low” genetic risk (below guidelines threshold for inclusion
in a special surveillance programme), records of all such women (who had been
referred but discharged) were scrutinised to confirm that the risk assessment
had been correct.
Then steps were taken to identify any breast cancers that had subsequently been
diagnosed. Initially, this was undertaken in Tayside as a pilot exercise, instig-
ated by myself, using local breast unit records to track subsequent cancers with
special attention given for the ones who developed breast and/ or ovarian can-
cers.
Later, the study was extended to all four Scottish cancer genetics services (based
in Aberdeen, Glasgow and Edinburgh, as well as Dundee) and cases of breast or
ovarian cancer were traced through the Scottish cancer registry.
The number of women-years of observation within each five-year age group
from the age of 30 years was calculated and the expected incidence of breast
cancer cases for unselected women in Scotland, within the same age groups,
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was derived from National cancer statistics. The findings are presented and
discussed in Chapter 6.
3.6 Health economic and management data
(sources)
NHS costs for each element of breast cancer management process were extrac-
ted, by myself with permission from Dr. John Dewar’s study on economic eval-
uation of the total costs of care of women with breast cancer. Further informa-
tion was obtained by me from the NHS “Blue Book” for costing (Scottish Health
Services Costs Book) and by personal application to Administration Personnel
in the Finance Department at Ninewells Hospital (as some of the information
required was not listed in the NHS health services costs book).
Existing (limited) publications on the costs and outcomes of various manage-
ment strategies for familial breast cancer have been consulted. Many refer to
healthcare systems that differ fundamentally from the UK National Health Ser-
vice but they nevertheless illuminate the universal nature of the difficulties faced
by those who have to set priorities and to justify expenditure.
The data I have been able to collect both from personal experience and through
participation in Scotland-wide, UK-wide and Europe-wide collaborations have
generated real evidence that supports some of the recommendations made in
the published literature but, more frequently, exposes the frailty of the untested
assumptions that underlie many aspects of current practice.
Details of analytical methods and statistical techniques applied are included in
the following chapters.
A decision analytical model (decision tree) with current pathways of a patient
since referral to the Tayside breast cancer family history clinic was constructed
using the DATA 4 (Treeage) analysis programme software184 with a view to ana-
lyse the implications and costs for each pathway of the patient’s journey which
included decision about genetic testing, prophylactic surgery and breast cancer
treatment of patients under regular surveillance through the clinic.
CHAPTER 3. MATERIAL ANDMETHODS 71
Indirect costs (or impact on productive life of an individual) were not considered
for this analysis in view of the difficulties in collecting the data. In fact, indirect
costs are considered of debatable relevance in economic evaluations.93
The decision analytical model should give evidence on both clinical and eco-
nomic outcomes of this new clinic model for the Tayside cancer genetics ser-
vices helping to define best clinical practice and give better resource allocation,
identifying parameters that could affect the outcomes.
It became clear after the decision tree had been constructed in quite an extended
form, with all options of intervention, that real numbers could not be allocated
to every branch of the tree as some of the branches were not discrete options but
strategies. Strategies are not allocated numbers from which the “payoffs” can be
calculated for analysis of costs and cost-effectiveness.
After revision of the decision tree model, I concluded that patient numbers were
too small for complete population of the proposed tree and this approach was
set aside for possible future application.
However, costs for each element of the clinical practice (risk assessment, coun-
selling, surveillance, management of cancers and prophylactic procedures) have
all been calculated as have the benefits of the cancer family service in terms of
earlier diagnosis and prevention of breast/ovarian cancer.
3.7 Personal contribution to related studies in this
thesis
1. Since 1991, I have been responsible for the recording of clinical data of the
family history patients. Since 1994, I have been the sole breast surgeon in
continuous charge of the management of family history patients attending
the clinic in Tayside area.
2. I was involved in the planning of all the research elements in the collective
studies with colleagues involved in the same field of work.
3. The background reading and writing of introduction, literature review,
materials and methods are entirely by myself.
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4. In the triage study (Chapter 4), I was one of the grant holders for it and
was involved in detailed design of all components of the study. I had sole
responsibility for collating and analysing data on clinical investigations
(mammograms, additional views, ultrasound, fine needle aspiration, core
biopsy) and measuring costs of these procedures. I was co-author on two
related publications and first author in the third publication.
5. I extracted, analysed and forwarded to Professor Møller (Norway) all Tay-
side data on cancers arising among patients enrolled in the breast can-
cer family surveillance programme. This was a major contribution to the
European Collaborative Programme on surveillance for the early diagnosis
and treatment of breast cancer in women at significant risk for the disease.
I was co-author on three papers published to date arising from this collab-
oration (Chapter 5).
6. Chapter 5 also deals with the management of women at very high risk (ie.
carriers of mutation in the BRCA 1 and 2 genes) and represents my own
views drawn from my personal experience of the Tayside clinic and with
reference to the European Collaborative study (see above).
7. The studies on the incidence of breast cancer among women judged to
be "below the threshold" level of familial risk reported in Chapter 6 were
instigated by me as result of my personal observations from the Tayside
clinic.
8. I instigated and produced most data for a pilot study which appeared to
confirm my suspicion that the actual incidence of breast cancer was higher
than predicted by the current guidelines in determining individual’s risk
for the disease. I played a major role in the subsequent Scotland-wide
survey, collecting and verifying all the data from Tayside. I am co-author
of one of the resulting publications185 and a second one recently submitted
for publication (authors listed alphabetically by agreement).
9. On cost and effectiveness issues, I undertook all relevant background read-
ing, identified and interviewed individuals with particular expertise to
compile and update estimates of all costs incurred in breast cancer screen-
ing and disease management. I applied outcome data from the Tayside
clinic and from the European Collaborative Programme and then with the
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advice of Dr Manouche Tavakoli, my other supervisor, I undertook sensit-
ivity analyses by modifying the most critical parameters in order to reach
my own conclusions which I believe represent a uniquely comprehensive
measure of the cost-effectiveness of clinical practice in the field of familial
breats cancer management. I am first author on a manuscript reporting
this work, which is about to be submitted for publication.
10. The overall conclusions from this thesis rest, to a substantial degree, on
the original work which I have undertaken personally, as detailed above.
That has been supplemented by sharing "the experience of colleagues" for
example, the latter part of Chapter 4 and from my reading particularly in
the area of quality of life and other psychological aspects of familial breast
cancer.
Each of the following chapters relates to one or more of the “Key questions”
listed at the end of Chapter 2 and to one or more of the linked studies in which
I have participated. Detailed methods are described further in the appropriate
chapters.
Chapter 4
Verification of family history
The following key questions have been addressed in this section:
Do GP referrals to the genetics clinics match the established guidelines criteria?
How does accuracy of risk assessment change under different protocols?
What are the costs of enrolling a woman in a surveillance programme? What
savings are achieved by more accurate risk assessment? How does this compare
with the costs of undertaking that more accurate assessment? What other impact
does more accurate risk assessment have on delivery of a breast cancer family
service?
These questions translate into the following issues that can be addressed by spe-
cifically designed research studies.
The UK-wide survey of breast cancer family history clinics undertaken in 1998,
published by Wonderling and colleagues in 2001,45 indicated that some 26% of
referrals did not meet guideline criteria for women at “moderate” (or higher)
risk. For the four Scottish clinics, including Tayside, this figure was 33%. That
might be taken to imply that general practitioners (particularly those in Scot-
land) were failing in their “gatekeeper” role.
However, experience in the clinic had convinced me that adequate assessment
of familial risk takes a considerable amount of time and, in many cases, requires
access to hospital and National records.
GPs themselves have repeatedly pointed out40–47 that they are ill-equipped to
fulfil the role allocated to them in the 1996 Working Group Report and in sub-
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sequent guidelines.38, 39 Furthermore as we have recorded in published work,
the estimates of accuracy of cases of breast cancer reported by relatives seri-
ously underestimate the potential error rate when compiling an extended fam-
ily tree.186 Women are likely to benefit from appropriate genetic counselling
that improves their understanding of the concept of risk, helping them in de-
cision making. Genetic counselling requires risk assessment to be as accur-
ate as possible, particularly if it entails recommendations for molecular genetic
testing. Assessment of genetic risk status for the disease, should be delivered
by a trained healthcare professional with specialised knowledge of the subject
area.179
Through discussions with Tayside and North Fife GPs at study days and sem-
inars, it became clear that they rarely, if ever, took responsibility themselves
for deciding whether or not a woman concerned about possible familial risk
of breast/ovarian cancer should be referred to the cancer genetics service. In
practice, they referred them all.
I therefore decided, in consultation with my genetics colleagues, that we should
carry out a formal assessment of the risk status of all women referred to the
Tayside clinic and that the study should record the amount of effort required to
reach a confident risk assessment, the costs of that exercise and the implications
for cost-effective organisation of the service.
4.1 Evaluation of risk
The Tayside multidisciplinary breast cancer genetics clinic serves a population
of around 500,000 and operates within a network of Scottish regional cancer
family history clinics.
From 1994, patients who had been kept on regular follow up at a surgical clinic
because they reported a family history of breast cancer in their relatives, were
given an appointment to the new local joint breast cancer family history clinic
(women were seen by both a geneticist and a surgeon at the same session) for
formal evaluation of their risks for the disease.
New referrals to the clinic would follow the same process of risk assessment,
even if the given information about their family history appeared to place them
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in the “low risk” category.
Some of these women had been attending the surgical clinic for follow up for as
long as 17 years. Therefore, for the surgeons, those women were not regarded
as new referrals. Conversely, all women seen at this new clinic were regarded
as “new referrals” by the geneticists as they were seeing them, for the first time,
for formal assessment of their risk.
The number of referrals to the joint breast cancer family history clinic increased
and the clinic soon became overloaded, with the waiting time for patients soar-
ing far beyond the recommended time to be seen under the government guid-
ance (within 26 weeks from referral; this is due to fall to 18 weeks from Decem-
ber 2006).
The backlog of existing patients to have their outstanding risks assessed was in
excess of 400 and there were around 100 new referrals to the clinic per year, re-
quiring allocation of an appointment for formal assessment of their breast cancer
risks.
It is important to highlight that in 1994 the distribution of the risk categories
into low / moderate / high was somewhat haphazard before formal risk as-
sessment criteria were applied and that probably only 50% of the referrals to
the clinic came directly from GPs, the remainder coming via the symptomatic
breast service (though the symptoms originally justifying referral were no longer
relevant–they had resolved with exclusion of malignancy and, in some cases had
been, by admission, spurious, designed to obtain access to mammography).
When a “low risk” assessment was confirmed, further follow up for those wo-
men was not required but, in all cases breast examination and sometimes mam-
mography were performed during their consultation at the multidisciplinary
breast cancer family history clinic.
With the numbers of new referrals increasing and the existing backlog of pa-
tients of previous years to be assessed, the structure of the Tayside clinic needed
to be rearranged to ensure that women could be seen within the time recom-
mended by the Government.
We also hoped to address the concerns raised about the potential scale of de-
mand for the service and the apparent social class bias (over-representation of
women from social class 1 and a deficit of those from social class 5).63, 187–189
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There is no reason to believe that women at increased familial risk for breast
cancer should be found disproportionately in any one social class.
The “Triage” study described in this chapter is of importance as it is designed to
assess the efficacy of a Tayside breast cancer family service that imposed limits
on the number of women for whom it would be available.
With approval from the Tayside Medical Research Ethics Committee and fund-
ing from the Scottish Executive Health Department (Chief Scientist Office) as
described in Chapter 1, women referred to the Tayside breast cancer family ser-
vice were invited to participate in a study of “postal” risk evaluation and, if
assessment placed them below the “threshold” level of risk for inclusion in a
special surveillance programme, notification of that outcome either by letter or
by face-to-face interview.
During the period of thirty months between August 2000 and January 2003, 379
new referrals to the Tayside breast cancer genetic clinic were recorded (303 re-
ferrals per year per million population).
Of these referrals, over 75% of the patients came directly from primary care com-
pared with an average of only 49% in the UK survey reported by Wonderling in
2001. We also recorded an increase in referral rate of around 25% since the Won-
derling survey data were collected for our region.
Family history questionnaires were returned by 74% of the women referred. The
remaining 26% (97) of the women did not return their questionnaires, even after
a reminder letter (though many subsequently brought their completed question-
naire to the clinic appointment).
Sixty-five women (23%) who did complete the form did not give informed con-
sent to participate in the trial. In fact, only 18 of the 65 women actively declined
participation in the study; the remaining women simply did not return the con-
sent to the study or returned it unsigned.
A clinic appointment was offered to all women who either did not complete the
form or declined participation in the study. Breast examination was performed
on those women by an experienced breast surgeon (myself) and many of them
also had a mammogram prior to discharge to ensure that no breast abnormal
pathology was present. Some women brought the signed consent form to enter
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the study with them for their clinic appointment but this was too late for ran-
domisation.
In total, two hundred and ninety-one patients were offered an appointment at
the multidisciplinary clinic (this included the women who did not return their
questionnaires, moderate/high risk patients and women who did not consent
to enter the study).
Of the 291 appointments offered, twenty-eight (9.6%) patients either did not at-
tend their clinic appointment on at least two consecutive occasions, despite re-
minder letters that were sent to them, or cancelled their appointment. Six pa-
tients moved away from the Tayside area before their appointment date. Thus,
two hundred and fifty seven women were in fact seen at the clinic.
Thirty-seven per cent of women seen at the multidisciplinary clinic (n=94) re-
quired no further follow-up either because of their age (having become eligible
for the National Breast Screening Programme) (26) or because they were as-
sessed as “below threshold” risk (68).
In total, of the original 379 referrals to the clinic, 155 (41%) women were classi-
fied as “low risk” for breast cancer and should, in fact, have been “screened out”
by colleagues in the Primary Care setting as described in the current guidelines.
Among these, 68 (26.5%) of 257 women seen at the multidisciplinary clinic were
at “below threshold” risk for breast cancer.
For the women referred, information was recorded on the source and route of
referral as well as on employment status which, together with the women’s res-
idential postcode (correlating with deprivation category) enabled us to make a
socio-economic profile of the women.190
During the period of the study, we found that the social class distribution of wo-
men referred to the Tayside breast cancer family service matched that of newly
diagnosed cases of breast cancer in the same catchment area.189
This contrasted with a comparable audit in 1996/1997, when there was a marked
bias towards higher social class, with an excess of women with medical/nursing
backgrounds, as also found elsewhere.187–189
Of the 217 patients (77%) who consented to enter the trial, a full risk assessment
was performed prior to any clinic appointment and of these, 127 patients were
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categorised in the “moderate” or “high” risk categories. They were not random-
ised in the study; an appointment was made for them at the multi-disciplinary
clinic.
After full assessment of the women’s risks for the disease, 90 (41.5%) were ran-
domised into the study: 42 patients received an explanatory letter about their
low risk category and 47 patients were interviewed. (One woman, provisionally
assigned to the “letter” group was withdrawn, as explained later).
The term “low risk” was studiously avoided in communication with patients
and it was emphasised that all women, regardless of family history, are at meas-
urable risk of breast cancer, hence the need to remain “breast aware”.
Of the women interviewed, 45 were discharged from the clinic and 2, initially
thought to be at low risk, on interview with the genetics associate had their risk
status altered from an initial assessment of “low” to “moderate”; (i.e. some rel-
evant information had not been provided in the returned questionnaire prior to
the consultation). These were enrolled in the multi-disciplinary clinic for regular
follow up.
All letters sent to the women were copied to their GPs and the GPs were also
given a detailed letter explaining the women’s risk assessment. It was made
clear to the women that any new information about their relatives’ cancer history
should be notified to the cancer genetic service in order to allow further risk
assessment of the individual seeking advice.
Information was also given to them about lifestyle and the need to be “breast
aware”, and they were encouraged to participate in the National Breast Screen-
ing Programme from the age of 50 years. If any breast symptom should develop,
they should seek advice from their GP at first instance.
Three women at their interview with the genetic associate mentioned that they
had breast symptoms and they were promptly referred to myself, leading to
appropriate investigations of the symptoms. As no significant breast pathology
was found, all of them remained in the “low risk” category.
One “low risk” woman assigned to receive a explanatory letter was withdrawn
from the group as she was found to be affected with breast cancer on examina-
tion at the symptomatic breast clinic and, after treatment, was kept on surgical
follow up (she had, in fact, reported breast symptoms as well as a positive fam-
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ily history, so her planned route was first via the regular breast service and then
the cancer genetics clinic).
Thus, eighty-seven of the 379 women referred to the Tayside breast cancer ge-
netics clinic (23%) were discharged from the clinic without clinical or mammo-
graphic examinations.
One hundred and ten women were placed on regular annual follow up from
their first appointment at the Tayside clinic and 36 patients were temporarily
discharged from the clinic as being too young for regular screening. We recom-
mended that they should be re-referred when older, according to our protocol
(age 35 years or 5 years younger than the earliest onset in their family).
One patient in the category above was found to have a breast cancer during
pregnancy (she was to be re-referred to the clinic for regular surveillance to be
initiated when she reached age 34 years, but she was diagnosed at the age of 32
years) and is currently undergoing treatment. Her close relatives’ risk will be
reassessed in the light of this event.
In view of geographical distance, follow up at Perth Royal Infirmary Hospital
(part of the Tayside Teaching Hospitals Trust) was offered to 7 women.
Some of the women were placed on an 18-monthly follow up schedule, altern-
ating with the National Breast Screening Programme because they were still at
significant risk for the disease beyond the recommended age (50 years) for dis-
charge to the National Breast Screening programme. (See Figure 4.1)
The questionnaire on family history (see appendix) is designed to be clear and
simple. However, it usually requires cooperation between several members of
the family and, as a result, discussion about the implications of familial cancer
is inevitable. Raising the issue at an early stage of the process rather than later
has definite advantages because of the wider circle of relatives that are likely to
become involved in due course.
Holloway and colleagues76 in Lothian demonstrated in a study that the collec-
tion of the family history information in advance shortens consultation at the
cancer genetics clinic by up to 30 minutes.
With the questionnaires in hand, risk assessment begins with the drawing of
the family tree by the genetics colleagues. Once the drawing is completed, the
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Figure 4.1: Trial Project Summary. This shows the patient’s clinic detailed path-
way under the new model for the Tayside genetics breast cancer clinic.
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genetics colleagues expand the tree (if required) by collaboration with a cancer
registry-based genealogist.
Further checks of the information provided are then made by interrogating the
Scottish Cancer Registry and/or the records of the Registrar General for Scot-
land (births, marriages and deaths). The genetics associate can also request per-
mission from affected relatives for access to their hospital notes to obtain patho-
logical details, confirmation of dates of diagnosis etc.
In the Triage study, the extent of this checking varied in relation to the com-
plexity of the given family history. Some of the families’ information did not
require full check but hospital or official records were consulted for over 50% of
the referrals. For example, the genetics associate in Tayside used the cancer re-
gistry professional genealogist for 35% of the referrals to the clinic. This service
is provided by the Information and Statistics Division (ISD) of NHS Scotland.180
Thus evaluation of familial cancer risk proceeded in at least three stages, based
on
1. referral letter,
2. family history form, and
3. verification and extension from official records.
The aim of this staged process was to give as accurate as possible a breast cancer
risk assessment, though errors could not be eliminated completely. An outcome
that was not unexpected was an increase in the proportion of referrals to the
clinic that were classified as having a “low” genetic risk for the disease.
The analysis of various stages of the risk assessment process in our local clinic is
demonstrated in Table 4.1:
Based on data of 345 consecutive referrals (original 379 minus 34 which were
in fact, 28 women that failed to attend their clinic appointment and 6 women
that moved away from Tayside area by the time of their appointment). Based on
the referral letter (from GP or other clinician) only, the figures show that for one
third of the women no level of risk could be assigned, hence the need for further
information from the patient by filling the family history questionnaire. Those
figures show that for most categories of risk, progress through the three stages
CHAPTER 4. VERIFICATION OF FAMILY HISTORY 83
Table 4.1: Percentage of referrals placed in different risk categories at each stage
of the assessment process. * Hospital case notes, Cancer Registry, Registrar Gen-
eral’s records. Numbers in brackets represent the 95% confidence intervals.
Assigned risk Information base for risk assessment
Referral letter RL + Family History RL + F/H Form +
(RL) only (F/H) form official records*
Low 25% (21–30) 30% (25.5–35) 40% (36–46)
Moderate 35% (30–40) 57% (52–62) 50% (44–54)
High 6.5% (4–9.5) 6.5% (4–9.5) 10% (7–14)
Unknown 33.5% (29–39) 6.5% (4–9.5) 0 (0–1)
of risk evaluation it results in significant changes in the distribution of the study
population in relation to risk allocation.
When the questionnaire was completed and returned to the Genetics service by
post, or as we saw, returned during the course of the clinic appointment, all but
6.5% could be allocated to one of the three risk categories.
Hospital notes, Scottish Cancer Registry and public records of births, marriages
and deaths were checked and thereafter a more accurate risk level could be as-
signed to the women seeking advice.
Table 4.2: Sensitivity and specificity of risk assignment
“Low risk” after “High risk” after Total
full evaluation full evaluation
“Low risk” after
letter alone 84 2 86
“Higher” or “unknown” risk
after letter alone 54 205 259
Total 138 207 345
Table 4.2 clearly shows that more women have to be evaluated fully to establish
the low risk.
Sensitivity of letter alone = no. of true high-risk patients detectedtotal no. of true high-risk patients =
205
207 =99%.
Specificity of letter alone = no. of true low-risk patients detectedtotal no. of true low-risk patients =
84
138 =61%.
This ilustrates that GPs tend to err on the side of caution i.e. if in doubt they
refer their patients. This may reflect the concept that genetic risk assignement
should be left for genetics professionals to perform including the backup access
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they have to Cancer Registry and Registrars General records. In fact, the Cancer
Genetics team does not know the number of potentially high risk women that
are incorrectly screened out by their GPs as a few women are still encountered
who were wrongly reassured by their GP, for example when they were told that
breast cancer risk cannot be transmitted by a male relative.
The extent of these checks was variable, based on clinical judgement. Table 4.1
demonstrates the changes in distribution of risk categories at each stage of the
process (either increasing the risk estimates or decreasing) as the checks contin-
ued.
In moving from stage 1 to stage 3, the initial “uncertain” risk category was elim-
inated but the proportion of “low risk” assessments increased as the process was
followed through. However, it is important to note that some of the women con-
sidered to be at “low risk” on the basis of GP referral were assigned to a higher
category after further checks.
Hence the overall increase in proportion of “low risk” referrals from 25% to 40%
does not simply mean that an additional 15% of “low risk” cases were added to
the initial set. Accepting the referral letter at face value in order to assign risk
would have resulted in several women incorrectly being denied access to the
surveillance programme.
Resources for this exercise are not available in primary care and hence the ex-
pectations that GPs will be in control as “gatekeepers” in this field should be
modified. As noted earlier, several published papers have recorded reluctance
on their part to provide this service.40–42, 44, 74, 191
As previously mentioned, three out of ninety women, initially judged to be at
“low risk” based on the family history form check, had to be withdrawn from the
randomised trial because one was diagnosed with breast cancer at the clinic and
the other two because their risk level was revised and changed to “moderate”
when further information on the family history was elicited at the interview
with a genetics associate.
It must therefore be admitted that even very careful evaluation of genetic risk
will prove incorrect on some occasions. From the scheme presented in Figure 4.1
and the findings detailed later, we estimate that the error rate (failure to identify
“moderate” or “high” risk under the conditions we have applied) is around 4%.
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4.2 Cost implications of applying resources to
checking family history
A detailed survey of the activities in the multi-disciplinary clinic has been car-
ried out over the Triage trial period. It showed that 54% of “low risk” women
seen at the clinic actually had a mammogram performed.
It should be emphasised that these women were seen at the clinic because they
could not be randomised in the triage study (either because they had not con-
sented or because they had not returned a completed family history form). In
all cases, the intention was to discharge these women after a single visit to the
multi-disciplinary clinic.
Additional investigations were required in 18% of the women attending the
clinic (overall figure). However, 28.6% (22/77) of women judged to be at “low
risk” had additional investigations after a mammogram was performed. While
the basic Health Service cost for each visit to a multi-disciplinary clinic is estim-
ated at £25, if a mammogram is carried out as part of the investigations, cost
will rise to at least £100, while additional investigations carry the costs shown in
Table 4.3.
Table 4.3: Details and costs of the additional investigations performed according
to the risk category distribution of the women attending the Tayside clinic.
Extra
mammo-
grams
(£80)
Ultrasound
(£69)
MRI
£400)
Fine
Needle
Aspiration
(FNA)
(£100)
Core
biopsy
(£500)
Low risk 6/42 7/77 0/42 6/77 3/77
Moderate risk 12/106 7/157 2/106 2/157 3/157
High risk 2/24 0/35 0/24 0/35 0/35
TOTAL 20/172* 14/269 2/172 8/269 6/269
* Number of each additional investigation per mammogram performed (extra
views or MRI) or per clinical examination (ultrasound, FNA or core biopsy). The
costs per investigation were derived from Tayside University Hospitals Trust
“blue book”.
In the table above, the total number of investigations/ examinations exceeded
the number of women seen at the clinic because in some cases women were re-
called by the surgeon for further check of their breasts to make sure, for example,
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that a cyst that had been aspirated had not refilled or to check that symptoms
had settled.
The numbers of mammograms and clinical examinations are not identical be-
cause several women had had a mammogram within the preceding 12 months,
while others were seen at the clinic for counselling before the age at which mam-
mography would be recommended (normally 35 years).
Particular note should be taken of the “low risk” women examined (77) and
those who also had further investigations performed (42 mammograms, 6 extra
views, 7 breast ultrasound scans, 6 FNAs and /or core biopsy) as this represents
a total cost to the NHS of £8,110 (i.e. an average cost of £119 per each one of the
“low risk” women seen at the clinic). No breast cancers were diagnosed among
these 77 women.
Substantial costs for the NHS will continue to occur with very little return if wo-
men thought not to be at increased risk for breast cancer reach a multi disciplin-
ary breast cancer family history clinic. Many of them will have a mammogram
and further investigations performed, as demonstrated in this study.
Reasons for the additional investigations may reflect the need for reassurance
of the clinician discharging the women from the clinic that no underlying breast
abnormality is present. Furthermore, for many women who did not return the
family history questionnaire, the risk assignment could not be completed and
confirmed until after the woman’s consultation at the clinic. Hence they were
managed at the initial consultation as potentially at sufficient risk to warrant
inclusion in a surveillance programme.
Since surveillance for women at increased genetic risk for breast cancer is re-
commended from age 35-50 years, the potential NHS cost for each woman so
enrolled is at least £1,500 (£100 × 15). Thus, if the proportion of referred women
who do not require surveillance can be raised from 25% to 40%, savings will be
substantial.
For the Tayside clinic, with some 150 new referrals per year, imposing the strict
risk assessment protocol described can increase the number of women assessed
as “low” risk from 37 to 60. By avoiding the inclusion of these additional 23
women each year, savings of at least £2,300 are achieved in one year and, since
surveillance is avoided for a period of fifteen years in each case, the total saving
achieved is £34,500 (£2,300 × 15).
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Since we find that the necessary checks can be undertaken effectively by genetics
associates/genetics nurse specialists and occupy the equivalent of no more than
three sessions per week, the practice is clearly cost-effective.
As noted earlier, we do also rely on input from the medical genealogist at the
Cancer Intelligence Unit of NHS Scotland Common Services Agency. However,
she provides the specialist service for all four Scottish cancer family clinics (cov-
ering colorectal and other familial cancers in addition to breast/ovarian). The
Tayside breast cancer family clinic accounts for approximately ten percent of
referrals across Scotland to these clinics.
From our experience, an error rate of around 4% for risk assignment is expected
even when relying on family history information provided by the questionnaire
and subsequently subjected to full checking. This is likely to result in a small
number of cancers being missed through failure to provide surveillance where
it would, in fact, be justified.
On the other hand, as pointed out earlier, the strict assessment protocol we have
described does result in several women being reassigned from “low” to “mod-
erate” or even “high” risk categories.
Thus, sequential checking of the family history information provided is expec-
ted to achieve, to a degree, the aim of concentrating resources on those families
most likely to benefit from the programme.
Only a long term “follow up” check of the women discharged from the clinic
(“low” genetic risk) however will reveal the true incidence of breast cancer in
this category.
If we extrapolate our findings (noting that the Wonderling 2001 study45 found
great similarity among the 22 clinics surveyed) then, considering that the total
UK population is around 55 million, the number of women referred to breast
cancer family clinics each year would be 16,500. If the proportion correctly iden-
tified as below the “moderate risk” threshold were increased from 25 to 40% (i.e.
6,600 instead of 4,125–a difference of 2,475) the annual saving to the NHS would
be £ 3,712,500 (2,475 × £100 × 15).
Even if the total number of clinics operating across the UK increases to between
35 and 40, that still permits substantial investment in professional staff without
a net rise in operating costs.
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In terms of the key questions set out at the start of this chapter, I have shown
clearly that Primary Care is not the appropriate level at which to "screen out"
or "screen in" women whose family history would justify inclusion in a special
breast cancer genetics service.
The three-stage protocol I have evaluated greatly improves the accuracy of risk
assignment while still falling short of perfection. A minimum cost of enrolling
a woman in a special "family history" breast cancer surveillance programme is
£1500, rising as investigations additional to mammography are included. These
costs do not appear to be justified for the majority of women whose family his-
tory places them at less than the guidelines “threshold” level of risk.
Applying the three-stage risk assessment protocol described leads to an over-
all increase of around 15% in the proportion of referred women who could be
discharged as falling below the "treshold" risk level. The cost of conducting the
formal risk assessment is clearly outweighed by the savings achieved and, in
addition, some women who could have been excluded (incorrectly) on the basis
of incomplete ascertainment of risk, can now be enrolled in the surveillance pro-
gramme.
4.3 Patient and GP satisfaction
I collaborated in the following component of the Triage study, addressing the
question “How acceptable, to patients and GPs is a system whereby familial
breast cancer risk is assessed before any clinic appointment is offered and where
women at less than “moderate” risk (not eligible for a surveillance programme)
may receive that information only by post?”
A recent meta-analysis of studies on genetic counselling demonstrates that coun-
selling of individuals at increased risk for breast and ovarian cancers signific-
antly decreases general anxiety levels. However, it did not show a significant
reduction in psychological distress among those individuals, with conflicting
evidence whether counselling actually increases or decreases the accuracy of in-
dividuals’ risk perception.192
Even though, as explained in Chapter 3, I had only limited involvement in the
women’s interviews or giving information of their “low risk” status by letter, I
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thought it was relevant to give some consideration in this thesis to the subject
of the impact that the information (and hence exclusion from special surveil-
lance programmes) can have. The following section summarises the satisfaction
outcomes found during the course of the study.
The women who agreed to participate in the study (investigating the ways of
communicating the information that their familial breast cancer risk assessment
falls below the current guidelines for management in a secondary or tertiary
care setting, by either a letter or personal interview) and who were randomised,
received a questionnaire 3 months after their interview or receipt of the explan-
atory letter, to assess how satisfied they were with the experience of delivery of
risk assessment and subsequent advice (“satisfaction questionnaire”).
The questionnaire itself was based on one designed and applied in the Welsh
“TRACE” study.78 It comprised well-established and validated psychological
measures as well as free-text boxes (see Appendix).
The questionnaire distributed to general practitioners was much simpler, and
simply sought their opinions on how the process had affected their own patients
(Appendix).
Analysis of the “satisfaction” questionnaire was performed by Dr Gozde Oza-
kinci from the Department of Health Psychology at the Bute Medical School, St
Andrews University.
Seventy-one of the 90 women randomised in the study (79%) completed and
returned the three-month “satisfaction questionnaire”. Those women had been
referred by 82 General Practitioners, of whom 64 (78%) responded to our follow
up questionnaires (with replies relating to 69 women - 77%).
In summary, the data showed that the two methods of delivering the informa-
tion to the participants were acceptable to both the referred women and to their
GP’s although the women expressed a slight preference for interview.
There was some confusion in the understanding of absolute and relative breast
cancer risk information given to the women and this demonstrated that provi-
sion of numerical information was unsatisfactory.
Comments in the free text boxes revealed that some women remain convinced
that their risk was underestimated, while, conversely, a substantial minority ap-
peared to believe that they were not at risk for breast cancer at all.
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Expanding a little on the above summary, some extracted items in the question-
naire showed the following outcomes as quantifiable responses and free text
answers to open ended questions:
When asked about breast cancer concerns (6 items) the correlation inter-item
was good and the items were averaged to generate an index of breast cancer
concerns. No difference between “letter” and “interview” groups was seen: in-
dependent samples t-test; t(69) = −0.636, p = 0.527.
Ten items were included in the question about actions since referral and correl-
ation among items varied but all were significant. Samples t-test did not reveal
any difference between “letter” and “interview” groups. All ten items were
tested.
“Women’s experiences since referral” had 12 items and correlations between
them were all significant so the scores were averaged and an independent samples
t-test was used. The difference between averaged scores for “letter” and “inter-
view” groups did not reach significance; t(69) = −1.676, p = 0.098.
Independent samples t-test used for the question about “personal breast cancer
risk estimate” indicated a significant difference between “letter” group (mean
score 2.0) and “interview” (mean score 2.38). Those receiving the risk assessment
information at interview, perceived that their risk was slightly higher than those
informed by letter; t(69) = −2.246, p = 0.028.
When we came to the question of “concern about personal breast cancer risk”
the independent t-test showed no significant difference between “letter” and
“interview” groups; t(69) = −0.705, p = 0.483.
In the “Population lifetime risk of breast cancer” question, respondents were in-
vited to estimate the population risk in two formats. In one of those formats, five
responses were missing and therefore only 64 responses were analysed, inde-
pendent t-tests showed no difference between “letter” and “interview” groups;
t(64) = 0.424, p = 0.673 and t(69) = 0.194, p = 0.846.
The following question on “your own lifetime risk of breast cancer” was also
posed in two formats. Five responses were also missing from one of these.
The differences were not significant for either format between the groups. In-
dependent samples t-tests were as follows: t(64) = 1.036, p = 0.304 and t(69) =
−0.249, p = 0.804.
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Both population and personal risk estimates were inaccurate and the correla-
tions between estimates in the different formats by the same respondent were
poor.
In five of the twelve items in the question about “satisfaction with the process”,
the “interview” group expressed significantly higher levels of satisfaction when
compared with the “letter” group (p range 0.020 to 0.001). However, the mean
scores for the “letter” group were still between the “quite satisfied” and “very
satisfied” range.
None of the differences found between “letter” and “interview” groups were
significant when scores were analysed in the General Health Questionnaire for
each of the four subgroups. Independent samples t-test was also carried out on
each one of them.
The majority of the respondents indicated when answering the open questions,
that they were contented with the process, although some of them left the text
box blank.
Seven women stated that after assessment they now believed that they were at
very “low” risk for the disease, perhaps even below the general population risk
(four from the “letter” group and three from the “ interview” group). Some ex-
tracted answers are shown: “Quite happy that I am at considerably low risk”. “I was
happy to learn that it doesn’t run in families and I am more relaxed about everything”.
“Happy to know my risks are not increased by my mother having developed breast can-
cer”.
A further seven women stated the opposite - that they had not accepted the
assessment that they were not at increased genetic risk (four from the “letter”
and three from the “interview” group). The extracted answers reflect this: “I
don’t know if I believe what you told me; you are giving me a result from statistics
which can prove whatever you want to prove. You are not giving me medical facts”. “I
cannot feel reassured by the response I received”.
No women have complained to their GPs about the way their risk status was as-
sessed or communicated. Only four of the women have returned to their family
practitioner with further concerns about breast cancer in the 18-48 months since
receiving their clinic report.
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Two of them simply wished to have further discussion about the information
that they had received from the genetics clinic. The other two women had new
breast symptoms (breast discomfort) and these were investigated at the regional
breast service. So far no breast cancers were recorded by the women’s GPs.
The GPs replies to their “satisfaction” questionnaire revealed that nearly all were
completely satisfied with the women’s management at the clinic model (62/64).
Two GPs expressed some dissatisfaction with the new clinic model. One of them
had reservations in view of the time elapsed between his referral and the com-
munication of the woman’s “low” risk assessment (several months). The second
GP was dissatisfied because he did not have any record of the outcome of his
referral although a copy letter of the outcome was sent to him at the time of the
woman’s consultation.
Forty-six GPs (72%) had no reservations about the policy of risk evaluation be-
fore any clinic appointment was offered to the women referred. Similarly, they
accepted that appointments would not be offered to women judged not to be at
increased genetic risk for breast cancer (after full assessment) with an explanat-
ory letter being a satisfactory substitute (46/64).
However, 17 GPs had some reservations (one with “serious” reservations) in
relation to the difficulty for some women in completing the standard Family
History background questionnaire sent to them prior to any appointment at the
clinic. Those issues will be discussed further in the final chapter covering re-
commendations for the future of the service.
Our analysis demonstrates that “postal” assessment and communication of risk
status is a feasible and acceptable element of a comprehensive clinical service
for familial breast cancer. However, there is a need to improve the explanation
of actual risk levels.
This latter finding is consistent with previously published conclusions from sev-
eral other groups.193–196 Communication of risk in a clear and rational way is
evidently very difficult to achieve.
Further consideration should also be given to the development of healthcare
systems that address the needs of women worried about their risk for breast
cancer who believe they should be offered more (e.g. formal counselling and
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breast screening) from the breast cancer family history service, even though very
few are likely to benefit in terms of earlier diagnosis.197
4.4 Conclusions
The Triage study has provided some answers to the key questions set out at the
opening of this chapter.
Do GP referrals to the clinics match the established guidelines criteria?
Our evidence shows clearly that GPs are right to have concerns about their abil-
ity to make accurate assessment of their patients’ genetic risk for breast cancer.
The figures (Table 4.1) suggest that they tend to err on the side of caution, that is
they refer to the Genetics clinics many more patients than the guidelines would
justify. This is consistent not only with published reports cited in the thesis but
also with informal reports from GPs study days at which they have discussed
their practice in this regard.
How does accuracy of risk assessment change under different protocols?
The data summarised in Table 4.1 showed that successive stages of intensifica-
tion of family history extension and verification lead to increasing accuracy and
precision of risk assessment. The Scottish clinics are in particularly fortunate
situation in being able to call on the expertise of a medical genealogy service
attached both to the Scottish Cancer Registry and the Registrar General for Scot-
land’s records of births, marriages and deaths.
Nevertheless, since this work was completed, there has been a study undertaked
in Teeside which showed that deployment of genetic risk assessment profession-
als ("GRAPS") resulted in an outcome which is almost identical to that recorded
in Table 4.1.198
What are the costs of enrolling a woman in a surveillance programme? What savings
are achieved by more accurate risk assessment? How does this compare with the costs of
undertaking the more accurate assessment?
On Tayside, we were able to undertake the complete (3 stages) protocol of risk
verification (assessment) for all referrals by using less than 50% of the time of a
genetics nurse specialist or genetics associate. The savings amount to approx-
imately £34,500 each year which is considerably more than the salary cost. This
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calculation is of course, simplistic, being based simply on the increase from 25
to 40% in the proportion of referrals jugded to fall below the guidelines risk
threshold for surveillance.
In fact, the change is more complex because for some patients, the risk assess-
ment was actually increased so that targeting of the screening programme be-
came more effective. At present, it is not possible to attach a monetary value to
this aspect of the change.
What other impact does more accurate risk assessment have on delivery of a breast cancer
family service?
GPs are very content with the model but the impact on those patients who
no longer receive appointment to the multidisciplinary clinic is evidently more
mixed. It is clear that a number of them resent exclusion from regular mam-
mography while others misinterpret the reassurance about their level of risk,
apparently believing that they are at lower risk than the normal population.
Future work
Our study has not examined an important issue of the practical benefit (or lack
of it) to a woman who is enrolled in a special surveillance programme. That
issue needs to be addressed and indeed later on, this thesis sets out to do so
(Chapter 5).
It is possible that in the future more objective (molecular genetics) methods of
assessing inherited breast cancer risk will become the “gold standard” and it
will be of interest to compare current indirect methods with these. The concerns
of women judged to be at less than threshold risk also need to be addressed to
see whether more appropriate provision can be made for them.
Appropriate studies are currently being planned but are beyond the scope of
this thesis.
Chapter 5
Cancers detected in the surveillance
programme
In this section the questions are as follows:
• What is the rate of detection of breast cancers in young women (35–50
years of age) at increased familial risk undergoing annual screening?
• What is the sensitivity of cancer detection (i.e. rate of interval cancers)?
• Is clinical examination a useful adjunct to mammography in these respects?
• Do screen-detected cancers in this setting carry a better prognosis than
non-screen detected? – either in terms of pathological stage at diagnosis
or in terms of outcome on follow-up?
• Are there differences in effectiveness of surveillance according to category
of genetic risk? If so, are these differences sufficient to suggest that differ-
ent management strategies may be appropriate for different groups?
5.1 Tayside experience
Cancer case distribution shown in Table 5.1 below reflects the evolution in the
assessment of patients at risk for the disease, based on my personal experience
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in Tayside. All figures quoted include both invasive cancers and carcinomas in
situ.
It is evident from Figure 5.1 that among the “formerly symptomatic” women
followed up between 1977 and 1994 because of their family history, several were
rather quickly found to have a breast cancer (first visit).
It is difficult, in retrospect, to know what part a suspicion of underlying can-
cer may have played in the decision to organise regular follow-up, particularly
during the period before mammographic screening became routine (late 1980’s).
The lack of this important screening tool also accounts for the high proportion
of cases during that period who were “symptomatic” at presentation (i.e. they
had an abnormality detected by themselves or by the examining surgeon).
Despite the lack of “genetic rigour” applied during the years to 1994, the policy
of providing regular follow-up for women with a family history of breast cancer
was innovative and has resulted in the Tayside breast cancer family history clinic
having probably the longest follow up period in the UK.
With the introduction, from 1994, of formal criteria for assessing women with a
family history of breast cancer, there has been a shift in the detection of breast
cancers from mainly symptomatic towards screen-detected cases.
The intention was to restrict regular screening to women at significantly in-
creased risk for the disease and enrolment in the surveillance programme has
been more tightly controlled since 2000 (as explained in Chapter 4).
Thus the three time periods 1977–1994, 1995–1999 and 2000–present reflect pro-
gressively more stringent selection of the screened population (see Figure 5.1
and Table 5.1).
Although interval cancers were detected during each period of the Family His-
tory Clinic in Tayside region, in no case had the follow-up interval exceeded the
scheduled twelve months. Two of the women had their breast cancer diagnosed
at 10 and 11 months prior to their next follow-up appointments.
Two women became symptomatic while waiting to be seen at the clinic, one
of them was referred to the clinic and before she was sent an appointment she
discovered a lump. This was investigated through the symptomatic clinic and a
breast cancer was diagnosed. She was 28 years of age.
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Figure 5.1: Percentage of breast cancers detected as prevalent (first visit) incident
(screened) or incidental (interval) tumours according to year of attendance at the
Tayside clinic.
The second woman had been seen at the clinic and the recommendation was that
she should commence regular screening from age 34 years, she was diagnosed
with breast cancer at the age of 32 years.
These two cases of interval cancers diagnosed at such young ages clearly give
rise to suspicion of a strong hereditary component.
Table 5.1 summarises the numbers of breast cancers, cancer deaths and muta-
tions detected through the three distinct periods of the Tayside breast cancer
family history clinic.
The findings summarised in the above Figure and Table 5.1 are consistent with
the view that the application of progressively tighter checks on eligibility for
the surveillance programme has meant that fewer “low” risk women have been
included.
In the period before 1995, 55% of the breast cancers occurred in this subgroup,
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Table 5.1: Breast cancer cases since “family history” clinic started in Tayside.
Period 1977–1994 1995–1999 2000–present
No. cancer cases* 20 patients 25 patients 17 patients
Familial risk levels
“Low” 11 (55%) 8 (32%) 4 (23.5%)
“Moderate” 2 (10%) 9 (36%) 3 (17.6%)
“High” 7 (35%) 8 (32%) 10 (58.9%)
Age distribution
Mean 45.7 yrs. 46.8 yrs. 50.4 yrs.
Range 30–72 28–61 32–64
No. (%) <50 yrs old at diagnosis 14 (70%) 15 (60%) 9 (53%)
No. (%) screen detected 8 (40%) 18 (72%) 12 (70%)
No. (%) early stage (T1 or T2, N0)* 13 (65%) 18 (72%) 15 (88%)
No. (%) disease-free at 5 years 19 (95%) 19 (76%) 8 (100%)
BRCA mutations** 1 4** 3
Breast cancer deaths 3 4*** 0
*DCIS cases were also included (2/20, 4/25, 2/17). **BRCA1/2 mutations were
identified retrospectively until the late 1990s. One patient had mutation on both
BRCA1 and 2 genes. ***One BRCA1 mutation carrier. The 5-year disease free
survival rate for cancers diagnosed since 2000 can be calculated only for the
minority (n=8) who have been followed for five years. Bilateral breast cancer
was diagnosed (some were synchronous) as follows: 2 cases in 1977, 1 in 1995
and 3 cases in 2000-present periods. However, for the purpose of this table,
calculations are based on the first cancer only.
whereas from 1995–99 and since 2000, the proportion has declined to 36% and
then to 23.5%.
This does, however, remain a substantial proportion and begs the question of
the real risk of breast cancer in women, with some family history of the disease
that are denied access to the surveillance programme. That issue is addressed in
Chapter 6.
Whenever patients thought to be at “low” genetic risk were found to have a
breast cancer the risk estimate, for them and their close relatives, was changed,
as discussed more fully in Chapter 6.
There are no significant differences between the three time periods in mean age
at diagnosis of breast cancer, nor in age ranges. For the two later time periods
(1995–99 and 2000–present), there are no significant differences in any of the
other parameters measured (proportion diagnosed by age 50 years, proportion
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screen-detected, proportion “early stage” or proportion disease free at 5 years
from diagnosis).
This largely reflects the limited number of cases available for analysis from a
single clinic. In order to draw more definite conclusions about the outcome of
surveillance for women at increased familial risk, we recognised the need to
pool data from several centres operating similar programmes, as described in
the latter part of this chapter.
Nevertheless, certain useful conclusions can be drawn from the Tayside data.
First, since 1995, 46 breast cancers have been diagnosed in 42 women attending
the clinic.
Over that period, we have undertaken almost 8,000 clinical and mammographic
screens and, given that the great majority of women attending the clinic are
under 50 years old, the expected number of cancers in 8,000 woman years of
observation (from the Scottish Cancer Registry data) is about 12.
Thus, women attending our clinic appear to be at least 3.8 times greater risk
than the general population. The actual rate of cancer detection (5.8 per 1,000
screens) is perhaps lower than the figure of 8 per 1,000 predicted by Kollias and
colleagues98 but the numbers fluctuate considerably from year to year and are
still too small to make a definitive statement on that point.
The proportion of screen-detected cancers correlates well with those diagnosed
at an early stage (T1 or T2 and node-negative tumours) and with 5-year disease-
free survival.
The findings in these respects are gratifying because in breast cancer, the pro-
gnosis is directly related to the stage of the disease at diagnosis as well as the
tumour cell biology. Our findings support the earlier report of Kollias and col-
leagues,98 who found that surveillance led to diagnosis of breast cancer at an
early clinical and pathological stage in young women with a family history of
the disease. Prognostic factors are always assessed carefully in any individual
who develops cancer.
In breast cancer, axillary node status is perhaps the most important prognostic
indicator.199 Other prognostic factors used are tumour size, histological grading
and hormone receptors status.
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Prognostic indicators are taken into account in determining the patient’s man-
agement, for example in the decision whether or not to use chemotherapy, the
nature of the drugs employed, as well as the extent of surgery and radiotherapy.
These therapeutic decisions will obviously influence the cost of treatment (as
discussed more fully in Chapter 7). More importantly, the prognostic factors
relate to the prospect of long-term survival (the term “cure” is perhaps inappro-
priate in breast cancer which can have an extremely long natural history) and
five years disease-free survival is a moderately useful surrogate for that.
Note that, over all three time periods more than half of the breast cancers were
diagnosed before age 50 years (compared with approximately 20% of unselected
cases).
The prognostic significance of young age at onset is controversial. Several pa-
pers have been published on the subject and some have found young age of on-
set to be an adverse prognostic factor (survival being worse in young, compared
with older women with breast cancer). This may well be related to different
tumour biology.99, 200, 201
In order to evaluate the results of the “Familial Cancer” surveillance programme,
I instituted and supervised a retrospective survey of breast cancers in women
under age 50 years who had presented to the Tayside breast cancer service without
previously having participated in any regular screening programme.
The study was undertaken by a medical student (Jane Kenyon) as part of her
Honours BSc (Med Sci) course and I subsequently extended the analysis, adding
material from patients whose notes had been difficult to trace. The study was
carried out in 2002 and referred to patients diagnosed before 1997 so that 5-year
follow-up data were available.
All details of investigations, surgical and other treatments and associated costs
were recorded. These are discussed further in Chapter 7.
Table 5.2 records the major findings in this cohort of 40 unscreened young wo-
men with breast cancer, for comparison with the cases identified among women
participating in the familial cancer surveillance programme. It is evident that
the unscreened group presented with more advanced disease, and suffered cor-
respondingly more recurrent disease within five years.
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Table 5.2: Comparison with findings at diagnosis and outcome of young women
with breast cancer according to screening history. * Refers only to women with
five years follow-up. More years of follow up are required for the surveillance-
detected cancers group to allow better evaluation of the Tayside disease-free
survival rate.
Unscreened women
<50
Women from familial
cancer surveillance pro-
gramme 1995–present
Number of breast can-
cers
40 42
No. (%) screen detected 0 30 (71%)
No. (%) early stage (T1–
T2 N0)
22 (55%) 33 (78.5%)
No. (%) disease-free at
five years
91% for node negative *21 (100%) for node
negative
72% for node positive *6 (100%) for node pos-
itive
Breast cancer deaths 3 (node positive) 4 (two cases were node
positive, one of the
node negative was
a BRCA1 mutation
carrier)
While these findings may suggest that regular surveillance has been of benefit to
the women whose breast cancers were diagnosed within the familial cancer sur-
veillance programme, caution must be exercised because there are some specific
indicators that hereditary breast cancer may carry a different prognosis from
sporadic cases.
On the one hand, for those with a very strong family history, and hence an in-
creased likelihood of a BRCA1 mutation, breast cancer is liable to develop at a
very young age and to be associated with poor prognosis even if detected at an
apparently early stage.
It may be that the adverse prognosis for this group is directly attributable to the
BRCA1 mutation rather than the early age of onset.202–205 On the other hand, it
has been shown that familial breast cancers not attributable to BRCA mutations
(i.e. the great majority) tend to have favourable pathological characteristics and
hence may carry a better prognosis than sporadic cases.26, 27
Ideally, therefore, our comparison should be between breast cancers in women
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with a family history of the disease who have not taken part in a surveillance
programme and those at comparable risk who have done so.
For ethical and practical reasons, however, it is not possible to identify—and
follow prospectively—an unscreened cohort of women at increased familial risk.
5.2 European collaborative study data
The Tayside breast cancer family history service formed part of a multicentre
European Group (BIOMED 2 Demonstration Programme) from 1996-1999 with
the object of assessing clinical services for women with family histories of breast/ovarian
cancer.
Since 1999, the group has continued as an informal open collaboration compiling
data from patients in whom breast cancer was diagnosed through a surveillance
programme. I have been the principal Tayside contact for this aspect of the joint
study (see Table 5.3).
Table 5.3: Cumulative data of breast cancers diagnosed under surveillance pro-
gramme in collaboration with other European Centres. *not reported
1999 2002 2007
Total cases 161 249 442
No. patients contributed from Tayside 29 40 70
No. patients with BRCA1 mutation 0 36 89
No. patients with BRCA2 mutation 0 8 35
No. patients with no known mutation 0 205 318
% screen detected 75% nr* 70–80%
% node negative 82% 74% 77%
5 year disease-free survival for CaN0 88% 92% 95%
5 year disease-free survival for CaN+ 67% 72% 70%
5 year disease-free survival for BRCA1 mutation n/a 63% 70%
5 year disease-free survival for no mutation n/a 91% 92%
The first report182 included 29 cases from Dundee in a total of 161 (though 32
of these were carcinoma in situ). The mean age at diagnosis was 48.6 years
(comparable to our local experience) and 75% were diagnosed in the course of
planned investigations as part of their screening programme.
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Of these, some 20% of the cancers were identified on clinical breast examination,
though they were mammographically occult. That coincides with my own ex-
perience in Tayside and with the experience of colleagues in the very large clinic
at the Royal Marsden Hospital in London (Dr Ros Eeles, personal communica-
tion).
It was noted that the interval cancer rate (i.e. those presenting symptomatically
rather than screen-detected) rose if screening interval stretched beyond twelve
months. This tended to happen in the early years of service development be-
cause facilities became overwhelmed by rapidly rising demand in keeping with
the high rate of cancer detection.
Recurrence rates and survival were both related (as expected) to nodal status.
Interval cancers were more commonly node-positive (> 40%). The five year
disease-free survival was 88% for node-negative cases but only 67% for node-
positive tumours.
All these findings tended to confirm the value of regular surveillance for women
at increased familial risk of breast cancer, chiefly by demonstrating that the great
majority of their cancers could indeed be detected by clinical examination plus
mammography and that screen-detected tumours were mainly at an early stage.
However, it was recognised that longer follow-up was required. At that time
there were insufficient numbers of known BRCA1 or BRCA2 mutation-carriers
identified to draw any conclusions about the efficacy or otherwise of screening
for specific risk groups.
By the time of the second report,48 the number of breast cancers recorded had
risen to 249 (including 50 instances of carcinoma in situ), with a mean age at
diagnosis of 49 years. Thirty-six patients were known to have had pathogenic
BRCA1 mutations but only 8 BRCA2 mutations had been identified.
The BRCA1 mutation-positive cases tended to be of much higher histological
grade and were mainly oestrogen receptor (ER) negative, both characteristics
implying that they would be more aggressive tumours.
Although a similar proportion of BRCA1 mutation-positive and negative tu-
mours (70%) had no demonstrable nodal involvement at diagnosis, five-year
disease-free survival was markedly worse for the former (63% vs 91%). Node-
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positive patients, as expected, fared worse, as a group, than node-negative (72%
crude survival at 5 years vs 92%).
There were insufficient BRCA2 mutation-positive cases to analyse their outcome
separately but the combined findings at this stage showed clearly that BRCA1
mutation-carriers were not adequately managed by annual surveillance since
outcome was poor even when tumours were diagnosed at an apparently early
stage (small primary lesion without nodal spread).
A striking observation was that patients with BRCA1 mutations who under-
went oophorectomy at the time of breast cancer diagnosis (or within 6 months
thereafter) had much better survival than those who retained their ovaries. This
finding is difficult to explain, given the preponderance of ER negative tumours
among BRCA1 mutation carriers.
However, it is in keeping with other reported studies on both preventive effect of
oophorectomy in BRCA1 mutation carriers as well as its protective effect against
contra-lateral breast cancer.206
The third update on this cohort49 was published after completion of this thesis
but, as a major contributor to the study, I was permitted to incorporate the find-
ings into the present work. Essentially, they confirm the 2002 report in relation
to BRCA1 mutation carriers and, for the first time, they also showed that BRCA2
mutation-positive breast cancers have a good prognosis when diagnosed within
a surveillance programme.
The following information is derived from the analysis of this group:
Møller in collaboration with myself and other Norwegian and UK colleagues49
collected prospectively data on clinical, pathological and outcomes on all breast
and ovarian cancers diagnosed during the course of surveillance programmes
from several Family History Clinics until the end of 2005.
The data were analysed in relation to both BRCA1 and BRCA2 mutation status
(or none) of affected women, looking into survival outcomes for all the groups.
The conclusion, as previously mentioned, was that potentially good outcomes
are reserved for women with BRCA2 mutations when compared with carriers of
BRCA1 mutations. The latter unfortunately seem to have worse prognosis even
if their tumour is diagnosed at an early stage, but the addition of oophorectomy
to standard therapy improves survival.
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These series provide for the first time significant evidence for the efficacy of
surveillance programmes for breast cancer, based on genetic risk assessment,
allowing management of those women to be adjusted accordingly.
Most currently available guidelines for surveillance are based on the, now demon-
strably false, assumption that screening has uniform efficacy for all groups of
women at increased familial risk. This applies, for example, even to the 2006
report of the American College of Physicians.1
The most important new finding49 is the good outcome of surveillance for wo-
men with BRCA2 mutations as well as for mutation-negative patients, and the
lack of correlation between stage at diagnosis and outcome (for BRCA1 mutation-
carriers only).
Tayside patients have been included in the large multi-centre UK trial of MRI
for women at increased risk of breast cancer (MARIBS). Data emerging from
this and other trials from around Europe are demonstrating that this method is
very efficacious in detecting small carcinomas, particularly for BRCA1 mutation
carriers.
The recommendation seems to be that this subgroup should have MRI scanning
performed every six months.50, 203, 207 However, funding is not yet in place to
implement that policy across the UK.
Further information on the regular use of MRI (Magnetic Resonance Imaging) as
screening tool for “high risk, BRCA1 mutation carrier” women is awaited as the
lack of correlation between tumour stage and outcome means that even earlier
detection of cancer may not improve survival. Longer follow up is required of
MRI-detected cases to address this issue.
5.3 Surveillance of women at high risk
As demonstrated in Chapter 4, the great majority of women referred to the Tay-
side Familial Breast Cancer service are at “Moderate” rather than “High” risk.
The latter category is defined by having a family history that predicts a likeli-
hood greater than 60% that a predisposing cancer gene mutation of high pen-
etrance is present (in the family). That in turn translates into a history of four or
more close relatives (one first degree, or second degree via an intervening male)
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with breast cancer or ovarian cancer or one first-degree relative with both breast
and ovarian cancer. Evidence has been presented earlier in this chapter that car-
riers of BRCA1 mutations are not adequately protected by regular annual breast
screening, but require alternative management. Furthermore, BRCA1 mutation-
carriers are liable to develop breast cancer at a particular early age. Thus, there
are sound reasons for investigating “high risk” women as a matter of urgency,
with a view to identifying as many BRCA1 mutations as possible.
All women assessed to be at “high”genetic risk for breast/ovarian cancer were
offered regular surveillance through the Tayside familial breast cancer clinic and
were counselled by the geneticists on the availability of tests for specific gene
mutations. The implications of such testing and the limitations of the procedure
were explained in detail.
Only recently MRI scanning became available for women at high genetic risk for
breast cancer (women carrying a genetic mutation in one of the genes causing
breast cancer; eligible women who declined genetic testing; women belonging
to families that indicate a probable genetic fault but in which there is no surviv-
ing relative to be tested or in which relatives have been tested but no genetic
abnormality had been identified).70, 130, 207 At the time of our study period, wo-
men were not routinely screened by MRI (only if participating in the MARIBS
study), in view of the outcomes published recently there is great pressure to
get this investigation incorporated into the currently run screening programme
for high risk women. This unit (Ninewells) is now in the process of selecting
eligible indviduals who will meet the current recommendations. Longer follow-
up is required for this group of women undergoing MRI screens, particularly
BRCA mutation carriers, as the possible survival benefits are still unclear. MRI
scanning could also generate unecessary anxiety as it could lead to unnecessary
biopsies.
From 1994 to 1999, mutation testing was essentially funded through research
grants and was undertaken independently in molecular genetics laboratories in
Aberdeen, Dundee, Edinburgh, Glasgow and St. Andrews, though there was a
high degree of cooperation between the centres, leading to the publication of a
compilation of over 100 BRCA1 and BRCA2 mutations detected in Scottish and
Northern Irish families.21
Given the restricted resources for these studies, it is not surprising that discovery
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of a given mutation could take several years and great patience was required on
the part of both patients and clinic staff. Even in 2006, it remains extremely diffi-
cult to find certain mutations –for perhaps 15% of cases in which there is virtual
certainty that a BRCA mutation is present, current techniques fail to find them.
This applies even to the “state-of-the-art” commercial facility at Myriad Genet-
ics Inc. in Utah. Despite the long waiting time for results in the UK, requests for
testing at the Myriad facility (which undertakes to complete the process in a few
weeks) have been very rare in Scotland. There have been none from the Tayside
clinic.
From 2000 onwards, the laboratory service for detection of “cancer gene” muta-
tions in Scotland has been funded through the Molecular Genetics Consortium
(part of the Common Services Agency of the NHS Scotland) and BRCA mutation-
detection has been the responsibility of the Aberdeen and Glasgow laboratories,
working in partnership.
The first requirement for molecular screening is a living affected relative. Unfor-
tunately some patients do not have any surviving relatives who can be asked if
they are willing to give a blood sample for genetic testing for BRCA1 and BRCA2
mutations. It is possible that, as technology advances, DNA extracted from fixed
tissue blocks (e.g. lymph nodes) removed at surgery, may be acceptable material
for that purpose but at present this is only attempted in a research setting.
Once a result had been obtained, the affected relative was informed of it and in-
formation was shared with the family. If she tested negative for the genetic fault,
after completion of the full screen of BRCA1 and BRCA2, an undertaking was
given that, if this was the family’s wish, as new diagnostic techniques became
available, the DNA would be tested further in the hope of eventually identifying
the precise cause of the “high risk” cancer pattern – either a “difficult to detect”
BRCA mutation or an alteration in a currently unknown “cancer gene”.
If a pathogenic mutation had been found, the patient who had originally sought
advice about her genetic risk was given further counselling about genetic testing
and its implications for themselves and other family members, before deciding
whether to proceed to formal testing of her own mutation status.
The option was given to discuss prophylactic surgery even before taking the
decision whether or not to have the “gene test” but, in my experience such dis-
cussions usually follow rather than precede testing.
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The technical procedure for molecular testing is relatively simple once the pre-
cise mutation in the family is known, since only the affected region of one gene
has to be sequenced. Results are provided within six weeks and practice in the
Tayside clinic has always been to give the result in the course of a face-to-face
interview, where the patient is accompanied by a partner, relative or by a friend.
During the 30 months period of the “Triage” study, 21 women (from a total of 33)
considered to be at very high genetic risk for breast cancer were offered genetic
testing through our clinic.
One woman declined to be tested and remains on regular follow-up. Another
woman tested negative for the genetic fault found in her relative and this puts
her in the “population average” risk category. She has since been discharged
from follow-up.
Two women who underwent genetic testing were found to carry the same muta-
tion as their affected relative. Unfortunately, no blood sample was available
from relatives of 12 women considered at “high risk” for the disease as there
was no living affected relative to be tested for BRCA mutations.
Over the same period, sixteen women (5%) considered at increased risk for
breast and other cancers in the Tayside genetic clinic were referred to other spe-
cialists (referral would also include their relatives).
Thirteen women were referred to the gynaecologists to consider ovarian cancer
screening or prophylactic surgery, three to colorectal surgeons for investigation
of possible hereditary non-polyposis colorectal cancer syndrome–HNPCC.
5.4 The place of prophylactic surgery
With the increase in knowledge of hereditary breast cancer risk the relative mer-
its (or otherwise) of different options (surveillance or prophylactic intervention)
available for women referred to the cancer family clinic ought to become clearer
but, in fact, the necessary evidence is proving difficult to compile. The following
questions are relevant, though answers are currently far from complete:
1. How do women in Scotland react to discussions of prophylactic oophor-
ectomy and/or prophylactic mastectomy?
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2. What is the take-up rate for surgery and at what age?
3. Is uptake of prophylactic surgery related to objective estimate of risk or to
family responsibilities (young children, etc) or to other identifiable factors
such as social class?
4. On follow up, are women satisfied with the results of the surgery and,
(if possible) how content with their decision are women who opt not to
proceed to surgery?
Cost/ benefit issues in relation to prophylactic surgery or screening are covered
in Chapter 7.
As discussed in Chapter 2, bilateral prophylactic mastectomy has been shown
to be highly effective in providing long-term protection against breast cancer for
women at very high genetic risk. Before the BRCA genes were discovered, a
few women with very striking family histories opted for this procedure, even
though their own risk of carrying the (then unknown) causal mutation could
not have been greater than 50%.
In such a setting, it could be argued that the surgery was treating anxiety as
much as preventing cancer. However, anxiety can be very debilitating and,
given the family situation, the decision to proceed with total removal of the
breasts is defensible.
In recent years, the technical aspects of total mastectomy and reconstruction
have advanced considerably and greater numbers of women at high risk are
now in a position to know their own genetic status. Furthermore, the findings of
the European Collaborative Group set out earlier in this chapter indicate that, for
BRCA1 mutation-carriers, annual surveillance alone provides inadequate pro-
tection.
In my experience, patients at high risk are willing to consider prophylactic sur-
gery, yet the uptake is still very low. There is almost certainly a “cultural” com-
ponent in this decision and therefore clinicians must consider the women’s val-
ues and cultural background as well as her personal preferences when discuss-
ing with them the issues of prophylactic risk reducing interventions.
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Issues arise in relation to the long-term impact of breast removal on women’s
sexuality and psychosocial consequences both of the surgery and of their muta-
tion carrier status.
In the McLeish study (2003),189 the proportion of women from the Tayside clinic
opting for prophylactic surgery was small in comparison to other centres in Eng-
land and other European countries. There appeared to be unrealistic expecta-
tions of mammography and little perception of the relative value of prophylactic
surgery among the risk-reducing measures currently available.
McLeish also found that a third of the women in the survey considered prophy-
lactic surgery to be “not really acceptable” or “unacceptable”. These findings
were similar to those of Meijers-Heijboer et al. (2000)208 in the Netherlands.
This makes the demand for prophylactic breast surgery considerably weaker
than for mammography. McLeish also found that attitudes to prophylactic ovarian
risk-reducing surgery were guarded, though more favourable than towards pro-
phylactic mastectomies.
In France, Eisinger et al. (2000)209 reported that only 4.7% of the women in
their study found it acceptable to consider surgical intervention as a cancer risk-
reducing measure in young women. When a causal BRCA mutation has been
demonstrated, however, attitudes to surgery may change and the Dutch group
led by Meijers-Heijboer (2000)208 found that as many as 51% of such women
would opt for prophylactic surgical intervention.
No form of prophylactic surgery should be treated lightly and total mastectomy
with reconstruction of the breast is a major procedure. It is therefore import-
ant to alert women to the real risks of such interventions before they are asked
to take a decision. For example, there can be surgical complications, varying
from haematomas or infection to failure of reconstruction, requiring removal of
implants or reconstructed breast tissue (in the case of reconstruction failure).
Even in the technically simpler case of oophorectomy, complications can include
infection, bleeding, urinary and/or bowel injuries and, of course, premature
menopause which may require a period of hormone replacement therapy. All of
these possible complications (together with the natural reluctance to go “under
the knife”) no doubt contribute to the limited uptake of risk-reducing surgery.
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To date, I have not detected much shift in attitudes but the disappointing out-
come of regular screening for BRCA1 mutation-carriers has not yet been publi-
cised and is only beginning to be disseminated through the clinic, so attitudes
towards surgical intervention to reduce cancer risk may change. Furthermore,
with the prospect that the NICE guidelines on inherited breast cancer may be ad-
opted widely across the UK (including Scotland), the proportion of “high risk”
women eligible for genetic testing will be higher than at present (under SIGN
guidelines).
This may contribute to an increase in numbers of known mutation carriers.
Overall, therefore, I expect demand for prophylactic surgical interventions to
increase substantially in the future (as discussed above).
Since the study commenced, two women found to carry the same (BRCA2)
mutation as an affected relative, have discussed prophylactic bilateral mastec-
tomies. Only one has undergone the procedure to date. I ought to highlight that
the number of women being considered for bilateral prophylactic mastectomy
has increased gradually over the past decade. However, the number of women
who decided to go ahead with surgery remains very low.
While the foregoing refers to prophylactic mastectomies in women who are
aware of their “high risk” status but are disease-free, there is a second category
of women for whom preventive mastectomy is considered, namely “high risk”
women who have already been diagnosed with unilateral breast cancer, have
had their primary cancer treatment but seek advice on risk-reducing surgery for
the contra-lateral (unaffected) breast. This would also include those who, some
time after their breast cancer treatment, were found to carry a mutation in one
of the BRCA genes.
It is understandable that patients, who have already experienced cancer, may be
less reluctant to contemplate the drastic measure of complete breast tissue re-
moval. Most of them are satisfied with their decision to undergo the procedure.
A study by Geiger and colleagues210 has demonstrated contentment with the
decision to have prophylactic contra-lateral surgery in 86.5% of their cohort
(n=371) and also reported contentment with subsequent quality of life (compar-
able to that of breast cancer survivors who had declined risk reducing surgery).
However, their study results applied to a wide range of women with breast can-
cer diagnosis and because the study had little information on patients with fam-
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ily histories of breast cancer, the results may not apply specifically to “high risk”
breast cancer women.
Since 1994, eleven patients from the Tayside breast cancer family history clinic
were treated for breast cancer and subsequently have had prophylactic contra-
lateral breast surgery. In two of these, an unsuspected carcinoma was found
on pathological examination of the removed tissue. Neither was an invasive
malignancy (they were DCIS) and both patients remain on regular follow up.
One has a BRCA1 mutation and the other BRCA2. One other patient who had
contra-lateral prophylactic surgery has since died from metastatic breast cancer.
She was a BRCA1 mutation carrier.
Of those eleven patients with previous breast cancer and who underwent contra-
lateral prophylactic mastectomy, four were known to carry a mutation; one of
them in fact had mutations in both BRCA1 and 2 genes.
Although data were not formally collected, in informal conversations with those
individuals it emerged that the major factors influencing their decision to un-
dergo the procedure were: a) molecular confirmation of their high risk status
and b) perceived needs of their family—particularly their commitments to the
raising of children.
The mean age for undertaking bilateral prophylactic mastectomy in women who
had previous breast cancer diagnosis was 45 years (range: 34–59) and, for those
undergoing prophylactic mastectomy only because of their high risk status (no
previous breast cancer), it was 44 years (range: 36–56; there was no significant
difference between the two groups).
5.5 Bilateral salpingo-oophorectomy
Ovarian cancers are still being detected at advanced stages of the disease as clin-
ical manifestations of ovarian malignancies are only apparent late in the evolu-
tion of the disease.61, 159, 160 It is clear that the current available methods of sur-
veillance for ovarian cancer are neither sensitive nor specific and perhaps give
false reassurance on the basis of negative test results.
Nevertheless, as discussed above, the McLeish study,189 based on Tayside and
Lothian, in keeping with findings from other European centres, recorded general
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reluctance to consider prophylactic oophorectomy as an alternative to screening.
Patients at moderate or high risk levels for ovarian cancer were given the oppor-
tunity to see a gynaecologist with a special interest in inherited ovarian cancer,
for discussion of the options currently available for both surveillance and risk
reducing surgery. Unfortunately colleagues in Ninewells Gynaecology Depart-
ment do not keep a structured database of the patients referred. I am currently
addressing this and plan to collect more comprehensive prospective and retro-
spective information on the patients.
From the Genetics Department in Ninewells, from 2000 to the end of 2003, 112
patients from 76 families, judged to be at significant risk of ovarian cancer, were
referred to the Gynaecology Department to discuss the pros and cons of having
ovarian cancer screening or risk reducing surgery.
Of these, only 28 patients have undergone bilateral prophylactic salpingo-oo-
phorectomies: twelve were mutation carriers, eight of whom had previous breast
cancer treatment. Four of these women did not have previous breast cancer. The
remaining cases were at high risk of developing breast and/or ovarian cancer.
(Table 5.4)
Table 5.4: Bilateral salpingo-oophorectomies carried out in women attending the
Tayside breast cancer family service.
Patients undergoing salpingo-oophor-
ectomy
28
BRCA1 or 2 mutation carriers Previous breast cancer: 8
No previous breast cancer: 4
Non-mutation carriers (i.e. no mutation
yet identified)
Previous breast cancer: 3
No previous breast cancer: 13
Until relatively recently only the ovaries were removed, usually by a laparo-
scopic approach. With the increased recognition that fallopian cancers are also
related to inherited ovarian cancer, it is now common practice to remove the fal-
lopian tubes at the time of oophorectomy, particularly for proven BRCA1 and
BRCA2 mutation carriers.
One patient, known to be a BRCA1 mutation carrier, who underwent prophy-
lactic bilateral salpingo-oophorectomy in 2003 and bilateral prophylactic mastec-
tomies in 2004 has since presented with ascites and further investigations reveal
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that she has primary peritoneal carcinomatosis. She is the first patient from our
series to have developed malignancy after prophylactic oophorectomy, though
it is a well recognised danger, as discussed in Chapter 2. It happens that this
patient was found to have a borderline ovarian tumour at the time of her pro-
phylactic oophorectomy. Current thinking suggests that borderline ovarian can-
cers are unrelated to BRCA1 or 2 mutations so the significance of this finding is
unclear.61
One other patient who had undergone prophylactic bilateral salpingo-oophor-
ectomy recently presented to the breast clinic with a locally advanced breast
cancer and is currently undergoing treatment. She carries a mutation in the
BRCA1 gene. This highlights the fact that oophorectomy, though it is a useful
measure for reducing breast cancer risk in BRCA1 and 2 mutations-carriers158, 159
does not completely abolish it. A residual 30–50% of a pre-existing large risk is
still substantial. This particular lady has had several consultations in the past to
discuss prophylactic bilateral mastectomies but declined to have it performed
as she was reluctant to “lose” the nipple and areolar complex as part of the
proposed surgery.
As in prophylactic mastectomy, the uptake of prophylactic salpingo-oophorect-
omy in this series seemed mostly related to knowledge of molecular identific-
ation of a genetic BRCA fault, previous diagnosis of breast cancer and family
related reasons.
The knowledge that ovarian screening is not as effective as breast surveillance
and that prophylactic oophorectomy does not have a cosmetic impact (in con-
trast to prophylactic mastectomy) means that oophorectomy is more acceptable
for women seeking advice on prophylactic surgical intervention despite poten-
tial problems with menopausal symptoms.
The mean age for women undergoing bilateral salpingo-oophorectomy was 47
years (range: 33–62). Unfortunately complete data were not available on 7 cases,
so that calculation was performed for only 21 women. Of the patients (28) who
underwent prophylactic oophorectomies, 12 were proven mutation carriers, (10
BRCA1 and one BRCA2) plus another who had a mutation in both BRCA1 and
BRCA2 genes.
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5.6 Conclusion
The questions posed at the beginning of this chapter are listed again and a sum-
mary of our studies conclusions were:
What is the rate of detection of breast cancers in young women (35-50 years of age) at
increased familial risk undergoing annual screening?
We find that the rate of cancer detection is 5.8 per 1000 screens and we would
anticipate that the rate will rise as tighter criteria are applied for inclusion in
surveillance programmes and as more BRCA-mutation carrying families are
identified. This compares with the target rate for the National Breast Screen-
ing Programme (for women over 50 years of age) of six breast cancers per 1000
examinations. Although the NBSP is referring to three-yearly rather than yearly
examination. Despite the recognised stress associated with regular screening
and the unavoidable instance of further investigations which ultimately prove
negative, it is clear that women at increased familial risk of breast cancer value
access to a screening programme and many studies have shown that the overall
psychological impact is at worst neutral.
The evidence that regular screening leads to diagnosis of breast cancer at an
earlier stage must, at present, be interpreted with some caution since the com-
parison group (women diagnosed before age 50 years without having particip-
ated in a regular programme) were not selected on the basis of family history
and were presumably mainly sporadic cases. As such, the biological behaviour
of their cancers may not have been entirely comparable to those of the “family
history” group.27
What is the sensitivity of cancer detection (i.e. rate of interval cancers)?
Sensitivity (at 70-80%) of screen detected cancers is marginally lower than the
target for older women in the NSBP which probably reflects the greater tech-
nical difficulty of detecting small cancers in mammographically dense breasts of
young women. It is notable that when screening intervals extends much beyond
12 months, the rate of interval cancers rises substantially. MRI has been shown
to improve sensitivity of breast cancer detection particularly for women at high
genetic risk for the disease but it is time consuming and expensive (it takes about
1 hour to complete the investigation and further time is given for analysis of the
images obtained). Its impact on overall survival has not yet been measured.
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Surveys (including one from Tayside and Lothian) have shown, however, that
there may be an unjustified belief in the “magical” properties of mammographic
screening so that many women will choose regular surveillance over prophy-
lactic surgery. In fact, mammography alone as a tool for screening women at in-
creased risk of developing breast cancer is not advisable as some cancers could
be missed if only mammography is used.
Is clinical examination a useful adjunct to mammography in these respects?
Our data strongly support inclusion of clinical examination. About 20% of can-
cers are detected b clinical examination in addition to mammography. Further-
more, the opportunity to discuss concerns with the breast surgeon or experi-
enced breast care nurse must improve the experience of surveillance. The com-
bination of both breast examination and mammography is the best method of
screening women at increased breast cancer risk currently available. The use of
MRI is still being analysed as part of a UK-wide trial of screening “high” breast
cancer risk women to which I have contributed.
Do screen-detected cancers in this setting carry a better prognosis than non-screen de-
tected? – either in terms of pathological stage at diagnosis or in terms of outcome on
follow-up?
On both counts, screen detected cancers do better. Over 40% of interval cancers
(i.e. not screen detected) were node positive compared with 25% of all cancers
in this cohort.182 All 3 of the reports of the International Collaborative Group
(in which I collaborated) confirm that node positivity equates to worse survival.
From the information that emerged via the European collaborative group, it is
now clear that, for BRCA1 mutation carriers, conventional mammographic and
clinical screening should no longer be considered a “safe” option, in view of the
high incidence of cancers and their poor prognosis despite apparently “early”
detection. Prophylactic surgery is of proven protective value and would be the
best currently available strategy for those patients.48, 49 The studies described in
this chapter demonstrate that regular surveillance for women with a family his-
tory of breast cancer is associated with detection of the disease at an early stage
and (excluding BRCA1 mutation-carriers) with a good outcome well beyond
five years.
Are there differences in effectiveness of surveillance according to category of genetic risk?
If so are these differences sufficient to suggest that different management strategies may
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be appropriate for different groups?
One of the most important outcomes of the work reported in this thesis is the
very clear demonstration49 that despite detection of cancers at an apparently
early stage, carriers of BRCA 1 mutations have a significant worse outcome than
those with BRCA 2 mutations or no demonstrable mutation. The implication is
that unless MRI or other new screening modalities change the outcome for wo-
men carrying BRCA 1 mutations, prophylactic surgery is a very realistic option
for them. They, however, benefit from oophorectomy at the time of the diagnosis
although their tumours are usually ER-negative.
Prophylactic surgical intervention is a serious option for those at very high ge-
netic risk for the disease and at present prophylactic bilateral salpingo-oophor-
ectomy is much more acceptable to Tayside patients than prophylactic total mastec-
tomy. This probably reflects a "cultural norm" for those women. In Tayside, the
uptake of prophylactic bilateral mastectomy has been low; probably because the
nature and scale of this intervention is seen as very disturbing, specifically with
regard to body image and sexuality.
Women at “high” genetic risk, who have been diagnosed with unilateral breast
cancer are evidently more prepared to contemplate prophylactic removal of the
unaffected breast.
The intervention of bilateral salpingo-oophorectomy appears to be rather more
acceptable to the patient, perhaps because it has been suspected for some time –
and increasingly evident from experience over the past years - that this proced-
ure is much more effective than screening, not only reducing ovarian cancer risk
but also providing measurable protection against breast cancer.158, 168, 206
All Tayside patients offered the option of prophylactic surgery (either mastec-
tomy or oophorectomy) were at high genetic risk. However, of those who pro-
ceeded to oophorectomy, 12 of 28 were known carriers of BRCA mutations.
There is indication that molecular confirmation of “high risk” status increases
the likelihood that the patient will proceed to prophylactic surgery.
Similarly, of the patients who have had unilateral prophylactic mastectomy after
diagnosis of cancer in the contra-lateral breast, 8 out of 11 were known mutation-
carriers. Five women underwent bilateral prophylactic mastectomy; only one of
them carried a proven BRCA mutation.
CHAPTER 5. CANCERS DETECTED IN THE SURVEILLANCE
PROGRAMME 118
As mentioned before, formal data were not collected regarding the reasons that
led to the decision of prophylactic risk reducing intervention. After informal
conversation with those individuals some reasons were given - mainly the know-
ledge of their molecular “high risk” status, family related considerations and
previous breast cancer diagnosis.
The mean age for women having prophylactic salpingo-oophorectomy was cal-
culated for 21 patients (data were not available for 7 patients) and not surpris-
ingly was at slightly older age (mean 47 years: range 33–62) than the ones having
prophylactic mastectomy (45 years for the affected women having contra-lateral
breast cancer and 44 years for the ones having prophylactic mastectomy in view
of the risk status).
Knowing what we do know about the inadequacy of current breast screening
protocols for BRCA1 mutation- carriers and the poor sensitivity and specificity
of annual ovarian screening (specifically for premenopausal women) there is
perhaps a need to reconsider the “non-directive” counselling approach process
for women at high genetic risk.
Reluctance to contemplate major prophylactic surgery is understandable but
there is an onus on the part of those of us who accept responsibility for the
management of women at increased genetic risk to ensure that, in presenting
options to them, the relative efficacies of these options, their limitations and the
possible complications are all clearly understood.
5.7 Future work
Longer-term follow-up is still required to establish the true value of surveillance
programmes because breast cancer is a disease that can recur many decades
after its treatment and because the numbers, particularly of BRCA 2 mutation-
carriers, are still rather low to convince doubters that their outcome in a screen-
ing programme is very different from that of BRCA 1 mutation-carrying indi-
viduals.
MRI detected cancers must be followed up to determine whether earlier de-
tection leads to significant improvement in outcome, particularly for BRCA 1
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mutation-carriers as currently they fare worse even if their disease is detected
and treated early.
The development of newer forms of treatment for established breast cancers (for
example the use of platinum-based cytotoxic chemotherapy agents) may have
a significant impact in outcome of BRCA 1 mutation positive carriers and this
must be kept in mind so that future guidelines can be modified accordingly.
We need to look more closely at women’s attitudes to prophylactic surgery and
devise effective ways of presenting the options clearly but without inducing dis-
abling anxiety. Studies looking at the long-term effects of those interventions are
currently being planned but are beyond the scope of this thesis.
Chapter 6
True incidence of breast cancer in
“low risk” women up to age 55 years
This section of the thesis deals specifically with the question:
Are current settings for the actionable risk "threshold" valid?
Published guidelines (NICE and SIGN) recommend that women concerned about
their risks for breast cancer and/or ovarian cancer should, at first instance, seek
advice from their primary care team who should perform initial risk assessment
and only those with an assessed risk above the specified threshold should be re-
ferred to specialist services for appropriate screening, counselling and possible
interventions aiming to reduce their lifetime risk for the disease.
Over the years, data were gathered on any breast cancer that was detected among
women who had been referred to the Tayside familial breast cancer service. This
included information from the period 1977–1994 when surgeons in Tayside were
perhaps pioneering regular surveillance for ladies with a family history of breast
cancer in the UK.
As previously mentioned, unlike the practice since 1994, no strict criteria were
followed to enrol those women in a regular surveillance. Since 1994, when a
more structured clinic for women at increased familial risk for breast cancer was
developed in Tayside with input from geneticists, there has been formal risk
assessment of the women referred to the clinic.
Through my direct involvement in the Tayside symptomatic breast service, I
noted that several patients discharged from the “ cancer family” clinic, as being
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below the required level of familial risk for enrolment in regular surveillance,
were later presenting with breast cancer. Many of these patients had been re-
ferred via the symptomatic clinic (pre-1994) but there were some who had atten-
ded the family history clinic after 1994, who had never complained of any breast
symptoms.
I therefore decided to investigate the true incidence of breast and /or ovarian
cancer in women thought not to be at significantly increased familial risk. My
suspicions that there could be flaws in the currently used guidelines to identify
“low” risk women were supported, but only much later, by the report of Amir
and colleagues,211 to the effect that most commonly applied models to assess and
predict breast cancer risk from family history tended to underestimate the true
risk. They reached their conclusions from a prospective evaluation of five such
protocols. The underestimation was more apparent in women at the “lower”
end of the risk spectrum. However, the numbers were rather small to power the
conclusions.
An initial pilot study, carried out only among Tayside clinic referrals, did seem to
indicate that the actual risk to these women was greater than 1.7 times the (age-
matched) general population level quoted in most guidelines as the “threshold”
for enrolment in a regular surveillance programme.
However, the numbers were not large (8 cancers expected, 17 observed) and
I could not guarantee that all cancers had been recorded since I could only in-
clude those presenting to the Tayside breast surgery service. In addition, some of
the cancers recorded were in women who had originally presented with symp-
toms before 1994 (see Chapter 5), which might have influenced the incidence of
tumours.
I therefore asked colleagues from the other 3 Scottish centres holding a family
history clinic to collaborate with the Tayside group, providing information on
the number of breast cancer cases detected in their “low risk” women cohort.
The list would then be presented to the Scottish Cancer Registry to search for
any cancers subsequently diagnosed.
This would provide a more secure basis for measuring the age-specific incidence
of breast cancer among women referred to the “family history clinics” in Scot-
land but judged to be at “low” (i.e. “below threshold”) genetic risk and excluded
from any regular surveillance programme.
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This particular section of my thesis may not give immediate answers but hope-
fully will provide enough information to allow continuing studies to look into
the accuracy of threshold setting for true “low risk” women for whom regular
surveillance at an early age is not justified.
As the 2004 NICE guidelines recognise, the raw data on which current thresholds
have been set are insubstantial and validation is urgently needed.39
From 1994, all four Scottish centres used guidelines created by the Scottish Of-
fice Home and Health Department which were incorporated into the Scottish
Intercollegiate Guidelines Network in 199838, 72 (see Table 2.1, page 21). This was
therefore the starting date for the survey.
NICE guidelines set a different threshold from the Scottish guidelines by the
removal of any age restriction in the case of just two affected relatives with breast
cancer. Under “NICE” this would be sufficient for classification as “moderate”
genetic risk, whereas SIGN (and most other guidelines published up to 2004)
required that both relatives must have been diagnosed before age 60 years.
The term “NICE moderate” is used hereafter to describe the subgroup of wo-
men who would have been at “moderate risk” under NICE guidelines but were
treated as “low risk” under SIGN guidelines.
Records of all 4 Scottish “breast cancer family history clinics” were examined to
identify all women referred to the clinics from the period between January 1994
and December 2003 who had been placed in the “low risk” category after assess-
ment of the family history and for whom follow up was not arranged (according
to SIGN guidelines that time).
We then asked the Scottish Cancer Registry to inform us whether any of the wo-
men identified as “low” risk were subsequently diagnosed with cancer. Special
attention was given to breast and/or ovarian cancers. Permission from the Pri-
vacy Committee of the Scottish Cancer Registry was sought and granted for this
information to be collected. The Registry records were complete to the end of
2002 and 90% complete for 2003 at the time of the study.
Confirmation and further clinical and pathological details of the breast and/or
ovarian cancer cases identified through the Cancer Registry were sought through
full check of the surgical and pathological findings in the individuals’ case notes.
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We calculated the period that elapsed between discharge from the clinic and
December 2003 for each woman referred. From that, and the date of birth, it
was possible to calculate the number of years spent in each five-year span (35–
39 years, 40–44 years and so on) between discharge and December 2003. These
were aggregated to give the total number of woman years of observation.
Corresponding “expected” numbers of breast cancer cases were then derived
from the Scottish Cancer Registry figures.212
We identified 2074 women in total who met the criteria required (“low” genetic
breast cancer risk). They had been followed up for an average period of 4 years
and complete data were available for 98% of them. For the remaining 2%, some
data (e.g. post code or exact date of clinic discharge) were missing but sufficient
information was recorded to include them in the overall analysis.
From January 1994 to December 2003, 28 invasive breast cancers in 26 women
from all the Scottish centres were diagnosed among patients not considered to
be at significantly increased familial risk for the disease. Two patients with sim-
ultaneous bilateral breast cancers were counted as two cases each (both of these
women were aged just 50 years at their diagnosis).
At least one of them now belongs to a “high risk” category as two further early
onset breast cancer cases have subsequently been detected in close relatives.
The expected number of cancers was 14.4, giving a relative risk of 1.94 assuming
that the cancer ascertainment was complete. This is a conservative assumption
because the Scottish Cancer Registry can never be 100% complete and, for ex-
ample, would have no record of cancers diagnosed outside Scotland. The figure
is considerably higher than the relative risk threshold set by the currently avail-
able guidelines of 1.7.
NICE guidelines define women at “moderate risk” for breast cancer as those
with a risk of 3–8% between age 40 and 50 years or a lifetime risk of 17% or
greater, but less than 30%. For the “high risk” category, the risk before age 50
years must be greater than 8% and lifetime risk greater than 30%. Women at high
risk will have an approximate chance of 20% or greater of carrying a mutation
in one of the major genes implicated in familial breast cancer.
The guidelines classify “low risk” as being at near population risk, that is a risk
of less than 3% between age 40 and 50 years and a lifetime risk of less than 17%.
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In theory they should be dealt with in the primary care setting.
When NICE criteria were applied to our series, nine of the 28 cancers diagnosed
before the end of 2003 were in women with a “moderate risk” classification. If
those women are excluded from the analysis, the overall relative risk falls to
1.32.
Table 6.1 summarises the findings of this study where data on 28 breast cancers
were recorded among 2074 women discharged from breast cancer family history
clinics in Scotland during the period of January 1994 to December 2003.
Table 6.1: Summary of the study findings on the incidence of breast cancer in
“low risk” women discharged from regular surveillance programmes.
Age
range
Women-
years of
F/U
Breast Ca ex-
pected (popula-
tion data)
Breast Ca recorded
Total cohort Exluding
“NICE moder-
ate” cases
<35 843 0.25 0 0
35–39 1341 0.8 1 1
40–44 1552 1.9 2 1
45–49 1522 2.7 4 3
50–54 1405 3.9 11 8
55–59 846 2.5 5 5
60–64 454 1.4 2 0
65+ 320 0.95 3 1
TOTAL 8283 14.4 28 19
Of the 28 breast cancers recorded in the total cohort, 18 were screen detected and
10 were symptomatic. The cancer types were as in Table 6.2.
Table 6.2: Findings from the survey of “low risk” women breast cancer diagnosis
(according to pathological findings)
Node-negative Node-positive
Invasive ductal carcinoma 13 6
Invasive lobular carcinoma 2 1
Invasive tubular carcinoma 4 0
Mixed types 2 0
TOTAL 21 7
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Figure 6.1: Observed and expected breast cancer cases in “low” risk women seen
through the family history clinics across Scotland (1994–2003)
The incidence of breast cancer in “low risk” women in Scotland over the period
age 1994–2003 is shown in Figure 6.1. A further nine invasive cancers were recor-
ded since December 2003 (Figures 6.2 and 6.3), but since data for the latest period
(2004/2005) are very incomplete, these have not been included in calculations of
relative risk. They can, however, be included in evaluating the age-distribution
of cancers and family histories of those affected.
The age group between 45–59 seems to be the most important for the questions
raised on the “low” risk threshold as they constituted some 46% of our total
cohort but generated 71% of the breast cancers (84% if the NICE “moderate”
subgroup are excluded). The relative risk level was the highest in this group
when compared with the other groups in the study (2.2 if the NICE “moderate”
cases are included, 1.8 if not).
In fact, all but two of the 20 cancers in this age group were diagnosed by age 56
years and one more at 57 years.
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Between the ages of 45 and 55 years, the risk for women with a “weak” fam-
ily history of breast cancer does appear to be higher than that seen in the nor-
mal population and at a level greater than the predictions on which current
guidelines are based.
Given that the large peak of cancers occurring in the 50–54 years of age group is
accounted for by cases diagnosed at first NBSP mammographic screen (6 aged
50 years, 2 aged 51 years and one at age of 52 years) there is a strong suggestion
that more regular screening would lead to earlier diagnosis in these “low risk”
women.
By the same argument, most of those recorded as presenting in the 55–59 years
age group might have been detected by regular screening up to the age of 55
years since almost all were actually diagnosed by age 56 years.
Hence there could be a case for review of the criteria for regular surveillance in
the 45–55 years age group.
All the tumours discussed so far were invasive breast cancers. Two thirds were
detected by clinical and/or mammographic examination, (through the National
Breast Screening Programme in most of the cases).
Other relevant cancers for our study included: three DCIS (ductal carcinoma
in situ) cases; one woman was found to have an unexpected second focus of
invasive disease in her mastectomy specimen after surgery (not scored here as
a separate cancer), three epithelial ovarian cancer cases (serous, endometrioid
and mucinous types respectively). A single case of ovarian borderline tumour
was also identified.
With the changes made in the multidisciplinary clinics (Edinburgh and Dun-
dee), since 2004, women found to be at “low” genetic risk for breast cancer no
longer attend the clinics and therefore do not have clinical examination nor a
mammogram before being discharged.
Of the total number of cancers (36) detected (including the ones from January
2004), 12 would, under the most recent guidelines of NICE, have had their fa-
milial risk classified as “moderate ” rather than “low”, as per SIGN guidelines
(see Figure 6.3).
Re-examination of the family history background of 400 from the total number of
patients in this particular study suggests that less than 10% of them would in fact
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Figure 6.2: Breast cancers detected by year of diagnosis in “low risk” women
across Scotland during study period
be reclassified as “moderate” risk if the NICE criteria were used. “NICE mod-
erate” women are therefore substantially over-represented among those who
developed breast cancer.
The findings suggest that the NICE criteria are more accurate in determining
familial breast cancer risks than the ones used in Scotland (SIGN guidelines) or
other widely used algorithms to quantify breast cancer risk, though all of them
have substantial confidence intervals.23, 24, 36
In the group of “NICE moderate” women affected with breast cancer, half of
them were over 60 years of age. As breast cancer is an age-related condition,
there could be an increased number of breast cancer cases in those women and
among their (older) relatives but not necessarily indicating an increased genetic
risk for the disease.
Only three cancers in total were recorded before age 45 years and this repres-
ents no excess over expected numbers. These observations further support the
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concept that the age group 45–55 years is the one on which we should concen-
trate in judging the provision that should be made for women with a “limited”
family history of breast cancer.
This age group should receive special attention, as their risk up to the age of
56 years could be significantly higher than that of the normal population. They
would perhaps benefit from regular surveillance starting at 45 years of age and
continuing to age 55 or 56 years, possibly at 18 month intervals rather than an-
nually and interdigitating with the NBSP from age 50 years.
The minority with a very strong family history, suggestive of a BRCA mutation
will be at risk from a much earlier age and, as discussed in Chapter 5, require
rather different service provision.
To my knowledge, this is the first serious study of how the various guidelines
and risk assessment protocols actually work in practice. The group of women
identified in our cohort should be followed up for longer period of time in or-
der to establish whether any further modifications would be necessary to the
guidelines. This would contribute to the urgent requirement identified in the
2004 NICE report, for proper validation of risk assessment models used in fa-
milial breast cancer genetics clinics.
Interestingly, hardly any of the women diagnosed with cancer reported this back
to the breast cancer family history clinics although, in most instances, the new
cancer case changed the risk for close relatives to “moderate”. This is a cause for
concern because, at their discharge discussion with the genetics associate and
in the explanatory letter from the clinic, they had been advised to inform the
genetics clinics of any change in their own symptoms or their family history.
Preliminary findings for the years 2004 and 2005 are in keeping with the ex-
cess risk observed. It will be very important to follow this cohort for at least
further few years so a more accurate analysis of the true incidence can be per-
formed to generate a substantial evidence base to allow further modifications to
the guidelines for the familial breast cancer services.
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Figure 6.3: Number of breast cancers detected in “low risk” women by the age
at diagnosis (all cases 1994–2005 included)
6.1 Conclusions
Given the haste which the guidelines were drawn up in response to the demand
for breast cancer family services, it would have been unreasonable to expect
the threshold setting to have been absolutely correct. By taking a minimal risk
of 1.7 times the population risk level, it was anticipated that the incidence of
breast cancers in a population enrolled in special screening programmes would
approach 6 per 1000 examinations, (the same as the National Breast Screening
Programme for older women) and as I have shown in Chapter 4, this expectation
has been fulfilled.
Nevertheless, I have demonstrated that at least one subgroup of women cur-
rently excluded from surveillance by the SIGN guidelines (1998) threshold cri-
teria ought to be included, these are women with 2 affected close relatives at
least one of whom was aged 60 years or older at diagnosis.
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6.2 Future work
The Scottish "low risk" cohort needs to be studied in greater detail and for a
longer period to identify further modifications to the threshold setting. Collab-
oration with the Scottish centres, Cancer Registry-ISD, genealogy service and
Registrar General should continue to enable data collection for analysis. We are
looking into the development of a UK-wide collaboration following this group
of women, however there may be some difficulties elsewhere in the UK as those
registry and central records services may not be as fully functional as in Scot-
land. Unfortunately a European-wide collaborative study will also prove diffi-
cult, owing to the diversity of clinic settings and availability of supporting ser-
vices.
Chapter 7
Costs and cost-effectiveness issues
This chapter deals with just one question but it is the central issue of the whole
thesis:
Is current management of women at increased familial risk of breast cancer cost-effective?
That can be broken down into a number of elements:
1. What are the cost associated with current practice?
2. What are the benefits?
3. Can potential changes in practice be identified that may reduce costs, in-
crease benefits or both?
The terms “cost” and “benefits”, of course, are not restricted to monetary defin-
itions. They also encompass patient experiences, anxieties and their resolution.
These latter elements may be more difficult to quantify but, as far as possible I
have taken them into account.
7.1 Background and methods to obtain cost figures
and their accuracy
For those with a family history of breast cancer their lifetime risk of developing
breast cancer may be substantially increased and as at least some forms of hered-
itary breast cancer tend to occur at young age of onset, it is generally accepted
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that the NBSP (National Breast Screening Programme), available from the age of
50 years, provides insufficient protection. Debates about whether or not screen-
ing young women for breast cancer is beneficial are continuing.114, 122, 213
Health economics aims to evaluate any new healthcare intervention to obtain a
full measure of its benefits and costs to society. There are very limited published
data on the subject of cost-effectiveness of familial breast cancer management
and such readily available information as exists on cost issues related to the
treatment of breast cancer patients with new (and expensive) drugs and inter-
ventions is not completely up to date.65, 87, 89, 103, 148
Most of the published analyses relate to hypothetical models and only limited
hard data have been used in the calculation of costs and effectiveness in the
management of women with familial breast cancer risk.1, 90, 91, 151, 214 There is,
in my view, a danger in undertaking and publishing apparently detailed cost-
effectiveness projections which lack a secure evidence base because they can
be taken as authoritative and may have considerable influence on the com-
missioning of services (under insurance-based or publicly funded systems) yet
ultimately prove misleading. A very clear example is the impressive report
published this year in the Annals of Internal Medicine (the official journal of
the American College of Medicine) entitled “Cost-effectiveness of preventive
strategies for women with a BRCA1 or a BRCA2 mutation”.1 The authors “ap-
plied a Markov process and used 25000 Monte Carlo simulations with TreeAge DATA
Pro software to estimate the cost-effectiveness of [several different] preventive strategies”.
Their findings are extraordinarily detailed but, for the purposes of their study,
the authors “assumed that BRCA1- or BRCA2- positive women who developed cancer
would have the same conditional probability of death as women with cancer in the gen-
eral population”. Further, they comment that “Most other studies have not suggested
that mortality is higher for mutation carriers than for other women with breast cancer.
The higher the mortality assumed to be associated with BRCA1 or BRCA2 mutations
given surveillance alone, the greater are the survival and cost-effectiveness benefits of
preventive interventions. We used the most conservative estimates of each parameter
so that our model would, if biased, favour surveillance over other preventive interven-
tions”. Real data, as documented for example in Chapters 5 and 6 of this thesis,
demonstrate that the assumptions underlying the study are incorrect. Carriers of
BRCA1 mutations who develop breast cancer have very different risks of dying
CHAPTER 7. COSTS AND COST-EFFECTIVENESS ISSUES 133
from it, compared to BRCA2 mutation-carriers or women with a family history
of the disease but no demonstrable mutation. The relative cost-effectiveness of
surveillance or of prophylactic intervention for different categories of women at
increased familial risk can only be assessed with real validity if these facts are
accommodated in the calculations.
My own approach has been to measure the real (mainly modest) shifts in stage
of breast cancer diagnosis achieved through screening and hence the modest
gains in survival for those affected. Costs calculations were also based on real
data gathered as described below.
I began by collating all clinic procedures for each woman attending. I have also
identified all the Tayside cancer family service women in whom breast cancer
was detected. From their case notes, I tabulated all the procedures performed,
drugs used and in-patient stays for the duration of treatment.
Costs figures were calculated using available information published locally or
nationally, the main sources being the report by my Tayside colleague Dr John
Dewar103 on costs of breast cancer management and unit costs derived from the
Scottish Health Statistics on breast cancer - ISD Scotland (blue book). For further
details I contacted Mr Derek Colley, Mr Glen Finnie from the Finance Depart-
ment at Ninewells Hospital, Mr David Carson Head of Financial Performance
Management for NHS Tayside.
Because of the different outcome from screening (detailed in Chapter 5), BRCA1
mutation carriers were treated as a special group, for whom prophylactic sur-
gery should be considered as a preferred management option.
I have not been directly involved, as yet, in formal studies of patients’ psycho-
logical reactions to risk assessment, screening or other aspects of management,
apart from those reported in Chapter 4. However, reference is made to the rel-
evant literature wherever appropriate.
7.2 Basis of calculations
The survival benefit of detecting breast cancer at an early rather than at an ad-
vanced stage for a “typical” breast cancer patient was the principal base for cal-
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culation of cost-effectiveness of surveillance (see Chapter 1 for an introduction
to the staging and current management of breast cancer).
I have used the term “typical” breast cancer patient as a hypothetical individual,
though, in reality, no such “typical” breast cancer patient exits. Nevertheless, I
believe the composite pictures upon which my calculations are based, are real-
istic and derived from the observations in the Tayside clinic, across Scotland
and through multi-national European collaborative programmes described in
the preceding chapters.
The following assumptions, all supported by the findings discussed in preced-
ing chapters and in most recent UK standard reviews of clinical aspects of breast
cancer215, 216 are made in order to generate the figures from which costs and be-
nefits are finally calculated:
1. Within a “breast cancer family” surveillance programme, breast cancers
are detected at a rate of six per thousand annual examinations.
2. Seventy-seven percent of the breast cancers detected among women in
such a surveillance programme are “early stage” and node negative.
3. Fifty-five percent of cancers detected among young women (<50 years)
who have NOT been enrolled in any screening programme are “early stage”
and node negative. This means that surveillance increases the proportion
of “early” cancers by 22%.
4. “Early” node-negative breast cancers have a 70% prospect of complete
eradication (“cure”) by primary surgery, radiotherapy and, where appro-
priate, adjuvant chemotherapy.
5. “Late”, node-positive breast cancers have only a 30% prospect of com-
plete eradication (“cure”) by primary surgery, radiotherapy and adjuvant
chemotherapy.
6. Those not “cured” by their primary treatment (30% of “early” cases, 70% of
“late” node-positive cases) will require additional treatment and investig-
ations, often involving expensive drugs such as taxanes and/or Herceptin
and are likely ultimately to require palliative care.
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7. The quality of life (after primary treatment) for “cured” patients is excel-
lent and, since we are dealing mainly with women around age 50 years,
“cure” of breast cancer provides a further 25 years of life (25 QALYs).
Combining the stage at diagnosis, the cost of specific element of treatment and
the proportion of patients requiring each element, generates Table 7.1.
Table 7.1: Costs for “typical” pre-menopausal women that developed breast can-
cer: two distinct scenarios are presented, “early” stage at presentation (70% an-
ticipated cure) and “late” stage (70% anticipated recurrence with ultimate treat-
ment failure)
Late stage Early stage
(T3/T4 N+) (T1/T2 N−)
Anticipated “cure” rate >10 years 30% 70%
(i.e. disease-free survival)
% Cost % Cost
Initial inpatient stay (average five 85 £1,908 100 £2,245
nights @ £449), £2245
WLE + ax. surgery, £1,673 15 £251 60 £1,004
Mx + ax. surgery, £2,421 70 £1,695 0 £0
Mx + ax. surgery + reconstr., £4,513 0 £0 40 £1,805
Anthracyclines × 6, £1,836 50 £918 60 £1,102
FEC × 6, £3,155 50 £1577 0 £0
Taxanes, £9,160 70 £6,412 15 £1,374
Herceptin (2yr), £44,000 25 11,000 5 £2,200
Bisphosphonates (2yr), £4,000 50 2,000 10 £400
Tamoxifen (5yr), £43 50 £21 50 £21
Radiotherapy (standard), £1,500 100 £1,500 60 £900
Palliative radiotherapy, £400 70 £280 15 £60
Palliative care inpatient stay 70 £36,110 25 £12,896
(15 nights @ £3439), £51,585
TOTAL cost £63,672 £24,007
(WLE = wide local excision; ax. surgery = axillary surgery; Mx = total mastectomy;
reconst = breast reconstruction; FEC = chemotherapy regime using 5-fluorouracil, epi-
rubicin and cyclophosphamide). Note that, in deriving the total treatment cost for each
category of “typical” patient, allowance is made for the proportion within each category
that will actually require any given component of the treatment options. Cost figures
are derived from reference103 and sources cited in text.
The figures for “early stage” cancers include around 15% of cases of DCIS on
the grounds that detection at this “pre-cancerous” stage will prevent later de-
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velopment of invasive cancer, which is, of course an important purpose of the
screening programme.182
For each woman with breast cancer diagnosed in stage 1 or 2, rather than stage
3 or 4, there is, from the calculations, an average saving in direct healthcare costs
of £39,665 (£63,672 − £24,007).The additional costs for late stage patients are
accounted for by more extensive initial surgery, greater requirement for costly
“second line” chemotherapy and particularly by the cost of palliative care in the
last year of life. This last figure may seem surprising but palliative care requires
a high staff/patient ratio and expensive accommodation and facilities. For com-
parison, the 2004 figures from the Kaiser Permanent Health Care Organisation
in the USA1 are shown in Table 7.2. “Acute care” costs – i.e. initial surgery,
radiotherapy and chemotherapy are higher than I have estimated for Tayside
and palliative care is cheaper but still much the most expensive element of the
“package”. Figures from two Canadian studies were given in Chapter 2; though
some years out of date now, their findings are broadly in line with the above.95, 96
Table 7.2: Representative costs of management options for familial breast cancer
in North America (quoted in1). Conversion £1 = 1.8 US$
Treatment element Cost (converted to
£ sterling)
Primary surgery, radiotherapy and £14,670
chemotherapy (with in-patient stay)
Yearly costs thereafter £3,770
Palliative care in last year of life £21,630
Prophylactic mastectomy £6,280
Prophylactic salpingo-oophorectomy £2,570
From the costs calculations in Jane Kenyon’s study (Chapter 5), which I su-
pervised, patients with nodal involvement were more expensive to treat with
a mean cost of £7,423.7 when compared to £5,836.4 for node negative patients.
However, very few of the patients in that study had reached the terminal care
stage and drugs such as taxanes and Herceptin were not yet available (chemo-
therapy regimes then in use were based on CMF and anthracyclines). Therefore
the full cost implication for the NHS cannot be derived directly from that study.
We have found that surveillance increases the proportion of “early stage” breast
cancer diagnosis from 55% to 77% (tables 5.2 and 5.3). Thus, for every hundred
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breast cancers arising in women enrolled in an annual screening programme,
22 are “transferred” from the poor to the good prognosis category and hence, in
cost terms, from the left to the right hand column of Table 7.1, with a total saving
in direct healthcare costs of £872,630 (22 × £39,665).
The detection rate for breast cancer in a cancer family service surveillance pro-
gramme has been estimated at 8 per thousand screening examinations.98 The
figure for Tayside has been about 5.8 per thousand, though this is likely to in-
crease as more stringent criteria are applied for entry to the programme.
Therefore, taking 6 per thousand as a realistic figure, the shift to earlier stage
at diagnosis would affect 1.32 women per thousand screens (22% of 6), with a
saving of £51,358 in NHS costs (1.32 × £39,665).
Coincidentally, the Tayside service now undertakes about one thousand screens
per year and, as recorded in Chapter 4, the NHS cost is just over £100 per screen.
Hence, the net annual cost of the Tayside programme is around £100,000, less
the savings (calculated above) of £51,358 – i.e. £48,642.
If each woman shifted from “late” to “early” stage diagnosis through screening
improves her prospect of long-term survival (“cure”) by 40% (from 30% to 70%)
and cure adds 25 years of high quality of life (25 QALYs), the gain is 13.2 QALYs
per year (25 × 0.4 × 1.32) at a cost of £3685 per QALY (£48,642 ÷ 13.2).
This does not take into account the fact that many women in their 40’s and 50’s
years are in productive employment and/or undertaking important family re-
sponsibilities which have an economic value. In practice, therefore, the net cost
to the national exchequer per QALY gained is likely to be much less than £4,000.
I have arrived at a much lower cost per life-year gained than was calculated
in the pilot study by Kenyon.217 She reported a figure of £19,619 per life-year
gained by screening young women at increased risk of developing breast cancer.
However, as noted above, in that small study, the five-year time-span was a
limiting factor and the true cost of follow-up, treatment for recurrent problems
and palliative care was not included. Her calculations were based largely on the
costs of primary surgery, radiotherapy and chemotherapy which, as shown in
table 7.1, do not differ greatly for the “early” or “late” stage cases.
As discussed in Chapter 2, Heimdal and colleagues148 calculated the costs of
diagnosing familial breast cancer in Norway using empirical figures from the
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Norwegian Health Insurance system and the cost per year gained was estimated
at 753 Euros. This could increase to 832 Euros if a new strategy was implemented
for identifying all “high risk” family by testing for genetic founder mutations
in a Norwegian population. They also concluded that “inherited breast cancer
could be cured for the cost of 750–1,600 Euros per each year gained”.
Why our figures differ is explained in the following few lines:
Their costs, based on Norwegian health insurance charges, were lower (110
Euros per screen). Translating those figures in to pounds gave a cost of £78.50
per screen (110 Euros ÷ 1.4).
They assumed a 75% “cure” rate for cancers diagnosed in the screening pro-
gramme and a gain of 30 years of life for each woman so diagnosed, attribut-
ing all of this to the screening programme – i.e. assuming 100% mortality if no
screening.
Their breast cancer detection rate was very high because they concentrated on
families bearing Norwegian “founder” mutations in BRCA1.
In our own calculations, we have allowed for the fact that some 30% of the “early
stage” screen-detected breast cancers in young women will ultimately recur and
prove fatal, whereas around 30% of the “later stage” cancers (typically those
presenting in women not enrolled in a surveillance programme) are “cured” by
primary treatment.
In addition, some non-screened cancers (55%) present at an early stage while
some detected in a surveillance programme (23%) are already node positive.
The more recent study by Gui et al. (2006)218 from the Royal Marsden Hospital,
though based on a shorter time interval (16 months) and only 1132 patients, pro-
duced results comparable to our own. Only 2 out of 13 breast cancers diagnosed
in their cancer family clinic had nodal involvement and over 85% of the cancers
were diagnosed at screening mammography.
Realistically, therefore, any surveillance programme will have much less than
100% efficiency in transforming “fatal” breast cancer into the “curable” category.
Despite this, our figures show that the cost per QALY gained is modest com-
pared with many other interventions (e.g. coronary artery by-pass surgery, renal
transplantation).219, 220
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7.3 Sensitivity analysis
Our calculations are particularly sensitive to changes in two specific parameters,
namely the rate of detection of breast cancers in a surveillance programme and
the effectiveness of screening in terms of shifting diagnosed breast cancers on
average towards an earlier stage. For both, we have used values that correspond
closely to what we have actually observed; however if, for example, the breast
cancer detection rate falls to 4 per 1000 screens, while the shift to a curable stage
at diagnosis remains at 22%, then the cost saving of £39,665 will be achieved for
only 0.88 women per year (rather than 1.32), i.e. an annual saving of £34,905.
The cost of screening 1000 women per year is fixed at £100,000 so the net cost
(£100,000− £34,905) becomes £65,095 and if each woman shifted to the “curable”
category still gains 40% of 25 years (i.e. 10 years) of high quality life, 8.8 QALYs
are gained each year, at a cost of £7396 per QALY.
Conversely, if the cancer detection rate rises to 9 per year (as suggested by Ker-
likowske and colleagues in 1995127), then the saving rises to £78,537 (1.98 ×
£39,665) and the net annual cost falls to £21,465 (£100000 − £78,537) for a gain of
19.8 QALYs, reducing the cost per QALY to £1084.
If the shift to earlier stage at diagnosis of breast cancer applies to 15% of cancers
rather than 22%, then the saving per 100 cancers detected reduces from £872,630
to £594,975 (15 × £39,665) and if the detection rate remains at 6 per year, the
annual saving becomes £35,669 (0.9 × £39,665), set against a fixed annual cost
of £100,000, giving a net annual cost of £64,301 for a gain of 9 QALYs, costing
therefore £7145 per QALY.
Raising the proportion of patients whose cancers are detected at a significantly
earlier stage from 22% to 30% has the opposite effect. The saving per 100 can-
cers becomes £1,189,950 (30 × £39,665) so the saving per year (if 6 cancers are
diagnosed) is £71,398 (1.8× £39,665) and the net cost per year reduces to £28,601
(£100,000 − £71,398) for a gain of 18 QALYs. Each QALY gained then costs only
£1589.
Realistically, the number of cancers detected per year is likely to rise above
the current level, rather than to fall, as more stringent procedures are applied
for selection of those eligible to enter surveillance programmes (see Chapter
4). On the other hand, the proportion of breast cancer patients who benefit
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directly from earlier diagnosis through screening may actually be lower than
the 22% we have measured if, as discussed earlier, some of the apparent be-
nefit derives from intrinsic biological differences between familial (non-BRCA-
associated) and sporadic tumours.
Variations in these parameters can be combined, as illustrated in Table 7.3.
Table 7.3: Effects of changing sensitive parameters (numbers of breast cancers
detected per year and percentage of patients who benefit from “stage shift” of
their cancer) on cost effectiveness of surveillance programme for familial breast
cancer
Breast % shift to Br Ca pts. QALYs Annual Annual Cost per
cancers “curable” benefitting gained* saving net cost QALY
detected / yr stage per year £** £*** £
6 22 1.32 13.2 51,358 48,642 3685
4 22 0.88 18.8 34,905 65,905 7396
9 22 1.98 19.8 78,537 21,463 1084
6 15 0.9 9 35,669 64,301 7145
6 30 1.8 18 71,398 28,601 1589
4 15 0.6 6 23,799 76,201 12,700
4 30 1.2 12 47,598 52,402 4367
9 15 1.35 13.5 53,548 46,452 3433
9 30 2.7 27 107,096 −7096 −263
*Assumes 10 QALYs per additional patient detected at “early” stage (25 × 0.4).
** Assumes saving of £39,665 per additional patient detected at “curable” stage
(from Table 7.1). *** Assumes fixed annual screening cost of £100,000 (for 1000
women screened).
Table 7.3 shows that, under the most favourable assumptions (9 breast cancers
detected per year and 30% of these shifting from adverse to good prognosis
as a result of surveillance) the savings actually exceed screening costs so that
each QALY gained saves the NHS around £250. At the other extreme, if only 4
cancers are detected each year and just 15% of these benefit from diagnosis at an
earlier stage (compared with no screening) then each QALY gained could cost
over £12500.
7.4 Carriers of BRCA mutations
The foregoing discussion applies to the cancer family clinic population in gen-
eral, the great majority of whom do not carry BRCA1 or BRCA2 mutations. The
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minority (about 5%) who carry BRCA1 mutations represent a special case. Even
when diagnosed early, breast cancers in this group carry a very bad prognosis
and prophylactic surgery is a serious option for them.
At present, around 12% of breast cancers diagnosed among the Tayside breast
cancer family clinic population (5 out of 42 cases since 1995) are known BRCA1
mutation carriers. This percentage may increase in the future as mutation de-
tection becomes more efficient and as more efforts are directed towards known
mutation carrier positive families.
The costs of treatment for a BRCA1 mutation-positive breast cancer are compar-
able to those shown for “late stage” cancers in table 7.1 i.e. long-term survival
with conventional treatment is about 30%.
At present, we see no evidence that screening will achieve a shift in survival pro-
spects for them. The question then is how cost-effective is prophylactic surgery
for this group?
Table 7.4 shows current costs for women undergoing risk-reducing surgery as-
suming all patients who have prophylactic mastectomy (+/- reconstruction) also
have bilateral salpingo-oophorectomy (BSO) as a separate procedure.
Table 7.4: Cost of prophylactic surgical intervention for BRCA1 mutation carri-
ers.
Procedures Cost
Bilateral salpingo-oophorectomy (BSO)* £1,500
In-patient stay (av. 3 nights @ £449) £1,347
Bilateral mastectomy £2,421
In-patient stay (av. 5 nights @ £449) £2,245
TOTAL (BSO and mastectomy) £7,513
Bilateral mastectomy and reconstruction (TRAM flap) £4,513
In-patient stay (average 8 nights @ £449) £3,592
TOTAL (BSO + Mx + TRAM) £10,952
(TRAM flap = transverse rectus abdominus myocutaneous flap reconstruction)
*Assuming all patients who have prophylactic mastectomy (+/- reconstruction)
also have BSO (as a separate procedure). Cost figures derived from reference103
and sources cited in text.
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7.5 Savings (direct health care) from prophylactic
surgery
For one BRCA1 mutation carrier (who has 80% lifetime risk of cancer and a
70% risk of death from breast cancer if it should occur), the risk of death from
cancer is reduced by oophorectomy from 56% to 28% as risk tends to be reduced
by half. The risk of death from cancer is reduced by mastectomy plus bilateral
salpingo-oophorectomy (BSO) from 56% to 5%.
Therefore, applying the figures from tables 7.1 and 7.4, the direct healthcare cost
of each BRCA1 mutation carrier who does not have prophylactic surgery is 56%
of £63,672 plus 24% of £24,007, i.e. £41,418. This is reduced by half through BSO
and by 95% if BSO is combined with bilateral mastectomy.
Hence, BSO at a cost of £4,850, saves £20,709 per patient, while combined pro-
phylactic mastectomy and BSO, at a cost of £7,961, saves £39,347 per patient.
These figures apply to BRCA1 mutation carries only (around 5% of clinic popu-
lation at present) but given the very high lifetime risk of breast and/or ovarian
cancers, the savings apply to almost all of these (in contrast to the situation for
non-BRCA1 mutation carriers, only a minority of whom will actually develop
cancer).
Years of life gained by prophylactic surgery for BRCA1 mutation-positive wo-
men are around 25 years. Therefore prophylactic surgery is highly cost-effective
in this group.
Limited studies on psychological consequences of prophylactic oophorectomy
and mastectomy suggest that the impact is usually manageble221, 222 but this is
an area that requires much more work.
The psychological price of annual screening, with its attendant reminder of risk
for breast cancer and the anxiety level acccompanying the wait for the results
of screening applies to all women attending a “family history” surveillance pro-
gramme. It is difficult to quantify this cost accurately, however, recent reviews
demonstrate that the impact on general anxiety or cancer-specific worry is broadly
neutral.223, 224 It is clear that women aware of their possible increased risk for
breast cancer strongly favour entry into regular surveillance programmes with
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mammography screening, regarding its availability as providing peace of mind
and comfort rather than a source of anxiety.187, 189
7.6 Conclusions
I have arrived at estimates of the net economic cost of management for women
in different categories of familial risk of breast cancer. While there is clearly
some margin of error around the estimates, I believe they are the most robust
currently available.
For the great majority of women eligible for inclusion is special surveillance
programmes, the net cost per QALY falls within the range £-263 to £12,700, with
a median value of £3685. Even the highest of these estimates lies within the limit
considered acceptable by NICE.225
For women who carry a pathogenic mutation in BRCA1 gene, screening, as cur-
rently practiced, does not provide adequate protection but prophylactic surgery
is plainly cost-effective. New diagnostic procedures, such as MRI, may change
the situation but several years of follow-up of MRI-detected breast cancers in
this subgroup will be required to verify or refute this. A most important out-
come of the studies reported in this thesis is recognition that management needs
to be tailored to the nature of the genetic risk i.e. it should be different for BRCA1
mutation-carriers compared to BRCA2 mutation-carriers or those with no muta-
tion in either gene.
Of course there are some remaining issues, such as the residual risk of develop-
ing primary peritoneal carcinoma and of other BRCA1 associated cancers (1–2%)
after undergoing risk-reducing surgery.
Other genes are yet to be found and new data will no doubt emerge, leading to
further recommendations for both the treatment of hereditary breast cancer and
prophylactic interventions in their relatives seeking advice about their risks for
breast cancer.
At the moment, the best intervention available for those women at high risk
either of developing a first breast cancer or of developing a second breast cancer,
after initial treatment, is prophylactic surgery.
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It is to be hoped, therefore, that with new evidence available on the outcomes
of women with a genetic mutation for breast and/or ovarian cancers the uptake
for prophylactic interventions in those women will improve.
Chapter 8
Conclusions and recommendations
Since the start of the 20th century, breast cancer management has seen major
transformation affecting diagnosis and treatment. More recently, emerging in-
formation on the genetic basis of the disease has given unprecedented potential
power for the identification of those at increased risk and opportunities for reg-
ular surveillance and prophylactic risk-reducing measures.
Developments in several medical fields have contributed to those changes, par-
ticularly with the discovery of genes responsible for breast cancer and applied
research for the evolving new era in medicine: the genetic revolution.
Unfortunately, cancer genetics services were not considered until recently as
part of routine healthcare provision, but have evolved mostly as part of research
programmes. Eventually, knowledge of the genetic implications of given condi-
tions (partly via the creation of advocacy groups) has prompted changes in the
consumer-client led world.
Changes in policy-making processes in health care have meant that comprehens-
ive genetic services for the population are beginning to evolve. Among these are
the design and implementation of guidelines for women at significant inherited
risk for breast cancer.
Proper assessment of genetic risks in the management of familial cancer allows
healthcare resources to be used in the best possible way in this country, target-
ing the individuals that are most likely to benefit from these services. Similar
“guidelines” approaches are emerging worldwide.
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8.1 Summary of the work recorded in previous
chapters
Risk assessment
It is, of course, necessary in order to achieve the aim of maximising cost-effectiveness,
to have accurate risk assessment of the individuals seeking advice.
Scotland is privileged in maintaining excellent and comprehensive Cancer Re-
gistry services as well as public records of births marriages and deaths. Access
to those services puts our cancer genetics clinics in a particularly strong position
to extend and verify self-reported family histories of breast and ovarian cancers
as well as other heritable malignancies.
Communication of “low genetic risk” assessments
The communication of risk outcome to those individuals considered to be at
“low genetic risk” by letter is acceptable; face-to-face interview only seldom
adds relevant information to what has already been collected through stand-
ardised Family History forms received at an early stage of the risk assessment
process.
Identification of “low genetic risk” and communicating this assessment without
the need for a clinic appointment could reduce direct cost to the NHS by at least
£100 per woman per year.
Co-operation
A truly effective cancer genetics service requires close co-operation between
primary care team, family members and the staff of the genetic service itself.
This is a more practical approach than allocating “gatekeeper” responsibility to
GPs who lack the time or facilities to fulfil that role and who are (rightly) reluct-
ant to adopt it.
As we have demonstrated, the percentage of “low risk” referrals increases con-
siderably when all appropriate resources (including use of a Cancer Registry
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–based medical genealogy service) are applied to the process of verification of
information provided in the family history form.
If the triage system, evaluated in this study, for selection of women at increased
risk for breast cancer is adopted as routine, no net increase in NHS resources for
familial cancers will be entailed.
It remains to be seen, however, to what extent the same policy could be imple-
mented in the UK regions that do not have comparable access to Cancer Registry
and genealogical data.
For the women who fail to return their family history questionnaire (and who
may have real difficulties in doing so) further discussion between clinic special-
ists and primary care team is currently addressing their management.
Unfortunately, mammographic surveillance and clinical examination cannot be
offered to those women who fall in the “lower risk” category. It is inevitable that
this generates disappointment. For those advised of a “low risk” assessment
but who remains anxious about the issue of cancer risk, something more than a
simple letter of reassurance may be required and this is also on the agenda for
discussion with the primary care teams.
Implementation of NICE recommendations
As presented in Chapter 6, there is some indication that cancers could be missed
if all women categorised by current guidelines as “below threshold” level of risk
are excluded from surveillance programmes.
Our immediate conclusion is that the NICE recommendations should be imple-
mented in Scotland – meaning that women with two close relatives diagnosed
with breast cancer at any age should be classified as “moderate risk”.
In the longer term, further studies are required to look into any other modific-
ation of criteria for entry to surveillance programmes – for example, whether
a subgroup of women with relatively “weak” family histories of breast cancer
should nevertheless be offered some extra screening, say from age 45 to 55 years.
Dietary and lifestile intervention studies could play a role in this group.
Continued follow up of the “lower risk” cohort described in this thesis should
contribute to resolution of this question but work is justified on a wider scale
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and it is to be hoped that other centres may be able to replicate or extend our
study.
Cost-effectiveness of surveillance and prophylaxis
Overall measures of cost-effectiveness of the services provided for familial breast
cancer are difficult because it takes time to gather and interpret the real data re-
quired to make sound judgements. It is perhaps unfortunate that a number of
seemingly authoritative statements and recommendations have been published
over the years based on false assumptions—for example, that all categories of
familial breast cancer fare equally well (or badly) under regular surveillance.
Estimates of the efficacy of surveillance or of prophylactic surgery appear some-
times to have been plucked from the ether. My attempts to derive true figures
for cost-effectiveness (Chapter 7) are admittedly, approximations that may well
have to be refined as more complete data become available but they do begin to
show a coherent picture.
Regular surveillance for the great majority of women at increased familial risk of
breast cancer (including those with BRCA2 mutations) is cost-effective, reducing
mortality and morbidity at a median estimated cost of around £3,700 per QALY
gained.
For the minority who carry mutations in BRCA1, however, screening is ineffect-
ive while prophylactic salpingo-oophorectomy, with or without total mastec-
tomy, offer useful protection and are clearly cost-effective. How many lives
are saved with such programmes and at what cost for the currently stretched
resources within the National Health Service? Continuing prospective audit
should ultimately answer these questions more authoritatively than the present
study is able to.
Development of medical practice
As part of their professional role, clinical experts in genetics and surgeons in-
volved in the care of women at genetic increased risk for breast/ovarian can-
cers must help policymakers to address the challenges encountered in this new
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evolving area of medical practice, with continuing evaluation of the benefits and
harms of delivering this service.
Guidelines must be refined to meet the increasing demands upon such services
and attention must be given to education of all members of the healthcare team
involved in the delivery of the service so that they can cope with the rapid
changes in knowledge of the underlying genetics and implications for service
provision.
We should ensure that all patients likely to benefit from this service provision
have access to it in the future. The value of genetic testing depends on the power
of measures in place to reduce risk for a given disease and/or to improve clinical
outcomes.
It is now well recognised that screening programmes for women at genetically
increased risk for breast cancer are effective in detecting most cases at an early
(“curable”) stage of the disease. This is also true for several other hereditary
cancers such as MEN-2 and APC. However, it is not true for hereditary ovarian
cancer and for some others, such as Gorlin’s syndrome or MEN-1, it remains
unproven.226–228
Providers of diagnostic genetics services have an obligation to disclose complete
and up-to-date information on availability, acceptability and potential efficacy of
the interventions on offer as many of the choices available will have significant
impact on the lives of those required to make them.229
It is now possible to define more precisely the type of care needed for women
who carry BRCA1 and/or 2 mutations, ranging from close surveillance to pro-
phylactic surgical interventions,49, 61, 229 making these options available to them
with advice based on the best currently available evidence.
8.2 A return to the original questions
As a result of my studies I believe I can give answers, at least in part, to the
questions set out in the Framework diagram in Figure 1.1.
Are current guidelines criteria of risk assessment valid? No, not entirely. The NICE
guidelines which remove any age restriction when assigning risk to a history
of two breast cancer-affected relatives appear to be more accurate than those
CHAPTER 8. CONCLUSIONS AND RECOMMENDATIONS 150
widely applied before 2004 but longer follow-up of the Scottish “lower risk”
cohort may reveal a case for further adjustments that will provide some protec-
tion, through surveillance, for a group of women at substantially increased risk
between the ages of 45 and 55 years.
Who should undertake risk estimation? This is very clearly a task for people with
professional training in the field and with access to a supportive infrastructure.
Genetics associates or Genetics Nurse specialists are very well placed for the
purpose. Close two-way interaction with Primary Care staff should be recog-
nised as an essential element of the risk assessment process.
How should discharge be managed for women referred to the service whose familial risk
places them below the threshold for enrolment in a surveillance programme? It has
emerged that their understanding of actual risk level is poor and that many be-
lieve they are at no increased risk at all, while others are dissatisfied with re-
fusal to provide regular mammographic screening. Attention to improvement
and standardisation of written information will be important but consideration
must also be given to provision of face-to-face support, perhaps through profes-
sionally led group discussion sessions. Information from focus groups will be
useful in developing these ideas.
How often should surveillance be undertaken? At what ages should it start and stop?
What methods should be used?” Our collaborative studies with Norway, Eng-
land and other European countries have shown that most breast cancers arising
in young women at increased familial risk can be detected at screening from age
35 years onwards, using a combination of expert clinical examination an mam-
mography (with ultrasound and biopsy as backup, where required). Twelve
monthly screening intervals (but no longer for young women) are satisfactory
and a starting age of 35 years or 5 years younger than the youngest affected relat-
ive means that few cases are missed. However, there is a case for looking further
at a later starting age (perhaps 45 years) for some women with relatively weak
family histories. Since risk, for many women, does not decline sharply at age
50 years, we should continue to collect data to establish whether continuation of
screening, perhaps at 18 months intervals, is advisable up to age 55 years. For
women who carry BRCA1 mutations, screening as currently practised, is unsuc-
cessful although tumours may be detected at apparently early stages. The place
of MRI for this group needs to be evaluated through longer follow-up.
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Is surveillance cost-effective? For the great majority of women at increased familial
risk, the answer appears to be “YES”. My calculations suggest that the cost per
QALY gained is of the order of £3,700. However, the possibility has not been ex-
cluded that some, at least, of the apparent “stage shift” from which these women
benefit, actually stems from the favourable biology of familial cancer rather than
as a direct result of the surveillance programme. For obvious ethical reasons, it
is not possible to resolve that question at present.
What is the place of prophylactic surgery? For carriers of BRCA1 mutations, prophy-
lactic salpingo-oophorectomy, with or without total mastectomy, is undoubtedly
cost-effective. For carriers of BRCA 2 mutations, salpingo-oophorectomy, com-
bined with lifetime mammographic surveillance appears to be a reasonable op-
tion. For all other women at increased familial risk of breast cancer, the only
strong case for prophylactic surgery depends on disabling anxiety, for which
alternative psychotherapy might be more appropriate. This presupposes that
women will participate in a good quality surveillance programme—results of
which are likely to be very satisfactory. Unilateral prophylactic mastectomy for
carriers of BRCA1 or 2 mutations who have already been diagnosed with cancer
in one breast raises difficult issues. With standard adjuvant chemotherapy the
risk of contra-lateral cancer is low for several years, while the chances of relapse
(distant metastases) from the initial tumour are high. Therefore a defensible po-
sition would be to delay a decision on further surgery for a year or two until it is
clear that early spread of the initial tumour has not occurred. On the other hand,
some women in this situation are very anxious to do everything possible to min-
imise their future risks and in several cases occult cancers have been found on
pathological examination of the “prophylactically” removed breast. The mes-
sage must be that each woman should be counselled and managed as an indi-
vidual.
I hope to have contributed to the future of women at genetically increased risk
for breast and ovarian cancer as well as demonstrating that the position of wo-
men at “low” genetic risk should be examined further, as there is now evidence
to suggest that, for some at least, the risk may not be as low as initially believed.
Figure 8.1 summarises my views on how a regional breast cancer genetics ser-
vice in Scotland should now be organised.
The specific changes from current practice are as follows:
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1. GPs are encouraged to refer to the Regional Cancer Genetics service any
women concerned about their family history of breats cancer.
2. Risk assessment is undertaken by trained professionals (genetics associ-
ates or genetics nurse specialists) with support from consultant clinical ge-
neticists, using family history forms completed by the family and verify-
ing, where necessary via clinical records, cancer registries and registers of
births, marriages and deaths.
3. NICE criteria for eligibility for special surveillance programmes should
be extended to Scotland and further adjustments to those criteria should
be evaluated through longer follow-up of the Scottish "low risk" cohort
described in Chapter 6.
4. Women known to carry BRCA1 or BRCA2 mutations or to have a family
history placing them at increased risk of ovarian cancer should be offered
prophylactic oophorectomy from age 40. This age criterion should be kept
under review as some centres suggest oophorectomy at around 35 years of
age.
5. Carriers of BRCA1 mutations (or those with a family history strongly sug-
gestive of this) should be enrolled in regular MRI screening and the out-
come of MRI-detected breast cancers should be monitored very closely.
These women should also have the option of having bilateral prophylactic
mastectomy performed.
6. Surveillance for women at moderate familial risk and who have a close
relative or relatives affected over the age of 50 years should involve con-
tinued screening, at 18 monthly intervals, at least to age 55, before being
discharged to the National Breast Screening Programme.
7. An important aspect must be provision for the gathering of further data
to generate a secure evidence base for future modifications in the interest
both of the NHS and of patients who rely on such a service.
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Figure 8.1: Optimal organisation of a regional breast cancer genetics service
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Abstract: 
 
A clinical/mammographic surveillance programme for women at increased genetic 
risk of breast cancer has operated in Tayside since 1994. Outcome measures – breast 
cancer detection rates, stage at diagnosis, recurrence rates and survival – have been 
recorded and compared with data for a consecutive series of young women diagnosed 
with breast cancer, and for affected young relatives of our index cases. Neither 
comparison group had been enrolled in any screening programme before age 50. All 
investigations and treatments have been documented and costed in detail. The 
findings demonstrate a shift towards earlier stage at diagnosis for cancers among 
participants in the surveillance programme. This translates into better survival and 
hence lower cost per Quality Adjusted Life Year (QALY) gained. That measure is 
particularly sensitive to variations in cancer detection rate and in the extent of 
beneficial “stage shift” achieved by surveillance but, based on observed values for 
both, the cost per QALY is less than £4000 while, if highly conservative values are 
substituted for the sensitive variables, the cost per QALY  rises to £12700. 
Introduction: 
 
A family history of the disease is recognised as a strong risk factor for breast cancer 
(Dixon, 2006). Published guidelines recommend that women with multiple affected 
close relatives or even with one first degree relative affected at an early age (generally 
under 40) should be offered annual screening by mammography, with or without 
clinical examination, from around age 35 to age 50 or 55 (Anderson et al, 2008). 
These guidelines were originally drawn up with only a limited evidence base but, with 
over ten years experience in many centres, it is now possible to evaluate the benefits 
and cost-effectiveness of surveillance. This report is based principally on findings 
from a single clinic serving a population of about half a million, centred on Dundee, 
in Tayside, Scotland.  
 
Factors that determine cost effectiveness of a clinical service for women with a family 
history of breast cancer are the number and cost (both financial and psychological) of 
investigations carried out, the yield of breast cancers detected, the pathological stage 
of these cancers, the cumulative costs of treatment and the outcomes (recurrence rate 
and overall survival). The most valid base for comparison would be corresponding 
costs and outcomes for women with comparable family histories who had not been 
enrolled in any surveillance programme. However, for ethical and practical reasons it 
is not possible to randomise such women to “surveillance” or “no surveillance” arms 
of a controlled trial. Therefore comparisons have been based on published data for 
Scottish and other populations and on retrospective analysis, first of a consecutive 
series of Tayside women diagnosed with breast cancer before age 50 (without 
reference to family history) and second, of young relatives of our index cases who had 
themselves suffered from breast cancer. Neither comparison group had been enrolled 
in any screening programme before age 50. 
 
Patients and methods: 
 
In the 11 years since January 1995, 46 breast cancers were diagnosed among 42 
women enrolled in the Tayside breast cancer family clinic surveillance programme. 
Seven of these occurred in women carrying a germ-line mutation in BRCA1 or 
BRCA2. Mean age at diagnosis was 48 years. For comparison we identified a 
consecutive series of 40 women diagnosed with breast cancer under the age of 50, in 
the same clinical centre since 1995 (allowing a minimum of five years follow-up). 
Pathological stage at presentation and five year recurrence rates were recorded for 
both groups (Table 1). In addition, from the families of 32 affected patients 
(excluding BRCA mutation-bearing families) we identified 37 relatives who had been 
diagnosed with breast cancer under the age of 55 and who had either never had access 
to pre-symptomatic screening or had been diagnosed at the first (prevalent) round of 
the National Breast Screening Programme (NBSP). Most of these diagnoses had been 
recorded at first clinic attendance of our patients, confirmed in the course of family 
risk assessment and updated by enquiry at subsequent annual clinic visits. Data on 
outcome were documented for the majority. 
 
Our local findings were also compared with the much larger dataset (442 recorded 
cancers) compiled from several collaborating European Cancer Family centres, 
including our own (Moller et al, 1999, 2002, 2007) to confirm that data generated 
from the limited Tayside series were not unrepresentative. 
 
All procedures carried out in the Breast Cancer Family clinic were tabulated over a 30 
month period so that accurate figures for surveillance costs, according to assessed risk 
level, could be derived (Reis et al, 2006). For each of the above patients in whom 
breast cancer was diagnosed, all subsequent investigations, surgical and 
radiotherapeutic procedures, hospital in–patient periods, out-patient clinic visits and 
drugs used were recorded and detailed unit costs were derived by reference to 
published UK data (Dewar, 2001), updated and supplemented where necessary by 
information from the Scottish Health Statistics on Breast Cancer (ISD Scotland “blue 
book”). Additional details were provided by senior staff of the Finance Department, 
Ninewells Hospital and Medical School, Dundee and from the Division of Financial 
Performance Management for NHS Tayside.   
 
Our economic analysis involves the following assumptions, all consistent with the 
observed data presented below, with recent UK reviews of clinical aspects of breast 
cancer (Rodger et al, 2006; Smith and Chua, 2006) and with published findings from 
breast cancer family services elsewhere in the UK and beyond (Gui et al, 2006; 
Tilanus-Lindhorst et al, 2000; Brekelmans et al, 2001).  
 
1. Within a “family history” surveillance programme, breast cancers arise at a rate of 
six per thousand annual examinations and 75% are detected at screening. 
 
2. Seventy-seven percent of breast cancers arising in women enrolled in such a 
screening programme are “early stage” (Path T1/2) and node-negative at diagnosis. 
 
3. Fifty-five percent of breast cancer arising in women under age 50 who have not 
been enrolled in any screening programme are “early stage” and node-negative. 
 
4. Path stage T1-2 node-negative breast cancer have a 70% probability of complete 
eradication (“cure”) by primary surgery, radiotherapy and, where appropriate, 
adjuvant chemotherapy. 
 
5. “Late” (node positive) breast cancers have only a 30% probability of complete 
eradication (“cure”) by primary surgery, radiotherapy and adjuvant chemotherapy. 
 
6. Those not “cured” by their primary treatment (30% of “early” and 70% of “late” 
cases) will require additional treatment and investigations, often involving expensive 
drugs such as taxanes and/or Herceptin and are likely ultimately to require palliative 
care. 
 
7. The quality of life (after primary treatment) for “cured” breast cancer patients is 
good (Casso et al, 2004; Mols et al, 2005; Helgesson et al, 2007) and, for women 
diagnosed at around 50 years of age, “cure” of breast cancer provides a further 25 
years of life (25 QALYs). 
 
 
Results: 
 
In the 11 year study period, the Tayside “family history” surveillance programme 
carried out just under 8000 annual screens, comprising clinical examination of the 
breasts and two-view mammography. The yield of 46 breast cancers therefore 
represents a rate of 5.8 per thousand examinations. As shown in table 1a, 34 (74%) 
were detected at screening and 36 (78.5%) were “early” stage (Path T1-T2, N0). Five 
year disease-free survival has been 100% for the 29 cases with this length of follow-
up. By contrast, for the 40 women (unselected for family history) diagnosed under age 
50 who had never been enrolled in a screening programme, only 55% presented at a 
similarly early stage and overall five year disease-free survival was 82.5%. For the 37 
affected relatives of our index cases who had never had access to regular screening, 
11 had died from breast cancer within 5 years of diagnosis, 6 more within ten years 
and only 11 were known to be alive 5 or more years from diagnosis (Table 1b).  
 
Table 2 records the use of resources, with unit and cumulative costs, calculated for 
“typical” pre-menopausal women diagnosed with either “early” or “late” stage beast 
cancer. These calculations, make allowance for the different proportions of “early” 
and “late” breast cancers expected to be “cured” by primary treatment and hence the 
varying requirement for “second line” drugs, palliative care and other components of 
management for advanced breast cancer. They demonstrate that the mean cost for an 
“early” cancer is £24,007, while for a “late” cancer it is £63,672, a difference of 
£39,665 per patient. Within the “early stage” category, 15% are assumed to be DCIS 
on the grounds that detection at this “pre-cancerous” stage will prevent later 
development of invasive cancer, which is, of course, an important purpose of the 
screening programme (Moller et al, 1999).  
 
Using these cost figures as a base, we then applied the finding that surveillance 
increases the proportion of “early stage” breast cancers diagnosed in young women 
from 55% to 77% (Table 1, adjusted slightly downwards by reference to the larger 
European dataset; Moller et al 2007). Thus, for every hundred breast cancers arising 
in women enrolled in an annual screening programme, 22 are “transferred” from the 
poor to the good prognosis category and hence, in cost terms, to the right hand 
column of Table 2, with a total saving in direct health care costs of £872,630 (22 x 
£39,665). 
 
It happens that the Tayside “breast cancer family history” service currently undertakes 
about 1000 screens per year so, from the above figures, the shift to earlier stage at 
diagnosis of breast cancer would apply to 1.32 women per year (22% of 6  cancers). 
The saving to the NHS would then be £51,358 (1.32 x £39,665), set against a cost of 
around £100,000 (@ £100 per screen). Hence the net annual cost of the Tayside 
programme is £48,642 (£100,000 minus the saving of £51,358). Now if each woman 
shifted from “late” to “early” stage diagnosis improves her prospects of “cure” by 
40% (from 30% to 70%) and “cure” adds 25 years of high quality life (QALYs), the 
gain is 13.2 QALYs per year (25 x 0.4 x 1.32) at a cost of £3685 per QALY (£48,642 
÷ 13.2).  
 
This does not take into account the fact that many women in their 40’s and 50’s are in 
productive employment and/or undertaking important family responsibilities which 
have an economic value. In practice, therefore, the net cost to the national exchequer 
is likely to be much less than £3685.  
 
Our calculations are particularly sensitive to variations in two specific parameters, 
namely the rate of detection of breast cancers in a surveillance programme and the 
effectiveness of screening in terms of “shift” to earlier stage at diagnosis. As 
discussed later, we believe the values we have used are realistic but if more optimistic 
or pessimistic figures are substituted, as shown in table 3, the cost per QALY can 
range from £12,700 to less than zero. Even the higher figure is well below the 
£30,000 attributed to the National Institute for Clinical Excellence, justifying the 
adoption of new drugs or procedures by the NHS (Appleby et al, 2007). 
 
Discussion: 
 
The costs associated with treatment of breast cancer are not fixed either in time or 
place. As new drugs emerge, they tend to be increasingly expensive and the 
indications for their use become ever more circumscribed so that to-day’s conclusions 
may be rapidly superseded. Practices and prices vary from country to country so the 
figures we have calculated for the UK may not apply precisely elsewhere. 
Nevertheless, the costs presented in Table 2 are in line with those quoted recently for 
a US Health care organisation (Anderson et al, 2006) and with an earlier US-based 
study (Berkowitz et al, 2000), both of which confirm in particular the extremely high 
cost of palliative care in the terminal phase of the illness. 
 
We have assumed an incidence of 6 breast cancers per year per thousand women in a 
“family history” surveillance programme, slightly higher than the figure we actually 
observed but substantially lower than reported elsewhere (Kerilkowske et al, 1995; 
Kollias et al, 1998; Tilanus-Lindhorst et al, 2000). In the early years of this study, 
criteria for enrolment in the screening programme were less strictly applied than 
currently. We and others have found that investment in checking, extending and 
validating reported family histories substantially alters the distribution of assessed risk 
and allows better targeting of screening (Campbell et al, 2003; Reis et al, 2006; 
Brennan et al, 2007). Applying that principle, as we have done since the late 1990’s, 
should increase the cancer incidence rate among those enrolled in surveillance. 
  
The relatively poor prognosis for breast cancer among young women (unscreened and 
unselected for family history) is well recognised (Chung et al, 1996; Peer et al, 1996) 
and there is now substantial evidence that pre-menopausal women with a family 
history of breast cancer, who are enrolled in an annual screening programme, can 
expect a much better outcome (Robson et al, 2004; Moller et al, 2007) . Our figures of 
75% of breast cancers in such women being screen-detected and 77% as small node-
negative tumours are conservative in comparison with the recently published 
experience from one large UK-based clinic (Gui et al, 2006). Five-year disease-free 
survival is admittedly a rather weak surrogate for long-term “cure” and it can be 
argued that, by introducing “lead-time bias”, the benefits of screening are exaggerated 
by this measure. Nevertheless, pathological stage, particularly nodal status, is strongly 
correlated with long-term outcome as well as with extent and cost of primary 
treatment (Dixon 2006). The marked difference, which we and others (Tilanus-
Lindhorst et al, 2000) have confirmed, between screened and unscreened cohorts of 
young women in this respect is therefore a powerful argument in favour of 
surveillance, particularly as longer-term follow-up continues to show  very high rates 
of overall and disease-free survival for the screened group (Moller et al, 2007). 
 
It remains to be demonstrated how much of the “gain” is attributable directly to the 
screening programme. It has been found (Lakhani et al, 2000) that breast cancers 
arising in women with a family history of the disease tend to be of lower grade and to 
carry a better prognosis than sporadic tumours. Follow-up of relevant cohorts have 
generated conflicting findings (Slattery et al, 1993; Malone et al 1996). The largest 
and most recent of these found, in the absence of special surveillance, no breast 
cancer survival advantage for women from “low or moderate” risk families compared 
to age-matched patients from the general population (Verkooijen et al, 2006). There 
are also data supporting the view that screening of women under 50 (irrespective of 
family history) can achieve a stage-shift in breast cancers at diagnosis (Smith, 2000). 
Our analysis of the outcomes of unscreened affected young relatives of our cohort 
(with comparable familial risk) suggests that screening has a large beneficial effect. 
Of course the comparison is far from ideal; some data on the relatives are missing; 23 
of them were diagnosed and treated more than 20 years ago, when management and 
outcomes were generally less satisfactory than to-day; there might be a greater 
incentive for women whose relatives had died from breast cancer to seek advice about 
familial risk compared to those whose relatives had survived; lead time bias could 
generate an apparent survival gain of up to two years without actually changing the 
outcome. Nevertheless, taking all of these caveats into account, there is a striking 
disparity between the 10 year survival of 90% recorded in the European multi-centre 
cohort for mutation-negative women enrolled in annual “family history” surveillance 
programmes (Moller et al, 2007) and the corresponding figure for our subgroup of 
unscreened relatives (54%, at best, if all 9 patients with incomplete follow-up 
information are assumed to remain disease-free). 
 
Carriers of germ-line BRCA1 mutations appear to represent a distinct subgroup that 
does not benefit from regular screening as currently practised (Robson et al, 2004; 
Moller et al, 2007). Although introduction of MRI scanning may change this picture, 
evidence of survival benefit is awaited. Despite detection of their cancers at an 
apparently early stage (small, node-negative primaries) their recurrence rate is high 
and in terms of costs and benefits, for the present, they should all be counted in the 
left hand column of Table 2. Note that this does not apply to BRCA2 mutation-
carriers who have a good outcome if screened regularly (Moller et al, 2007). Only 
some 10% of the Tayside “breast cancer family” clinic patients are thought to carry 
BRCA mutations, with BRCA1 slightly outnumbering BRCA2 carriers. Five of the 46 
observed breast cancers in the screened cohort were known (or later found) to be 
positive for BRCA1 mutations (and two for BRCA2). Placing all of these 5 in the 
“late stage” category or removing them entirely from the calculations has only minor 
effects on the figures presented in tables 2 and 3. However prophylactic surgery 
(bilateral salpingo-oophorectomy plus bilateral total mastectomy) are not only better 
options at present for women with known BRCA1 mutations but are also cost 
effective, given that the total cost of even this extensive surgery is around £11,000 
while the “average” cost of management after a breast cancer has been diagnosed is 
£63,672 (from Table 2). Women carrying BRCA2 mutations are also advised to 
consider prophylactic salpingo-oophorectomy whch has an NHS cost of less than 
£3000. The psychological “costs” should not, of course, be ignored or underestimated. 
Work in this area suggests that, with support, prophylactic surgery is acceptable to 
many women at high risk (Eisinger et al, 2000; Bebbington-Hatcher and Fallowfield, 
2003) but detailed discussion is beyond the scope of this report.  
 
The psychological price of annual screening, with its attendant reminder of breast 
cancer risk and the anxiety that accompanies the wait for results applies to all women 
enrolled in a “family history” surveillance programme. It is difficult to quantify but 
recent reviews conclude that the impact on general anxiety or cancer-specific worry is 
broadly neutral (Braithwaite et al, 2004; Hopwood et al, 2004) and it is very clear that 
women aware of their possible familial risk of breast cancer strongly favour access to 
regular mammography, regarding its availability as a comfort rather than a source of 
anxiety (Julian-Reynier et al, 1996; McLeish, 2003). 
 
Previous attempts to calculate the costs and benefits of management options for 
women at increased genetic risk of breast cancer have been hampered by paucity of 
objective data. The pioneering 1999 report of Heimdal and colleagues from Norway 
used standard health insurance charges to measure the costs of screening and assumed 
a 75% “cure” rate for women who developed breast cancers while taking part in a 
surveillance programme – not very different from what has subsequently been 
observed. However they estimated that early diagnosis resulted in 30 added years of 
life (rather than our figure of 25) and, for simplicity, attributed all of this gain to 
screening (assuming 100% mortality in the absence of screening). This resulted in a 
lower cost per life year gained than we have calculated but there is no fundamental 
conflict between our datasets.  
 
Two Canadian studies undertaken some ten years ago, and an even earlier UK survey, 
confirm that costs of management of advanced breast cancer are much higher than for 
early stage disease but all their figures are considerably lower than reported here, 
reflecting mainly the subsequent introduction of expensive new agents (Richards et al, 
1993; Will et al, 2000; Wai et al, 2001).  
 
Griffith and colleagues (2005) carried out a detailed analysis of costs for NHS (UK) 
cancer genetics services and arrived at figures for QALYs gained through surveillance 
or prophylactic surgery that, at first sight, appear rather low. However when our own 
calculations are re-expressed in equivalent terms, it is evident that the two datasets are 
consistent. Taking our estimate of 13.2 QALYs gained per year (1000 screens), that 
reduces to 0.013 QALYs per screen and if each woman in the surveillance programme 
is screened annually for fifteen years, she can expect to gain 0.19 QALYs. However 
all of the gain is concentrated in the minority of women (around 10%) in the 
programme who actually develop breast cancer during the period of surveillance. 
Griffith and colleagues did not attempt to estimate the cost savings achieved through 
surveillance programmes.   
 
Other published analyses (Schrag et al, 2000; Anderson et al, 2006) have concentrated 
on carriers of BRCA1 and BRCA2 mutations and, while the advantages of 
prophylactic surgery (particularly salpingo-oophorectomy) have been emphasised, the 
important fact that regular surveillance has very different efficacy for BRCA1 
compared to BRCA2 mutation-carriers has not been recognised. 
 
In conclusion, while financial considerations are not of prime concern in this area of 
health care (Moller, 2004), they must be taken into account when decisions are made 
about commissioning new services or evaluating existing ones (Turner 1999). We 
believe our detailed, evidence-based analysis of cost-effectiveness of a surveillance 
programme for women with a family history of breast cancer makes the case for 
continuing to support this approach. 
 
 
 
Table 1.  Characteristics of breast cancers in three cohorts of young women. 
 
a) 
 
 
 “Surveillance” Group      Unscreened 
(population)Group 
Number in 
group 
46 (42 patients) 
 
40 (40 patients) 
No. (%) screen-
detected 
34 (74%) 
 
0 
No. (%) “Early 
stage” (T1/2 N0) 
36 (78.5%) 
 
22 (55%) 
% Disease-free 
at 5 yrs 
Node negative  100% 
Node positive    100% 
 
Node Negative  92% 
Node positive    72% 
 Relatives of 
“surveillance” 
group 
Number in group 37 
Mean age 
(Range) 
45 yrs 
(28-54) 
Number (%) alive 
5yrs from diagnosis 
25 
(68) 
Number (%) alive 
10 yrs from 
diagnosis 
11* 
(29.7) 
Number (%) 
with incomplete 
information 
9** 
(24.3%) 
b) 
 * At least 3 died later from breast cancer. 
** 3 with less than 5 yrs follow-up, 6 no information. 
Table 2.   
 
Unit costs for management of breast cancer in NHS and distribution of costs 
according to stage at diagnosis. 
Component of management and 
Unit cost 
Late stage 
(T3/4 N+) 
Early stage 
(T1/2 N-) 
 %*            Cost** %*           Cost** 
Initial inpatient stay (5 nights @ £449/nt) 85               £1908 100             £2245 
WLE + Ax Surgery, £1673 15                 £251 60              £1004 
Mx + Ax surgery, £2421 70                £1695 0                    £0 
Mx + Ax surgery + reconstr, £4513 0                     £0 40              £1805 
Anthracyclines X 6,  £1836 50                  £918 60              £1102 
FEC x 6, £3155 50                £1577 0                    £0 
Taxanes, £9160 70                £6412   15              £1374 
Herceptin (2 yrs), £44,000 25             £11,000 5                £2200 
Bisphosphonates (2 yrs), £4000 50                £2000 10                £400 
Tamoxifen (5 yrs), £43 50                    £21 50                 £21 
Radiotherapy (Standard), £1500 100              £1500 60                £900 
Palliative radiotherapy, (£400) 70                  £280 15                  £60 
Palliative care in-patient stay (15 nights 
@£3493), £51,585 
70             £36,110 25            £12,896 
TOTAL COST £63,672 £24007 
* Percentage of patients in this category requiring this component 
**Cost for a “typical” patient in this category – i.e. unit cost x % requiring it. 
WLE = wide local excision; Ax. surgery = axillary surgery; MX = total mastectomy; 
reconstr = breast reconstruction; FEC = chemotherapy regime using 5-fluorouracil, 
epirubicin and cyclophosphamide) 
 Table 3 
 
Effects of changing sensitive parameters (numbers of breast cancers detected per 
year and percentage of patients who benefit from “stage shift” of their cancer) 
on cost-effectiveness of surveillance programmes. 
 
No.Breast 
Cancers 
diagnosed/yr 
% shift to 
“curable” 
stage 
No. Ca Br 
Patients 
benefiting/yr
QALYs 
gained* 
Annual 
saving 
£** 
Annual 
net cost 
£*** 
Cost per 
QALY £ 
 
6 
 
22 
 
1.32 
 
13.2 
 
51,358 
 
48,642 
 
3685 
 
4 
 
22 
 
0.88 
 
8.8 
 
34,905 
 
65,095 
 
7396 
 
9 
 
22 
 
1.98 
 
19.8 
 
78,537 
 
21,463 
 
1084 
 
6 
 
15 
 
0.9 
 
9 
 
35,669 
 
64,301 
 
7145 
 
6 
 
30 
 
1.8 
 
18 
 
71,398 
 
28,601 
 
1589 
 
4 
 
15 
 
0.6 
 
6 
 
23,799 
 
76,201 
 
12,700 
 
4 
 
30 
 
1.2 
 
12 
 
47,598 
 
52,402 
 
4367 
 
9 
 
15 
 
1.35 
 
13.5 
 
53,548 
 
46,452 
 
3433 
 
9 
 
30 
 
2.7 
 
27 
 
107,096 
 
-7096 
 
-263 
 
     *Assumes 10 QALYs per additional patient detected at a “curable” stage. 
  ** Assumes saving of £39,665 per additional patient detected at “curable” stage  
       (from Table 2). 
*** Assumes fixed annual screening cost of £100,000 (for 1000 women screened)
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Clinic letters
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Acute Services Division Clinical Genetics, Human Genetics Unit Clinical Group of Surgery & Oncology 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Our Ref CHI «Date_of_birth» «MPI» 
Pedigree No «Pedigree_No» 
Enquiries to 01382 632035  
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» «Postcode» 
 
  
 
Dear «Title» «Surname» 
 
We have been asked to advise you regarding your family history of cancer. Most 
cancers are not hereditary but there are rare hereditary forms of the condition. I would 
be most grateful if you would complete and return the enclosed form providing us 
with details of your family history. This will enable us to determine if you have 
relatives that are likely to have had hereditary cancer and if you are at increased risk 
from the condition.  
 
We will write to you and your family doctor as soon as we have evaluated your family 
history. We will arrange a genetics clinic appointment for you if your history indicates 
that you might benefit from additional screening for early signs of the condition or if 
we may be able to modify our estimate of your risk with genetic tests.  Please contact 
us if you are unable to complete the family history questionnaire, as we will not make 
a clinic appointment for you if we have not received a completed questionnaire or 
confirmation that you want a clinic appointment.   
 
If you have any queries regarding the information we are requesting please don’t 
hesitate to phone 01382 632035 and ask to speak to one of the Genetic Counsellors. 
 
We look forward to hearing from you. 
 
Yours sincerely 
 
David R Goudie 
Consultant Clinical Geneticist 
 
Enc: Family History Clinic Form + FREEPOST envelope 
 
cc: Registry 
 
 
 
If you do not return your completed questionnaire or contact us 
you may not receive a clinic appointment 
Signed electronically 
FHBCques 
 
  Dorothy Young, Genetics Associate, Clinical Genetics,  
Pathology Department, Ninewells Hospital, Dundee, DD1 9SY 
Tel: 01382 496369 Fax: 01382 494382 E-mail: 
dorothy.young@tuht.scot.nhs.uk      
 
Please quote ref. no.  «Pedigree_No» 
 
17 June, 2008 
 
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
 
Dear «Title» «Surname» 
 
You kindly agreed to participate in our Family History Breast Cancer clinic study. 
Our aim was to improve the service we provide. We would like to show whether 
women would prefer to attend a clinic to discuss their risk or are happy with a letter. 
Some women with a similar risk to your own were seen at our clinic while others 
received a letter. We are comparing their satisfaction with our service. 
 
We would be grateful if you could complete the enclosed questionnaire and return it 
in the prepaid envelope. This information will be used to assess the service we offered 
you and may be used to determine future service provision. 
 
Information will only be used in relation to this study and will be confidential.  
 
Please contact me on 01382 496369 if you have any questions or concerns. 
 
Thank you. 
 
 
Yours sincerely 
 
 
Dorothy Young 
Genetic Associate 
 
 
 
Enc. Breast Cancer Family History Project Questionnaire 
 Prepaid envelope 
 Acute Services Division Clinical Genetics, Human Genetics Unit Clinical Group of Surgery & Oncology 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Our Ref CHI «Date_of_birth» «MPI» 
Pedigree No «Pedigree_No» 
Enquiries to 01382 632035   
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» «Postcode» 
 
  
 
Dear «Title» «Surname» 
 
We have been asked to advise you regarding your family history of cancer. Most 
cancers are not hereditary but there are rare hereditary forms of the condition. I would 
be most grateful if you would complete and return the enclosed form providing us 
with details of your family history.  Our secretaries will arrange a clinic appointment 
for you and this will be sent to you nearer the time of your appointment.  
 
If you have any queries regarding the information we are requesting please don’t 
hesitate to phone 01382 632035 and ask to speak to one of the Genetic Counsellors. 
 
We look forward to hearing from you. 
 
Yours sincerely 
 
David R Goudie 
Consultant Clinical Geneticist 
 
Enc Family History Clinic Form + FREEPOST envelope 
 
cc Registry 
Signed electronically 
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FAMILY HISTORY CLINIC 
Clinical Genetics, Department of Pathology, Ninewells Hospital 
Dundee DD1 9SY   (tel 01382  632035) 
 
 
Your full name:     «Prename» «Surname» Maiden name: ……………………………………………… 
Address:                «Address» Any previous names: ………………………………………  
«Area»       
«Town» 
«Postcode» Telephone number: ………………………………………… 
 
Date of birth:        «Date_of_birth» Place of birth:  ……………………………………………… 
 
 
Please check the details given above and correct if necessary. 
 
 
Have any of your relatives attended our genetics clinics?    
If yes please give name & date of birth of relative………………………………………………………… 
 
 
NOTE: 
The following tables ask for information about your family please complete these tables as far as you are able to.  The first table is asking for information about 
your relatives who have had a cancer, it is essential for us to have as much information as you can give us, if you don’t know something and are unable to find 
out please write ‘don’t know’. If someone has had more than one cancer please tell us.  The next tables are asking for information about all of your relatives.  
Information about how people are related to each other, their ages (or their age when they died if they are deceased) are all important in the interpretation of 
your family history.  Please give us as much information if you can and let us know if it incomplete. 
  
        «Pedigree_No» 
                                                   Our ref no 
FOR OFFICE USE ONLY 
Date received: 
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FHBCQREM 
 
  Dorothy Young, Genetics Associate, Clinical Genetics,  
Pathology Department, Ninewells Hospital, Dundee, DD1 9SY 
Tel: 01382 496369 Fax: 01382 494382 E-mail: dorothy.young@tuht.scot.nhs.uk      
 
Please quote ref. no.  «Pedigree_No» 
 
8 November, 2006 
 
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
 
 
Dear «Title» «Surname» 
 
You kindly agreed to participate in our Family History Breast Cancer clinic study. For 
completion of this study it would be very helpful if you could return the questionnaire we 
recently sent you. 
 
Information will only be used in relation to this study and will be confidential.  
 
Please contact me on 01382 496369 if you have any questions or concerns. 
 
Thank you. 
 
 
Yours sincerely 
 
 
 
 
Dorothy Young 
Genetic Associate 
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MANAGEMENT SUMMARY (FHBC ave) 
Date printed: 08 November 2006 
 
 
Name:  «Prename» «Surname»    Ref. no. «Pedigree_No» 
CHI  «Date_of_birth» «MPI» 
Address: «Address»    «Area»    «Town»    «Postcode»   
Tel:   «Telephone» 
GP:   «Clinician_Name»     «Address_1» «Address_2» «Address_3» «Address_4» 
 
 
RISK ASSESSEMENT 
 
CONFIRMATION OF CASES (please specify- Pathology, Cancer registry, Death Certificate 
(Alison, MRC Registry), Hospital Notes, Oncology) 
 
………………………………………………………………………….Time spent………… 
………………………………………………………………………….Time spent………… 
………………………………………………………………………….Time spent………… 
………………………………………………………………………….Time spent………… 
 
OR 
 
Comment if no confirmations ………………………………………………………………… 
 
      
Risk altered after confirmations of cancers  YES / NO 
 
 
 
Cyrillic Risk: «Heterozygote_risk» 
 
 
Action:  
 odd Appointment (clinic- area 5 Tues,am): Date:………………. Time:………………. 
      attended :  time taken:………… 
      cancelled/DNA  next appt:………….. 
  even Letter to patient and GP Date sent:…………………………………. 
 
 
 
Please give details if assessed risk is changed either at appointment / after letter……………… 
………………………………………………………………………………………………….. 
 
 
Comments……………………………………………………………………………………… 
………………………………………………………………………………………………….. 
………………………………………………………………………………………………….. 
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 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
Your Ref  
Our Ref DRG/sb «Date_of_birth»  «MPI» 
Pedigree No «Pedigree_No» 
Enquiries to Dr David Goudie 
Extension 32135 
Direct Line (01382) 632151 
«Clinician_Name» 
«Source_Name» 
«Address_1» 
«Address_2» 
«Address_3» 
«Address_4» 
 
 
Email david.r.goudie@tuht.scot.nhs.uk 
 
Dear Dr «ClinicianSurname» 
 
Re:  «Prename» «NamesSurname», DOB «Date_of_birth», «Address», «Area», «Town», 
«Postcode» 
 
You referred this patient to the genetics clinic at Ninewells Hospital for assessment of their risk 
from familial cancer.  We have sent them a questionnaire to complete providing us with details 
of their family history on two occasions and given them the option of contacting us directly to 
confirm that they would like a genetics clinic appointment.  They have not returned the 
questionnaires or contacted us to confirm that they would like an appointment.  
 
We have not arranged a clinic appointment for them. Please re-refer them if they would like an 
appointment. 
 
Yours sincerely, 
 
 
David R Goudie 
Consultant in Clinical Genetics 
 
c.c. Registry  
 Casenotes 
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 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
Date of Clinic  
Your Ref  
Our Ref DY/«Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Genetic Counsellors 
«Title»«Prename»«Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
Telephone (01382)  632035 
 
Dear «Title» «Surname» 
 
 
I am sorry that you could not attend your recent appointment at the Family History Breast 
Cancer clinic on.  As you have failed to attend we are unable to arrange another appointment for 
you.  You should ask your GP to refer you back to this clinic and we will put you back on our 
waiting list. 
 
Please do not hesitate to contact us on 01382 632035 if you have any questions or concerns. 
 
 
 
Yours sincerely 
 
 
Dorothy Young 
Genetic Associate 
 
 
cc. «Clinician_Name» «Source_Name» «Address_1» «Address_2» «Address_3» 
«Address_4» 
Registry 
Case notes 
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 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
Date of Clinic  
Your Ref  
Our Ref DY/«Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Dorothy Young, Genetic Associate 
Extension 36369 
«Clinician_Name» 
«Source_Name» 
«Address_1» 
«Address_2» 
«Address_3» 
«Address_4» Telephone (01382)  632035 
 
Dear «Clinician_Name» 
 
RE: «Title» «Prename» «Surname» («Date_of_birth» «MPI») «Address» «Area» «Town» 
«Postcode» 
 
«Title» «Surname» has failed to attend the Family History Breast Cancer Clinic 
on«Pedigree_No». We have not organised any further appointments for her. I have enclosed a 
letter sent to her.  
 
However if she has moved address or out of the area please could you let us know. 
 
Thanks. 
 
Yours sincerely 
 
 
 
 
Dorothy Young PhD 
Genetic Associate 
 
Enc. 
 
cc. Registry 
Casenotes 
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Tayside University Hospitals Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
Date of Clinic  
Your Ref  
Our Ref /sm/jr/«Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to  
Extension  
Direct Line (01382)  
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
Email david.r.goudie@tuht.scot.nhs.uk 
 
Dear «Title» «Surname» 
 
We have been asked to assess your risk from cancer because of your family history of the 
condition. Thank you for providing us with details of your family history.  
 
Most breast cancer is not hereditary but some women with breast cancer have a hereditary form 
of the condition.  Women with hereditary breast cancer usually have close relatives that are 
affected at unusually early ages. 
 
The information that we have about your family history indicates that it is unlikely that a genetic 
fault causing breast cancer is present in your family.  Your own risk of developing breast cancer 
is not significantly increased compared to the risk for other women of your age.  It is therefore 
unlikely that you would benefit from additional screening for early signs of breast cancer at 
present if you have no breast symptoms. 
 
Although your risk from breast cancer is not significantly increased all women are at some risk 
from the condition.  Should you develop breast symptoms that you are concerned about you 
should seek medical advice.  You should ensure that you are enrolled in the National Breast 
Screening Program once you are eligible aged 50. There is evidence that regular screening for 
early signs of breast cancer is of benefit for women over 50 years of age. 
 
We have not arranged a clinic appointment for you at the breast cancer family history clinic but 
please do not hesitate to contact us if you have any other questions or if other members of your 
family develop cancer which might alter our estimate of your own risk. 
 
Yours sincerely 
 
 
 
 
Lorna McLeish 
Genetic Nurse Specialist 
 
 
 
 
 
David R Goudie 
Consultant Clinical Geneticist 
 
cc ADD REFERRING CLINICIAN (if diff. to GP) 
«Clinician_Name»  «Source_Name»  «Address_1»  «Address_2»  «Address_3»  
«Address_4» 
Registry File 
 Case Notes 
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Tayside University Hospitals Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
Date of Clinic  
  
Our Ref /sm/jr/ «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Dr D Goudie 
Extension 32035 
Direct Line (01382) 632035 
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
Email david.r.goudie@tuht.scot.nhs.uk 
 
Dear «Title» «Surname» 
 
We have been asked to assess your risk from cancer because of your family history of the 
condition. Thank you for providing us with details of your family history. 
 
Most breast cancer is not hereditary but some women with breast cancer have a hereditary form 
of the condition.  Women with hereditary breast cancer usually have close relatives that are 
affected at unusually early ages. 
 
Although it is possible that some of your relatives have had hereditary breast cancer, as you get 
older without developing the condition, the risk that you have a hereditary tendency to develop 
cancer diminishes. You are already eligible for breast screening through the National Breast 
Screening Program and so we have not arranged for you to have screening through the Family 
History Breast Cancer clinic. You should ensure that you are enrolled in the National Breast 
Screening Program as you are now eligible. There is evidence that regular screening for early 
signs of breast cancer is of benefit for women over 50 years of age. 
 
Gene testing is only possible in a minority of families with breast cancer. Identifiable faults in 
the breast cancer genes are infrequently found in families where less than four women have had 
breast cancer. It is unlikely that genetic tests would alter our estimate of your risk from breast 
cancer. 
 
Although we have not arranged a clinic appointment for you should seek medical advice if you 
develop breast symptoms that you are concerned about. Please do not hesitate to contact us if 
you have any other questions or if other members of your family develop cancer which might 
alter our estimate of your own risk.  
 
Yours sincerely 
 
 
 
 
Lorna McLeish 
Genetic Nurse Specialist 
Yours sincerely 
 
 
 
 
David R Goudie 
Consultant Clinical Geneticist 
 
cc ADD REFERRING CLINICIAN (if diff. to GP) 
«Clinician_Name»  «Source_Name»  «Address_1»  «Address_2»  «Address_3»  «Address_4» 
Registry File 
 Case Notes 
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Tayside University Hospitals Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed  
Date Dictated  
Date of Clinic  
Our Ref DY/ «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Dorothy Young, Genetic Associate 
Extension 36369 
Direct Line (01382) 496369 
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
 Email dorothy.young@tuht.scot.nhs.uk 
 
Dear «Title» «Surname» 
 
Thank you for agreeing to participate in our Family History Breast Cancer study and for 
completing the form with details of your family history.  Your risk of developing breast cancer 
has been assessed and it is not significantly increased compared to other women your age.  
 
Most breast cancer is not hereditary but some women with breast cancer have a hereditary form 
of the condition.  Women with hereditary breast cancer usually have close relatives that are 
affected and the hereditary forms of the condition tend to occur at unusually early ages. 
 
INSERT FAMILY HISTORY DETAILS. RATIONAL FOR RISK.  It is therefore unlikely that 
you would benefit from additional screening for early signs of breast cancer at present if you 
have no breast symptoms. 
 
Although your risk from breast cancer is not significantly increased all women are at some risk 
from the condition.  Should you develop breast symptoms that you are concerned about you 
should seek medical advice (symptoms you should look out for are described in the enclosed 
Tayside Breast Aware Leaflet).  You should ensure that your are enrolled in the National Breast 
Screening Program as you are now eligible. There is evidence that regular screening for early 
signs of breast cancer is of benefit for women over 50 years of age. 
 
Gene testing is only possible in a minority of families with breast cancer. Identifiable faults in 
the breast cancer genes are infrequently found in families where less than four women have had 
breast cancer. It is unlikely that genetic tests would alter our estimate of your risk from breast 
cancer. 
 
We have not arranged an appointment for you at the Family History Breast Cancer clinic but 
please do not hesitate to contact us if you have any other questions or if other members of your 
family develop cancer which might alter our estimate of your own risk. 
 
Yours sincerely 
 
 
Dorothy Young 
Genetic Associate 
Yours sincerely 
 
 
David R Goudie 
Consultant Clinical Geneticist 
 
cc ADD REFERRING CLINICIAN (if diff. to GP) 
«Clinician_Name» «Source_Name» «Address_1» «Address_2» «Address_4» 
Registry File 
 Case Notes 
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Tayside University Hospitals Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed  
Date Dictated  
Date of Clinic  
Our Ref DY/ «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Dorothy Young, Genetic Associate 
Extension 36369 
Direct Line (01382) 496369 
«Clinician_Name» 
«Source_Name»  
«Address_1»  
«Address_2»  
«Address_3» 
«Address_4» 
ADD REFERRING CLINICIAN (if diff. to GP) 
Email dorothy.young@tuht.scot.nhs.uk 
 
Dear «Clinician_Name» 
 
RE:  «Title» «Prename» «Surname»  («Date_of_birth» «MPI»)   
«Address» «Area» «Town»  «Postcode» 
 
«Prename» «Surname» completed a detailed family history questionnaire and we have assessed 
her risk of developing breast cancer. Women found to have a low risk of developing breast 
cancer that have agreed to participate in our study were randomised either to receive a letter or 
an appointment to one of our genetics clinics. I have enclosed a copy of an information leaflet 
and of our letter to «Prename» «Surname» explaining her risk from breast cancer.  She was not 
given an appointment for our genetics clinic. 
 
INSERT FAMILY HISTORY.  Fortunately her risk is not significantly increased. We have not 
arranged for her to have mammogram or a clinical examination of breasts.  
 
If «Prename» «Surname» or yourself have any further questions or concerns please do not 
hesitate to contact us at the above address or telephone me on 01382 496369. 
 
Yours sincerely 
 
 
 
Dorothy Young 
Genetic Associate 
Yours sincerely 
 
 
 
David R Goudie 
Consultant Clinical Geneticist 
 
Enc Patient Information Sheet 
 Signed Consent Form 
 
c.c. ADD GP if diff. from REFERRING CLINICIAN (if diff. to GP) 
Registry 
 Case notes 
 
 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
«Title» «Prename» «Surname» 
Date of Clinic  
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Your Ref  
Our Ref /sm/jr/«Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to  
Extension  
Direct Line (01382)  
«Address» 
«Area» 
«Town» 
«Postcode» 
Email david.r.goudie@tuht.scot.nhs.uk 
 
Dear «Title» «Surname» 
 
Most breast cancer is not hereditary but some women with breast cancer have a hereditary form 
of the condition.  Women with hereditary breast cancer usually have close relatives that are 
affected and the hereditary forms of the condition tend to occur at unusually early ages. 
 
Fortunately investigation of your family history indicates that it is unlikely that a genetic fault 
causing breast cancer is present in your family.  Your own risk of developing breast cancer is not 
significantly increased compared to the risk for other women of your age.  It is therefore unlikely 
that you would benefit from additional screening for early signs of breast cancer at present if you 
have no breast symptoms. 
 
Although your risk from breast cancer is not significantly increased all women are at some risk 
from the condition.  Should you develop breast symptoms that you are concerned about you 
should seek medical advice.  You should ensure that you are enrolled in the National Breast 
Screening Program once you are eligible aged 50.  There is evidence that regular screening for 
early signs of breast cancer is of benefit for women over 50 years of age. 
 
We have not arranged another appointment for you at the breast cancer family history clinic but 
please do not hesitate to contact us if you have any other questions or if other members of your 
family develop cancer which might alter our estimate of your own risk. 
 
Yours sincerely 
 
 
 
 
Lorna McLeish 
Genetic Nurse Specialist 
 
 
 
 
 
David R Goudie 
Consultant Clinical Geneticist 
 
cc ADD REFERRING CLINICIAN (if diff. to GP) 
«Clinician_Name»  «Source_Name»  «Address_1»  «Address_2»  «Address_3»  
«Address_4» 
Registry File 
 Case Notes 
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Tayside University Hospitals Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed  
Date Dictated  
Date of Clinic  
Our Ref DY/ «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Dorothy Young, Genetic Associate 
Extension 36369 
Direct Line (01382) 496369 
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
 Email dorothy.young@tuht.scot.nhs.uk 
 
Dear «Title» «Surname» 
 
It was a pleasure to meet you at our genetics clinic. Thank you for agreeing to participate in our 
Family History Breast Cancer study and for completing the form with details of your family 
history.  
 
Most breast cancer is not hereditary but some women with breast cancer have a hereditary form 
of the condition.  Women with hereditary breast cancer usually have close relatives that are 
affected and the hereditary forms of the condition tend to occur at unusually early ages. 
 
Fortunately investigation of your family history indicates that it is unlikely that a genetic fault 
causing breast cancer is present in your family.  Your own risk of developing breast cancer is not 
significantly increased compared to the risk for other women of your age.  It is therefore unlikely 
that you would benefit from additional screening for early signs of breast cancer at present if you 
have no breast symptoms. 
 
Although your risk from breast cancer is not significantly increased all women are at some risk 
from the condition.  Should you develop breast symptoms that you are concerned about you 
should seek medical advice.  You should ensure that your are enrolled in the National Breast 
Screening Program as you are now eligible. There is evidence that regular screening for early 
signs of breast cancer is of benefit for women over 50 years of age. 
 
Gene testing is only possible in a minority of families with breast cancer. Identifiable faults in 
the breast cancer genes are infrequently found in families where less than four women have had 
breast cancer. It is unlikely that genetic tests would alter our estimate of your risk from breast 
cancer. 
 
We have not arranged another appointment for you. Please do not hesitate to contact us if you 
have any other questions or if other members of your family develop cancer which might alter 
our estimate of your own risk. 
 
Yours sincerely 
 
 
Dorothy Young 
Genetic Associate 
Yours sincerely 
 
 
David R Goudie 
Consultant Clinical Geneticist 
 
cc ADD REFERRING CLINICIAN (if diff. to GP) 
«Clinician_Name» «Source_Name» «Address_1» «Address_2» «Address_3» 
«Address_4» 
Registry File 
 Case Notes 
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Tayside University Hospitals Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed  
Date Dictated  
Date of Clinic  
Our Ref DY/ «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Dorothy Young, Genetic Associate 
Extension 36369 
Direct Line (01382) 496369 
«Clinician_Name» 
«Source_Name»  
«Address_1»  
«Address_2»  
«Address_3» 
«Address_4» 
ADD REFERRING CLINICIAN (if diff. to GP) 
Email dorothy.young@tuht.scot.nhs.uk 
 
Dear «Clinician_Name» 
 
RE: «Prename» «Surname»  («Date_of_birth» «MPI»)   
«Address»  «Area»  «Town»  «Postcode» 
 
«Title» «Surname» completed a detailed family history questionnaire and we have assessed her 
risk of developing breast cancer. Women found to have a low risk of developing breast cancer 
that have agreed to participate in our study were randomised either to receive a letter or an 
appointment to one of our genetics clinics. «Title» «Surname» was seen at our genetics clinics to 
discuss her risk of breast cancer (a copy of the summary letter sent to her is enclosed with a copy 
of patient information sheet and her signed consent form). 
 
INSERT FAMILY HISTORY.  Fortunately her risk is not significantly increased. We have not 
arranged for her to have a mammogram or clinical examination.  
 
If «Title» «Surname» or yourself have any further questions or concerns please do not hesitate to 
contact us at the above address or telephone me on 01382 496369. 
 
Yours sincerely 
 
 
 
Dorothy Young 
Genetic Associate 
Yours sincerely 
 
 
 
David R Goudie 
Consultant Clinical Geneticist 
 
Enc Patient Information Sheet 
 Copy Signed Consent Form 
 
c.c. ADD GP if diff. from REFERRING CLINICIAN (if diff. to GP) 
Registry 
 Casenotes 
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 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
Date of Clinic  
Your Ref  
Our Ref /sm/jr/ «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to  
Extension  
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
Direct Line (01382)  
 
Dear «Title» «Surname» 
 
Most breast cancer is not hereditary but some women with breast cancer have a hereditary form 
of the condition.  Women with hereditary breast cancer usually have close relatives that are 
affected and the hereditary forms of the condition tend to occur at unusually early ages. 
 
The hereditary forms of breast cancer are caused by faults in genes (hereditary instructions) that 
normally tell the body how to make substances that protect against cancer. In some families the 
same genetic faults are associated with an increased risk from both breast cancer and cancer of 
the ovaries. We all inherit two copies of most genes. We inherit one copy from our mother and a 
second from our father. A woman with hereditary breast cancer has one normal and one faulty 
copy of one of the breast cancer genes. When she has children she can pass either her normal or 
her faulty copy of the gene on to each of her children. A daughter inheriting normal copies of the 
breast cancer genes from both of her parents will not have an increased risk from breast cancer 
and cannot pass the predisposition on to her children. A daughter inheriting a faulty copy of the 
gene will have an increased risk of breast cancer but not all gene carriers will develop the 
condition.  
 
It is possible that some of your relatives have a hereditary form of breast cancer. The majority of 
women with a family history like you will not develop cancer but your risks are higher than 
average. 
 
Early detection and treatment of breast cancer can improve the chance of successful treatment. 
We will arrange to see you each year at the Family History Breast Cancer Clinic to screen for 
early signs of the condition. 
 
In some families we can identify the precise genetic fault causing breast cancer using blood 
samples from surviving affected women. In families where a specific genetic fault has been 
identified we can test other family members to determine if they have inherited the faulty gene. / 
 62 
Page 2 
 
«Title» «Prename» «Surname»  
 
 
As you get older without developing breast cancer it becomes progressively less likely that you 
have inherited a faulty breast cancer gene. Unless you develop the condition yourself your 
daughters’ risk will not be sufficiently increased for them to be likely to benefit from screening 
for early signs of the condition before they are 50 years old, unless they have breast symptoms. 
Even in families with hereditary breast cancer it is rare for the condition to affect women before 
they are in their 30s.  
 
 
 
 
 
cc ADD REFERING CLINICIAN (if diff. to GP) 
«Clinician_Name» «Source_Name» «Address_1» «Address_2» «Address_3» 
«Address_4» 
Registry File 
 Case Notes 
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 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
Date of Clinic  
  
Our Ref /sm/jr/ «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Dr D Goudie 
Extension 32035 
Direct Line (01382) 632035 
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
Email david.r.goudie@tuht.scot.nhs.uk 
 
Dear «Title» «Surname» 
 
Most breast cancer is not hereditary but some women with breast cancer have a hereditary form 
of the condition.  Women with hereditary breast cancer usually have close relatives that are 
affected and the hereditary forms of the condition tend to occur at unusually early ages. 
 
Although it is possible that some of your relatives have had hereditary breast cancer, as you get 
older without developing the condition, the risk that you have a hereditary tendency to develop 
cancer diminishes. You are already eligible for breast screening through the National Breast 
Screening Program so we have not arranged for you to have screening through the Family 
History Breast Cancer clinic. You should ensure that your are enrolled in the National Breast 
Screening Program as you are now eligible. There is evidence that regular screening for early 
signs of breast cancer is of benefit for women over 50 years of age. 
 
Gene testing is only possible in a minority of families with breast cancer. Identifiable faults in 
the breast cancer genes are infrequently found in families where less than four women have had 
breast cancer. It is unlikely that genetic tests would alter our estimate of your risk from breast 
cancer. 
 
We have not arranged another appointment for you. Should you develop breast symptoms that 
you are concerned about you should seek medical advice. Please do not hesitate to contact us if 
you have any other questions or if other members of your family develop cancer which might 
alter our estimate of your own risk.  
 
 
Yours sincerely 
 
 
 
 
Lorna McLeish 
Genetic Nurse Specialist 
Yours sincerely 
 
 
 
 
David R Goudie 
Consultant Clinical Geneticist 
 
cc ADD REFERRING CLINICIAN (if diff. to GP) 
«Clinician_Name»  «Source_Name»  «Address_1»  «Address_2»  «Address_3»  
«Address_4» 
Registry File 
 Case Notes 
 64 
 
 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date Dictated  
Date of Clinic  
Your Ref  
Our Ref «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Genetic Counsellor / Dr D Goudie 
«Title» «Prename» «Surname» 
«Address» 
«Area» 
«Town» 
«Postcode» 
Direct Line (01382)  632035 
 
 
 
Dear «Title» «Surname» 
 
I am sorry that you could not attend for your recent appointment at the Family History Breast 
Cancer clinic.  We have not arranged another appointment for you.  Please ask your family 
doctor to re-refer you if you would like another clinic appointment.  
 
Yours sincerely 
 
 
 
     
Genetic Counsellor    
 
 
 
dd. «Clinician_Name» «Source_Name» «Address_1» «Address_2» «Address_3» 
«Address_4» 
Registry 
Case notes 
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 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed   
Date of Clinic  
Your Ref  
Our Ref «Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to  Genetic Counsellor 
Extension 362035 
«Clinician_Name» 
«Source_Name» 
«Address_1» 
«Address_2» 
«Address_3» 
«Address_4» 
Telephone (01382)  632035 
 
 
 
Dear «Clinician_Name» 
 
«Title» «Prename» «Surname» («Date_of_birth» «MPI») «Address» «Area» «Town» 
«Postcode» 
 
«Title» «Surname» has failed to attend for her appointment at the Family History Breast Cancer 
Clinic. We have not organised any further appointments but we would be happy to see her again 
if you wish to re-refer her.  
 
Yours sincerely 
 
 
 
 
Genetic Counsellor 
 
 
Enc Copy of letter to «Prename» «Surname»  
 
 
Cc Dr Marta Reis, Associate Specialist, Breast Office, Ward 10, Ninewells Hospital 
 Registry 
Casenotes 
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 Clinical Genetics Human Genetics Unit 
Ninewells Hospital & Medical School 
Dundee 
DD1 9SY 
Telephone No (01382) 632035 
Fax No (01382) 496382 
 
Date Typed 21st June 2005  
Our Ref DY/«Date_of_birth» «MPI» 
Family No «Pedigree_No» 
Enquiries to Dorothy Young  
Extension 36369 
Direct Line (01382) 496369 
«Clinician_Name» 
«Address_1» 
«Address_2» 
«Address_3» 
«Address_4» Email dorothy.young@tuht.scot.nhs.uk 
 
Dear «Clinician_Name» 
 
Thank you for participating in the Tayside study of breast cancer genetic service organisation. As 
you know, over the past 3 years we have assessed the acceptability of a triage system for women 
referred to the service, whereby risk of breast cancer is judged to be “low”, “moderate” or 
“high”, after construction and verification of a detailed family history. Women at moderate or 
high risk or who did not return their family history questionnaire were given appointments to the 
Friday multidisciplinary counselling/screening clinic. Women assessed at low risk during the 
study were randomised to either receive a letter explaining that they would not be enrolled in a 
special screening programme or were given the same information through a personal interview 
with a genetics nurse specialist or genetics associate. We greatly appreciate the views of GPs on 
these approaches and will be grateful if you can spare a few minutes to complete and return this 
short questionnaire in the FREEPOST envelope provided. 
 
The questions relate specifically to women who consented to be randomised, were found to be at 
low genetic risk, and who were told this by letter or interview. They do not refer to women who 
attended the surveillance clinic even if they were subsequently found to be at low risk and 
discharged.  
 
«Prename» «Surname» participated in our Family History Breast cancer study. I have enclosed a 
copy of the study information sheet. She was assessed from her family history questionnaire to 
be at low risk of hereditary breast cancer. As part of the study she was randomised to receive a 
letter to inform her of her risk.  
 
Please can you complete the short questionnaire and return it in the FREEPOST envelope. This 
will help assess how the study has affected your clinical workload. 
 
Yours sincerely 
 
 
 
Dorothy Young 
Genetic Counsellor 
 
 
Enc. 
 
c.c. registry 
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GP Questionnaire 
 
RE:  «Prename» «Surname» («Date_of_birth»  «MPI»)     
«Address», «Area», «Town»  «Postcode» 
 
1. Were you satisfied with the information and service provided? YES / NO 
 
If No, please indicate briefly the reason(s) ………………………………………… 
……………………………………………………………………………………… 
 
2. As far as you are aware, was your patient satisfied with the information/service provided?
        YES / NO 
 
If No, please indicate briefly the reason(s) ………………………………………… 
……………………………………………………………………………………… 
 
3. Since receiving her letter or interview, has the patient contacted you again to discuss breast 
cancer risk?       YES / NO 
 
If YES, please indicate briefly the reason(s) ………………………………………… 
……………………………………………………………………………………… 
 
4. How do you feel about a triage process whereby risk is fully assessed before a decision is 
taken whether or not to offer a patient a cancer genetics appointment? 
 
Completely satisfied  
Some reservations  
Major reservations  
Strongly opposed   
 
5. Would you be willing to participate in focus group meeting to explore further issues relating to 
organisation of cancer genetics services?   YES / NO 
 
 
6. Please add any comments on NHS cancer genetics services – local or national. 
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
……………………………………………………………………………………………………
…………………… 
 
Thank you for completing this questionnaire. 
 
 
For office use only: 
 
Please send payment of £10.00 To  
 
«Clinician_Name» «Address_1» «Address_2» «Address_3» «Address_4» 
 
Thank you 
………………………………………….(signed) 
 
Ref: 
«Pedigree_No
» 
